
<html lang="en"     class="pb-page"  data-request-id="74af14ad-94ab-44fe-96e1-21f96b4e0c0b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00722;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)" /></meta><meta name="dc.Creator" content="George V.  De Lucca" /></meta><meta name="dc.Creator" content="Qing  Shi" /></meta><meta name="dc.Creator" content="Qingjie  Liu" /></meta><meta name="dc.Creator" content="Douglas G.  Batt" /></meta><meta name="dc.Creator" content="Myra  Beaudoin Bertrand" /></meta><meta name="dc.Creator" content="Rick  Rampulla" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Lorell  Discenza" /></meta><meta name="dc.Creator" content="Celia  D’Arienzo" /></meta><meta name="dc.Creator" content="Jun  Dai" /></meta><meta name="dc.Creator" content="Mary  Obermeier" /></meta><meta name="dc.Creator" content="Rodney  Vickery" /></meta><meta name="dc.Creator" content="Yingru  Zhang" /></meta><meta name="dc.Creator" content="Zheng  Yang" /></meta><meta name="dc.Creator" content="Punit  Marathe" /></meta><meta name="dc.Creator" content="Andrew J.  Tebben" /></meta><meta name="dc.Creator" content="Jodi K.  Muckelbauer" /></meta><meta name="dc.Creator" content="ChiehYing J.  Chang" /></meta><meta name="dc.Creator" content="Huiping  Zhang" /></meta><meta name="dc.Creator" content="Kathleen  Gillooly" /></meta><meta name="dc.Creator" content="Tracy  Taylor" /></meta><meta name="dc.Creator" content="Mark A.  Pattoli" /></meta><meta name="dc.Creator" content="Stacey  Skala" /></meta><meta name="dc.Creator" content="Daniel W.  Kukral" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Luisa  Salter-Cid" /></meta><meta name="dc.Creator" content="Aberra  Fura" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="Joel C.  Barrish" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="Joseph A.  Tino" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article ..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 26, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00722" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00722" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00722" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00722" /></link>
        
    
    

<title>Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00722" /></meta><meta property="og:title" content="Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0023.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article will detail the structure–activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00722"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00722">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00722&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00722&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00722&amp;href=/doi/10.1021/acs.jmedchem.6b00722" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7915-7935</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00703" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00747" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide (BMS-935177)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George+V.++De+Lucca">George V. De Lucca</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qing++Shi">Qing Shi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingjie++Liu">Qingjie Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+G.++Batt">Douglas G. Batt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Myra++Beaudoin+Bertrand">Myra Beaudoin Bertrand</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rick++Rampulla">Rick Rampulla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lorell++Discenza">Lorell Discenza</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Celia++D%E2%80%99Arienzo">Celia D’Arienzo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Dai">Jun Dai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary++Obermeier">Mary Obermeier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rodney++Vickery">Rodney Vickery</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingru++Zhang">Yingru Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Yang">Zheng Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Punit++Marathe">Punit Marathe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+J.++Tebben">Andrew J. Tebben</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jodi+K.++Muckelbauer">Jodi K. Muckelbauer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=ChiehYing+J.++Chang">ChiehYing J. Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huiping++Zhang">Huiping Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Gillooly">Kathleen Gillooly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tracy++Taylor">Tracy Taylor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Pattoli">Mark A. Pattoli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stacey++Skala">Stacey Skala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+W.++Kukral">Daniel W. Kukral</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Salter-Cid">Luisa Salter-Cid</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aberra++Fura">Aberra Fura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joel+C.++Barrish">Joel C. Barrish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+A.++Tino">Joseph A. Tino</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Immunosciences Discovery Chemistry, <sup>‡</sup>Immunoscience Discovery Biology, <sup>§</sup>Molecular Structure and Design, Molecular Discovery Technologies, <sup>∥</sup>Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, and <sup>⊥</sup>ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div><div class="corresp-info"><strong>*</strong>G.V.D.L.: e-mail, <a href="/cdn-cgi/l/email-protection#573032382530327933323b2234343617353a247934383a"><span class="__cf_email__" data-cfemail="781f1d170a1f1d561c1d140d1b1b19381a150b561b1715">[email protected]</span></a>; phone, 609-252-3121.</div><div class="corresp-info"><strong>*</strong>J.A.T.: e-mail, <a href="/cdn-cgi/l/email-protection#03696c7066736b2d776a6d6c43616e702d606c6e"><span class="__cf_email__" data-cfemail="3f55504c5a4f57114b5651507f5d524c115c5052">[email protected]</span></a>; phone, 609-252-4809; fax, 609-252-7410.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00722&amp;href=/doi/10.1021%2Facs.jmedchem.6b00722" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7915–7935</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 17, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 May 2016</li><li><span class="item_label"><b>Published</b> online</span>26 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00722" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00722</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7915%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGeorge%2BV.%2BDe%2BLucca%252C%2BQing%2BShi%252C%2BQingjie%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D17%26contentID%3Dacs.jmedchem.6b00722%26title%3DSmall%2BMolecule%2BReversible%2BInhibitors%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%253A%2BStructure%25E2%2580%2593Activity%2BRelationships%2BLeading%2Bto%2Bthe%2BIdentification%2Bof%2B7-%25282-Hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2B%2528BMS-935177%2529%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7935%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00722"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3117</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00722" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;V. De Lucca&quot;},{&quot;first_name&quot;:&quot;Qing&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Qingjie&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;G. Batt&quot;},{&quot;first_name&quot;:&quot;Myra&quot;,&quot;last_name&quot;:&quot;Beaudoin Bertrand&quot;},{&quot;first_name&quot;:&quot;Rick&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Lorell&quot;,&quot;last_name&quot;:&quot;Discenza&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Obermeier&quot;},{&quot;first_name&quot;:&quot;Rodney&quot;,&quot;last_name&quot;:&quot;Vickery&quot;},{&quot;first_name&quot;:&quot;Yingru&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Punit&quot;,&quot;last_name&quot;:&quot;Marathe&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;J. Tebben&quot;},{&quot;first_name&quot;:&quot;Jodi&quot;,&quot;last_name&quot;:&quot;K. Muckelbauer&quot;},{&quot;first_name&quot;:&quot;ChiehYing&quot;,&quot;last_name&quot;:&quot;J. Chang&quot;},{&quot;first_name&quot;:&quot;Huiping&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Gillooly&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;Taylor&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Pattoli&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;Skala&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;W. Kukral&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Salter-Cid&quot;},{&quot;first_name&quot;:&quot;Aberra&quot;,&quot;last_name&quot;:&quot;Fura&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;C. Barrish&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;A. Tino&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;7915-7935&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00722&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article will detail the structure–activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clinical development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00722&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00722" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00722&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00722" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00722&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00722" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00722&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00722&amp;href=/doi/10.1021/acs.jmedchem.6b00722" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00722" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00722" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26pmid%3D27531604%26genre%3Darticle%26aulast%3DDe%2BLucca%26date%3D2016%26atitle%3DSmall%2BMolecule%2BReversible%2BInhibitors%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%253A%2BStructure%25E2%2580%2593Activity%2BRelationships%2BLeading%2Bto%2Bthe%2BIdentification%2Bof%2B7-%25282-Hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2B%2528BMS-935177%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D17%26spage%3D7915%26epage%3D7935%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/jmcmar.2016.59.issue-17/20160908/jmcmar.2016.59.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article will detail the structure–activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide <b>6</b> (BMS-935177) was selected to advance into clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases continue to be a very active area for drug discovery, targeting treatments in a wide range of therapeutic areas.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Bruton’s tyrosine kinase (BTK) is a nonreceptor tyrosine kinase expressed in all hematopoietic cells except plasma and T cells. Although only one of the five mammalian TEC family members, BTK is the most important from a target perspective, since it is critical for B cell signaling through the B cell receptor (BCR).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In addition to B cells, BTK is vital for signaling in low affinity activating Fcγ receptors (e.g., FcγRIII and FcγRIIa) in monocytic cells. BTK also regulates the expression of proinflammatory cytokines, chemokines, and cell adhesion molecules in response to receptor activation through FcεRI signaling in mast cells and basophils.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> RANK signaling, which controls osteoclastogenesis from monocytic precursors, is also BTK-dependent.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">B cells are essential to the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) as demonstrated by the clinical results for the B cell-depleting anti-CD20 antibody rituximab.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition to producing autoantibodies, B cells can control autoimmunity as sources of proinflammatory chemokines and cytokines, such as IL-6 and TNFα, and through their role as antigen-presenting cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Because BTK kinase activity is necessary for BCR-dependent proliferation of B cells as well as production of proinflammatory cytokines and costimulatory molecules (e.g., CD86), pharmacological inhibition of BTK is expected to affect several pathways by which B cells may mediate autoimmunity but without depleting B cells. Pharmacological and genetic studies in animal models strengthen the case that BTK inhibitors would be efficacious against autoimmune indications such as RA or systemic lupus erythematosus (SLE). BTK-deficient mice are less sensitive to both the (NZB X NZW)F1 model of lupus and the collagen-induced arthritis (CIA) model.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> BTK inhibitors reduce disease progression in the collagen antibody-induced arthritis (CAIA) and CIA models, in addition to murine lupus models.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The vital role of BTK in B cells is also observed in human x-linked agammaglobulinemia (XLA) immunodeficiency. XLA patients have inactivating mutations in the BTK gene leading to a loss of mature B cells and circulating antibodies.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">A key structural feature of the BTK kinase domain is the noncatalytic cysteine (Cys481) residue in the extended hinge region.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Numerous companies have targeted this residue to prepare irreversible BTK inhibitors, with the most successful being ibrutinib (<b>1</b>; Pharmacyclics/J&J), which is approved for various non-Hodgkin’s lymphomas (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Several additional BTK inhibitors have entered clinical trials for the treatment of autoimmune indications, including covalent inhibitors from Celgene (<b>2</b>), Hanmi (<b>3</b>), and Principia (<b>4</b>, structure unknown, 2014 press release),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> with the most advanced appearing to be <b>2</b>, currently in phase II trials in RA (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Efficacy results for these and other compounds entering clinical trials are eagerly awaited, since small molecule inhibitors of this mechanism have the potential to compete with biologics for the treatment of RA and several other autoimmune diseases. In addition to these covalent inhibitors, recent reports from Roche and Merck show continued interest in reversible BTK inhibitors.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BTK irreversible inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously disclosed the discovery of a novel carbazole series of BTK inhibitors, as well as the initial structure–activity relationships (SARs) leading to <b>5</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>5</b> inhibited BTK with modest kinase selectivity. Having identified a novel carbazole series of BTK inhibitors, we began an effort to address the liabilities of <b>5</b> and similar analogs. In the current paper, we disclose carbazoles with improved oral exposure, kinase selectivity, and BTK potency, leading to the discovery of the clinical development candidate <b>6</b> (BMS-935177).<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Initial lead <b>5</b> and optimized compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As we have reported previously, X-ray structural data for a member of the carbazole carboxamide series showed that the carbazole NH and both the carbonyl and NHs of the primary amide formed critical hydrogen bonds to the key hinge region of BTK.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> It was also noted that a small ortho-substituent on the C-4 phenyl ring improved both BTK potency and kinase selectivity when compared to the parent unsubstituted analog. In addition, X-ray structures showed the C-7 substituent bound in the solvent exposed extended hinge region of BTK.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> Several initial issues for the carbazole series required optimization, including kinase potency and selectivity, as well as oral exposure in mouse. Our efforts to address these concerns involved the use of a combination of focused library and individual analog synthesis as outlined in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. The 4-fluorophenyl amide of <b>5</b> was replaced with a variety of alkyl, aryl, and heteroaryl amides as well as ureas and carbamates using the aniline <b>7a</b>. To explore the SAR at the C-7 position, the piperazine of amide of <b>5</b> was replaced with a variety of alkyl, aryl, and heteroaryl amides starting from the acid <b>8a</b>. The acid substituent of a <b>8a</b> precursor was converted to aniline <b>9a</b> (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) which was used as the starting material to further explore the SAR at C-7 to give <b>9b</b>, incorporating a variety of alkyl anilines as well as a range of alkyl, aryl, and heteroaryl amides, ureas, and carbamates. From this thorough exercise two analogs were noteworthy, <b>10</b> and <b>11</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial optimization of carbazole core series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Potency, Selectivity, and Mouse PK of Carbazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0018.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0019.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of three determinations.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Fold enzyme IC<sub>50</sub> selectivity.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">PAMPA values were determined at pH 7.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">CMAX (maximum concentration) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t1fn4.a"><sup>Table e</sup><p class="last">AUC<sub>0–24h</sub> (area under the curve) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t1fn5"><sup>Table f</sup><p class="last">Null = compound was not detected.</p></div></div><div></div></div><div class="NLM_p">The polarity of the piperazine amide C-7 substituent coupled with the large number of hydrogen bond donors and acceptors in <b>5</b> led to low permeability as measured in PAMPA, contributing to low oral exposure in mouse (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The ortho-pyridyl analog <b>10</b>, designed to form an intramolecular H-bond with the amide NH to improve permeability, maintained good BTK potency with improved PAMPA and oral exposure as shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, although selectivity over the SRC family of kinases (LCK as an example found on T-cells) was still unacceptable. The goal of >50-fold selectivity over the SRC family was set to minimize the chances of being too immunosuppressive in vivo by targeting both B- and T-cells. With recognition that the C-7 substituents could potentially bind in the solvent exposed extended hinge region of BTK, modification of the side chain could be used to “tune” the properties of inhibitors. Analog exploration at C-7 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) often showed a dramatic effect on kinase selectivity and potency. However, many of these analogs were of high molecular weight with low oral plasma concentrations in mouse PK studies (results not shown). The amino acid at the C-terminal end of the hinge in BTK, Ala478, is often an acidic residue in SRC kinase family members such as LCK (Glu320). We predicted that a less basic C-7 group could improve selectivity over the piperazine amide. In order to keep the molecular weight low, compound <b>11</b> was prepared and found to be a potent BTK inhibitor with improved oral plasma exposure and LCK kinase selectivity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, analogs with a pendent meta-aryl or heteroaryl amide substituent on the C-4 phenyl, as in <b>10</b> and <b>11</b>, showed hydrolysis to an aniline metabolite as the major metabolic pathway in human and rat liver microsomes. In addition, in the case of <b>11</b>, concomitant N-dealkylation of the isopropyl group led to the corresponding bis-aniline metabolite, observed in liver microsomes and as a circulating metabolite after oral dosing in mice. Upon multiple day dosing in mice, compound <b>11</b> showed toxicity in vivo that could be attributed to the bis-aniline metabolite (data not shown). Predicting the extent of amide hydrolysis in humans based on preclinical data is potentially challenging,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> supporting the decision to stop further progression of these analogs.</div><div class="NLM_p">To avoid any possible aniline release, numerous medicinal chemistry approaches to stabilize amide hydrolysis were investigated. The most direct approach, synthesis of the cyclic amides, was also the most effective. The five-membered ring lactam <b>12</b> maintained BTK potency with acceptable permeability (PAMPA Pc 494 nm/s, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). As expected, <b>12</b> was stable to hydrolysis in vivo; however the plasma concentration in mouse was similar to <b>5</b>, which also contained the piperazine amide. It should be noted that the mouse liver microsome metabolic stability<a onclick="showRef(event, 'cit25e'); return false;" href="javascript:void(0);" class="ref cit25e">(25e)</a> of the three compound <b>5</b>, <b>10</b>, and <b>12</b> containing the piperazine amide was comparable. It was surprising that the exposure for lactam <b>12</b> was significantly worse than that of ortho-pyridyl analog <b>10</b>, designed to form an intramolecular H-bond with the amide NH, which points to the difficulty of predicting exposure based solely on one parameter, such as numbers of hydrogen bonds.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Potency, Selectivity, and Mouse PK of Carbazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0020.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0021.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Fold enzyme IC<sub>50</sub> selectivity.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">CMAX (maximum concentration) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t2fn3.a"><sup>Table d</sup><p class="last">AUC<sub>0–24h</sub> (area under the curve) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t2fn4"><sup>Table e</sup><p class="last">IC<sub>50</sub> values are shown as single determinations.</p></div><div class="footnote" id="t2fn5"><sup>Table f</sup><p class="last">ND = not determined.</p></div></div><div></div></div><div class="NLM_p">The SAR results from our previous C-7 analogs prepared for compound <b>5</b> (outlined in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) suggested that small polar nonbasic or weakly basic groups would be best for potency, selectivity, and PAMPA. Combining the C-4 lactam with a tertiary carbinol as a C-7 substituent led to analog <b>13</b> which maintained BTK potency and improved potency in the Ramos B cell calcium flux assay (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). In order to further optimize <b>13</b>, a second survey of alternative C-7 substituents was undertaken focusing on small polar groups. Ultimately, no other substituent was found to give better overall properties than the carbinol. An investigation of substituents on the phenyl ring of the lactam identified the fluoro-substituted analog <b>14</b>, which had improved BTK cell potency and mouse liver microsome metabolic stability compared to <b>13</b>. Compound <b>14</b> showed significantly improved oral plasma concentrations in mouse compared to <b>12</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), suggesting that it was suitable for further in vivo studies.</div><div class="NLM_p">BTK regulates antigen receptor (BCR) signaling in B cells, and one of the hallmarks of xid (x-linked immune defect) mice deficient in BTK is a defective neoantigen-induced antibody response. As a result, it was anticipated that activity against a keyhole limpet hemocyanin (KLH) induced antibody response in mice would provide an important pharmacodynamics (PD) readout of BTK inhibition.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In this model, anti-KLH antibodies of the IgM isotype appear in the first week after challenge, followed by isotype switching to IgG anti-KLH antibodies evident by day 14. However, <b>14</b> showed only a nonstatistically significant decrease in IgG when dosed orally at 30 mg/kg b.i.d. in the chronic KLH mouse model. The weak suppression of the anti-KLH response, coupled with a nonoptimal PK profile, prohibited further advancement of compound <b>14</b>.</div><div class="NLM_p">An extensive exploration of heterocyclic analogs of <b>14</b> was conducted to find compounds with improved potency and oral plasma concentrations (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). BTK potency was maintained in several 6,6 bicyclic ring systems, such as in analogs <b>15</b> and <b>16</b>, but they were either less LCK (or other kinase) selective or less potent in cells than <b>14</b>. The unsubstituted quinazolinone <b>6</b> showed improved Ramos B cell potency with similar LCK selectivity to <b>14</b>. Quinazolinones were substituted with an array of electron donating and withdrawing groups, as well as a range of both polar and lipophilic moieties. However, in none of these cases was the overall profile improved over the unsubstituted parent analog <b>6</b>. For example, a fluoro scan on the quinazolinone ring provided <b>17</b>–<b>20</b>. Although all of the fluoro analogs were potent BTK inhibitors, none showed significant improvements over <b>6</b>. All five analogs were investigated in mouse PK studies at 10 mpk, showing improved oral plasma concentrations compared to <b>14</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Quinazolinone analogs <b>21</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) and <b>22</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) were also prepared to investigate the requirements of the tertiary carbinol and the ortho-methyl substituent in the C-4 aryl linker, respectively. Compound <b>21</b> maintained BTK enzyme potency but showed lower oral plasma concentrations in mouse compared to <b>6</b>. Analog <b>22</b> had a significant drop in BTK enzyme potency, highlighting the importance of the C-4 aryl ortho-methyl substituent.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Potency, Selectivity, and Mouse PK of Carbazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0022.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">BTK<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">LCK/BTK<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Ramos,<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">CMax<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> (nM)</th><th class="colsep0 rowsep0" align="center">AUC<a class="ref internalNav" href="#t3fn3_a" aria-label="d">d</a> (μM·h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">44<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">32×</td><td class="colsep0 rowsep0" align="left">410<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn5" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4 ± 2</td><td class="colsep0 rowsep0" align="left">210×</td><td class="colsep0 rowsep0" align="left">30 ± 2</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">19</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Fold enzyme IC<sub>50</sub> selectivity.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">CMAX (maximum concentration) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t3fn3.a"><sup>d</sup><p class="last">AUC<sub>0–24h</sub> (area under the curve) after 10 mg/kg oral dosing in male Balb/C mice with PEG300/TPGS/ethanol (90/5/5 v/v/v) vehicle.</p></div><div class="footnote" id="t3fn4"><sup>e</sup><p class="last">IC<sub>50</sub> values are shown as single determinations.</p></div><div class="footnote" id="t3fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">Attempts to obtain an X-ray cocrystal structure of <b>6</b> bound to BTK were unsuccessful. However, close analog <b>23</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) provided a 1.9 Å X-ray crystal structure bound to the active site of BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>), as shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>. The carbazole NH and primary amide were bound to the hinge as expected,<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> forming crucial hydrogen bonds with the backbone carbonyl of Met-477 and both the backbone NH of Met-477 and the carbonyl of Glu-475, respectively. In addition, the primary amide formed a third hydrogen bond to a water in the gate keeper region, which was linked to an extensive water network that filled the pocket. The fluorophenyl ring was nearly orthogonal to the carbazole, with the ortho fluoro filling a small hydrophobic pocket formed by Leu-528 at the base of the ATP pocket and the backbone of Cys-481. The quinazolinone ring was in turn orthogonal to the C-4 phenyl linker, with the carbonyl interacting with a conserved water in the extended hinge region. Finally, the C-7 tertiary carbinol was water-exposed in the extended hinge region as predicted, stabilizing a water network that also included the quinazolinone carbonyl.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A, B) Compound <b>23</b> X-ray crystal structure bound to BTK kinase domain: (A) electron density mapping of <b>23</b>; (B) binding of <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>), including waters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although several analogs displayed in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> showed promising plasma concentrations in mouse, none displayed a superior profile for progression compared to the parent quinazolinone <b>6</b>. With the low aqueous solubility (<1 μg/mL) of <b>6</b>, further lipophilic fluoro substituents in <b>17</b>–<b>20</b> could be problematic in achieving dose linear oral exposures in further animal studies. Therefore, compound <b>6</b> was selected for detailed in vitro and in vivo characterization.</div><div class="NLM_p">A partial list of kinase selectivity data for compound <b>6</b> is summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Compound <b>6</b> is a potent, reversible inhibitor of BTK (IC<sub>50</sub> = 2.8 nM) and demonstrated good kinase selectivity when tested against a screening panel of 384 kinases at DiscoveRx (Fremont, CA; formally Ambit Biosciences),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> with only 16 kinases showing less than 15% control binding at 1000 nM. Consistent with this measure of selectivity, biochemical kinase assays against 60 kinases showed <b>6</b> to be more potent against BTK than any other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. With the exception of 7-fold selectivity over BLK, expressed specifically in B cells, the compound showed greater than 50-fold selectivity over the SRC family of kinases, including 1100-fold selectivity over SRC itself. Other kinases inhibited with a potency less than 150 nM (50-fold selectivity) included TRKA, HER4, TRKB, and RET.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Partial List of in Vitro Kinase Selectivity Data for Compound <b>6</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center" char=".">fold BTK selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="char" char=".">0.096</td><td class="colsep0 rowsep0" align="char" char=".">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK</td><td class="colsep0 rowsep0" align="char" char=".">0.180</td><td class="colsep0 rowsep0" align="char" char=".">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKA</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4</td><td class="colsep0 rowsep0" align="char" char=".">0.050</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKB</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LYN</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="char" char=".">3.19</td><td class="colsep0 rowsep0" align="char" char=".">1140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">131</td></tr></tbody></table></div></div><div class="NLM_p">Cell potency data for compound <b>6</b> are summarized in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. In B cells stimulated through the BCR, <b>6</b> selectively inhibited several different readouts. Compound <b>6</b> inhibited calcium flux in human Ramos B cells (IC<sub>50</sub> = 27 nM) and inhibited CD69 surface expression in peripheral B cells stimulated with anti-IgM and anti-IgG. However, <b>6</b> had no effect on CD69 surface expression in B cells stimulated through the CD40 receptor with CD40 ligand. Against IgG-containing immune complex-driven low affinity activating Fcγ receptor (FcγRIIa and FcγRIII) end points in peripheral blood mononuclear cells (PBMCs), <b>6</b> effectively inhibited TNFα production with an IC<sub>50</sub> value of 14 nM. To determine the whole blood potency, the ability of the compound to inhibit BCR-stimulated expression of CD69 on the surface of B cells in whole blood was measured in a FACS-based assay which allowed for gating on the B cells. Against this BTK-dependent end point, <b>6</b> showed mean IC<sub>50</sub> values of 550 ± 100 (<i>n</i> = 11) and 2060 ± 240 nM (<i>n</i> = 3) in human and mouse whole blood, respectively. The somewhat more potent inhibition in human compared to mouse whole blood may reflect both an intrinsic human potency advantage and protein binding differences between species (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Partial List of in Vitro Cell Activity Data for Compound <b>6</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cellular assay</th><th class="colsep0 rowsep0" align="center">receptor/stimulation</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Calcium flux in Ramos B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">0.026 ± 0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Proliferation of human tonsillar B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.008<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.008<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">CD40/CD40L</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TNFα from human PBMC cells</td><td class="colsep0 rowsep0" align="left">FCλR/immune complex</td><td class="colsep0 rowsep0" align="left">0.014<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Human whole blood CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mouse whole blood CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">2.06 ± 0.24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean ± standard deviation values of at least three determinations.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values are shown as single determinations.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Partial List of in Vitro Profiling Data for Compound <b>6</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">99.4% in human serum 99% in mouse serum</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutagenicity</td><td class="colsep0 rowsep0" align="left">Ames negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (patch clamp)</td><td class="colsep0 rowsep0" align="left">55% inhibition at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> inhibition (IC<sub>50</sub>)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>40 μM 1A2, 2B6, 2D6, 3A4; >8 μM 2C9, 2C8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility</td><td class="colsep0 rowsep0" align="left"><1 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF solubility<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">6 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF solubility<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">60 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA (pH 5.5 and 7.4)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">876 and 1023 nm/s</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 permeability<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (apical to basolateral)</td><td class="colsep0 rowsep0" align="left"><15 nm/s</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 permeability<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (basolateral to apical)</td><td class="colsep0 rowsep0" align="left">122 nm/s</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">See ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a> for assay methods.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">CYP = cytochrome P450; HLM CYP assay.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">FaSSIF = fasted state simulated intestinal fluid.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">FeSSIF = fed state simulated intestinal fluid.</p></div></div></div><div class="NLM_p">Some of the detailed in vitro profiling data for compound <b>6</b> are summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. Plasma protein binding for <b>6</b> was high for all species, with less than 1% free for human. The high protein binding could mitigate the effects of the hERG patch clamp IC<sub>50</sub> of ∼10 μM. Although the crystalline aqueous solubility was <1 μg/mL for <b>6</b>, simulated gastric fluid showed improved solubility, in both fed and fasted state solutions. The high PAMPA permeability and low aqueous solubility placed <b>6</b> in the BCS class 2 category. The Caco-2 values showed that <b>6</b> is a PgP substrate, although this is mitigated by the high passive permeability.</div><div class="NLM_p">In the KLH assay, <b>6</b> showed superior in vivo potency compared to <b>14</b>. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A, when dosed orally once daily at 5, 20, and 45 mg/kg to mice, the compound inhibited anti-KLH antibodies of the IgG isotype at day 14, with statistically significant reductions at all doses. In satellite mice from this study dosed with <b>6</b> at 5 mg/kg, the plasma concentration was maintained above the mouse whole blood BCR-stimulated CD69 IC<sub>50</sub> value of 2 μM for only approximately 5 h (see <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). However, this transient daily coverage at the low dose yielded a significant inhibition of IgG anti-KLH titers, indicating that significant pharmacological activity can be observed even with incomplete coverage of the whole blood IC<sub>50</sub> potency.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Efficacy of <b>6</b> (5, 20, and 45 mg/kg) vs vehicle in a mouse neoantigen (KLH) antibody response model. (B) Plasma exposures of <b>6</b> in satellite animals. Female BALB/c mice (8–12 weeks old, Harlan) were immunized ip with 250 μg of KLH in PBS on day 0. Mice were dosed daily by oral gavage with vehicle (EtOH:TPGS:PEG300, 5:5:90) or compound <b>6</b> at doses of 5, 20, or 45 mg/kg. Blood was collected on days 7 and 14 postimmunization. Serum was separated and analyzed for anti-KLH IgM titers (day 7) and anti-KLH IgG titers (day 14) by ELISA. (A) Day 7 IgM (gray bars) and day 14 IgG (dark bars) anti-KLH titers ((∗) <i>p</i> < 0.05 vs vehicle, ANOVA with Dunnett’s post-test). (B) Serum drug levels from day 1 satellite mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> shows the results of fully preventative dosing with <b>6</b> in a mouse CIA model. At once daily oral doses of 10, 20, and 30 mg/kg beginning on the day of primary immunization, <b>6</b> provided a clear dose-dependent reduction in both the severity and incidence of clinically evident disease in this rodent model of RA. At 10 mg/kg of <b>6</b>, disease severity was reduced about 40% compared to vehicle treatment, and the percentage of animals showing any signs of disease was reduced by a third. At the 10 mg/kg dose the plasma level of <b>6</b> was maintained above the mouse WB IC<sub>50</sub> of 2.06 μM (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) for 12 h, with a 24 h trough level of 277 nM. At the two higher doses of 20 and 30 mg/kg, disease severity was reduced by 85–90% compared to vehicle treatment, and disease incidence was reduced by two-thirds. At the 20 mg/kg dose the plasma level of <b>6</b> was maintained above the mouse WB IC<sub>50</sub> for 20 h, with a 24 h trough plasma level of 1171 nM. At the end of the study, the tibiotarsal joints were evaluated histologically and graded semiquantitatively for severity of inflammation, synovial hyperplasia, bone resorption, and cartilage erosion. Consistent with the clinically observed effects on disease incidence and severity, <b>6</b> dose-dependently inhibited both inflammation and bone resorption end points (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Microcomputed tomography of the hind limbs also showed that <b>6</b> provided a dose-dependent protection against the pitting, loss of bone mass, woven porous bone, and fusion of the small bones evident in the mice receiving only vehicle, with the animals receiving 20 mg/kg showing essentially complete protection as evidenced by the presence of a smooth bone surface and easily recognizable small individual bones of the foot and ankle (representative images in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The compound was also effective at 30 mg/kg po q.d. in blocking disease progression when administration of <b>6</b> is initiated after the booster immunization (pseudoestablished dosing mode; data not shown).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of <b>6</b> (10, 20, and 30 mg/kg) vs vehicle in a mouse collagen induced arthritis (CIA) inflammation model. DBA/1 male mice were immunized subcutaneously at the base of the tail on day 0 and again on day 21 with 200 μg of bovine type II collagen admixed with reconstituted Sigma Adjuvant System (SAS; Sigma-Aldrich). Mice were dosed daily by oral gavage with vehicle (EtOH:TPGS:PEG300, 5:5:90) or compound <b>6</b> starting on day 0. Mice were monitored 3 times per week for the development and severity of paw inflammation. Clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group: (∗) <i>p</i> < 0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0007.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Bone and inflammation efficacy of <b>6</b> (10, 20, and 30 mg/kg) vs vehicle in a mouse CIA model. Histological evaluation of rear paws from the CIA study. Lesions were scored on a severity scale of 0 (normal) to 4 in two separate categories, inflammation (cellular infiltration and pannus formation), and bone resorption. Results represent the mean ± SEM: (∗∗) <i>p</i> < 0.01 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0008.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representative microcomputed tomography (micro-CT) images of the hind paws of CIA mice treated with <b>6</b> (10, 20, and 30 mg/kg). Hind paws were excised post-mortem and analyzed by micro-CT after fixation in 10% neutral buffered formalin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the B cell independent mouse CAIA disease model, <b>6</b> was also efficacious, reflecting the involvement of activating Fcγ receptor pathways which were blocked by BTK inhibition.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> shows that q.d. oral doses of 10 and 30 mg/kg provided a significant, dose-dependent reduction in paw clinical scores. Indeed, mice receiving <b>6</b> at 30 mg/kg were virtually disease-free throughout the period of the study, and this regimen was more effective in this model than dexamethasone. These results indicate that inhibition of BTK by <b>6</b> in signal transduction pathways and cells (e.g., activating Fcγ receptors in monocytic cells) other than BCR signaling is likely contributing to the profound efficacy seen in the CAIA and CIA models of arthritis.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0009.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Efficacy of <b>6</b> (10 and 30 mg/kg) vs vehicle and dexamethasone (Dex) in a mouse anti-collagen antibody-induced arthritis (CAIA) inflammation model. Mice (<i>N</i> = 8–10 per group) were injected intraperitoneally (ip) with a mixture of four monoclonal antimouse type II collagen antibodies (1 mg of each). Daily oral dosing was immediately started with vehicle (EtOH:TPGS:PEG300, 5:5:90), compound <b>6</b> (10 or 30 mg/kg), or dexamethasone (dex, 1 mg/kg). Three days later, the mice were injected ip with 1.25 mg/kg LPS (<i>E. coli</i> O111:B4; Sigma). Thereafter, mice were monitored 3×/week for the development and severity of paw inflammation. Clinical scores are shown as mean ± SEM: (∗) <i>p</i> < 0.05 vs vehicle group, <i>n</i> = 8–10/group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the strongest attributes of compound <b>6</b> is excellent oral bioavailability in all preclinical species, from both suspension and solution dosing, despite its low aqueous solubility. The oral bioavailability for <b>6</b> with solution dosing ranges from 84% to 100% in rat, mouse, dog, and cynomolgus monkey, with low clearance in single intravenous (iv) infusion studies (summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). When dosed as a crystalline microsuspension in rats (5 mpk in citrate buffer at pH 4, with 0.02% DOSS and 0.5% methocel), <b>6</b> maintained excellent oral bioavailability of ∼100%. Projections based on the good pharmacokinetics across species as well as efficacy in mouse models suggested that compound <b>6</b> could provide significant clinical benefit with once a day dosing.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters for Compound <b>6</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cyno<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">5<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM), po</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.3</td><td class="colsep0 rowsep0" align="left">4.8 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (μM), po</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.7</td><td class="colsep0 rowsep0" align="left">2.7 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h), po</td><td class="colsep0 rowsep0" align="left">30.8</td><td class="colsep0 rowsep0" align="left">21.2</td><td class="colsep0 rowsep0" align="left">14.2 ± 2.1</td><td class="colsep0 rowsep0" align="left">32 ± 7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h), iv</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">5.1 ± 0.1</td><td class="colsep0 rowsep0" align="left">10.4 ± 2.1</td><td class="colsep0 rowsep0" align="left">10.6 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>), iv</td><td class="colsep0 rowsep0" align="left">4.9</td><td class="colsep0 rowsep0" align="left">6.4 ± 0.9</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V<sub>ss</sub> (L/kg), iv</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">3.2 ± 1.0</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i><sub>po</sub> (%)</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">100 ± 8</td><td class="colsep0 rowsep0" align="left">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Average of three animals with associated standard deviation.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Vehicle: PEG400/water/ethanol (70/20/10 v/v/v).</p></div></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthetic route utilized in the preparation of the bicyclic amide replacement carbazole analogs in <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The key reaction was a Suzuki coupling between the appropriate partners <b>24</b> and <b>25</b>. Bromocarbazoles <b>24</b> (Y<sup>1</sup> = Br) were reacted with boronic esters <b>25</b> (Z<sup>1</sup> = boronic ester) under Suzuki coupling conditions to give final compounds <b>6</b> and <b>12</b>–<b>23</b>.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Alternatively, the partners could be reversed with the carbazole boronic esters <b>24</b> (Y<sup>1</sup> = boronic ester) reacting with the bromide <b>25</b> (Z<sup>1</sup> = Br) using the same coupling condition to give the final products in generally good yields. The C-7 functionalized carbazole intermediates were prepared as shown in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The Fischer indole cyclization using ketone <b>26</b> and hydrazine <b>27</b> was accomplished by heating in acetic acid to give the tetrahydrocarbazole <b>28</b> in 58% yield. Acid intermediate <b>28</b> was activated with EDC and HOBt, then treated with ammonium hydroxide to give amide <b>29</b> in 76% yield. Aromatization of <b>29</b> with DDQ gave ester carbazole <b>30</b> in good yield. Reduction of <b>30</b> with lithium aluminum hydride gave the benzyl alcohol intermediate <b>32</b> (64% yield). The tertiary carbinol intermediate <b>31</b> was prepared directly from ester <b>30</b> using methyllithium in 84% yield. Ester <b>30</b> was hydrolyzed with LiOH to acid <b>34</b> which was then coupled with <i>N</i>-methylpiperazine in the presence of EDC and HOBt to provide bromoamide <b>35</b> in excellent yield (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Alternatively, acid <b>34</b> was subjected to a Curtius rearrangement to give the Cbz-protected intermediate <b>36</b>, allowing access to C-7 amino analogs <b>9a</b> and <b>9b</b> shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Bicyclic Amide Replacements<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) Suzuki coupling conditions: Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 50–75%.</p></p></figure><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>31</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH, 110 °C, 3 h, 58%; (b) NH<sub>4</sub>OH, EDC, HOBt, THF/DCM, rt, 16 h, 76%; (c) DDQ, THF, 0 °C to rt, 86%; (d) MeLi, −60 °C, THF, 84%; (e) LAH, THF, 0 °C, 64%; (f) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bis(1,3,2-dioxaborolane), PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 70–85%.</p></p></figure><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediates <b>35</b> and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LiOH, THF/ethanol/H<sub>2</sub>O, reflux, 6 h, 96%; (b) 1-methylpiperazine, EDC, HOBt, THF/DCM, rt, 16 h, 96%; (c) (i) diphenylphosphoryl azide, Et<sub>3</sub>N, dioxane, 50 °C, 1.5 h, (ii) benzyl alcohol, 85 °C, 18 h, 91%.</p></p></figure><div class="NLM_p">The bromoamide intermediate <b>35</b> underwent a Suzuki reaction with 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)aniline to give intermediate <b>7a</b> in 77% yield as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Coupling of <b>7a</b> with the appropriate acid then provided the final amides <b>5</b> or <b>10</b> in good yields. Alternatively, the bromo intermediate <b>35</b> was subjected to a Suzuki reaction with boronic ester <b>40a</b> to give the lactam <b>12</b> in 60% yield (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The synthesis of <b>40a</b> is summarized in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. The bromoaniline <b>37</b> was acylated with 2-(chloromethyl)benzoyl chloride <b>38</b>, and the resulting amide intermediate was cyclized in the presence of a base to give the bromolactam <b>39a</b>. Treatment with bis(pinacolato)diboron under standard conditions gave high yields of the boronic ester <b>40a</b>.</div><figure id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>5</b>, <b>11</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 77%; (b) 4-F-benzoic acid, EDC, HOAt, DIEA, ACN, rt, 16 h, 92%; (c) 4-fluoropicolinic acid, EDC, HOAt, DIEA, ACN, rt, 18 h, 96%; (d) Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 60%.</p></p></figure><figure id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Boronic Ester Intermediates <b>40a</b> and <b>40b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>3</sub>N, DCM, rt, 2 h, 48%; (b) KOtBu, THF, rt, 1 h, 75%; (c) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 86%.</p></p></figure><div class="NLM_p">The other key Suzuki partners required for the preparation of final compounds <b>6</b> and <b>13</b>–<b>23</b> were synthesized as shown in <a class="ref internalNav" href="#sch6" aria-label="Schemes 6">Schemes 6</a> and <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. The preparations of isoquinolinone <b>44</b> and 3,4-dihydroisoquinolinone <b>47</b> are summarized in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The condensation of bromoaniline <b>41</b> with cyclic anhydride <b>42</b> provided the corresponding cyclic imide which was subsequently reduced with NaBH<sub>4</sub> and dehydrated under acidic conditions to give bromoisoquinolinone <b>43</b>. The bromoisoquinolinone was then converted to the boronic ester <b>44</b> in good yield. The reaction of 1,3-dibromo-2-methylbenzene <b>45</b> with 3,4-dihydroisoquinolin-1(2<i>H</i>)-one <b>46</b> in the presence of CuI gave the bromodihydroisoquinolin-1(2<i>H</i>)-one <b>47</b> used to synthesize final compound <b>15</b>. The quinazolinones were obtained by the reaction of bromoanilines <b>48</b> with anthranilic acids <b>49</b> in the presence of triethyl orthoformate to give the bromoquinazolinones <b>50</b> in moderate to good yields (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). The bromoquinazolinones were then converted to the required boronic esters <b>51</b> in good yields. With the appropriate Suzuki partners prepared, the assembly of the final compounds (<b>6</b> and <b>12</b>–<b>23</b>, <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) was carried out under standard cross-coupling conditions in good yields as summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0016.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Intermediates <b>44</b> and <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH, 110 °C, 16 h, 36%; (b) NaBH<sub>4</sub>, MeOH, rt, 6 h, 95%; (c) TFA, DCM, rt, 2 h, 67%; (d) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 67%; (e) CuI, K<sub>2</sub>CO<sub>3</sub>, DMSO, 150 °C, 1.5 h, 15%.</p></p></figure><figure id="sch7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0017.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Boronic Ester Intermediates <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triethyl orthoformate, toluene, 110 °C, 16 h, 36–75%; (b) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 67–95%.</p></p></figure><div class="NLM_p">During the analysis of the NMR data of final analogs such as <b>6</b>, complex splitting patterns were observed. Hindered rotation of the carbazole C-4 bond as well as the bond to the quinazolinone caused by the ortho-methyl substituent on the phenyl linker (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) created atropisomers. Chiral SFC chromatography was able to separate the four possible atropisomers, although they could not be isolated without racemization back to the original mixture due to the low barrier to rotation at room temperature.</div><figure id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0010.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Two axes of hindered rotation of compound <b>6</b> and (B) chiral HPLC trace showing four atropisomers. In (A), arrows show bonds with hindered rotation leading to atropisomers. In (B), chromatographic conditions were the following: Chiralpak IB column, 4.6 mm × 250 mm, 5 μm, 35/65 MeOH/CO<sub>2</sub>, 100 bar back-pressure, 4 mL/min, column 0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a novel second generation series of carbazole BTK inhibitors has been identified. The potential problem of aniline formation from benzamides such as <b>5</b>, <b>10</b>, and <b>11</b> was solved by conversion to the corresponding lactams (such as <b>12</b>). Oral exposure was improved by replacing the C-7 substituent with the less-polar tertiary carbinol. Extensive exploration of other heteroaryl modifications of the lactam moiety provided 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide <b>6</b>, a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. These features, coupled with robust efficacy in mouse arthritis models dependent on both B-cell and non-B-cell mechanisms, predict that <b>6</b> should provide useful clinical efficacy in autoimmune diseases. On the basis of in vitro potency, in vivo activity, and pharmacokinetic profile, compound <b>6</b> was selected for further studies in support of clinical development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedures</h3><div class="NLM_p">All reagents were purchased from commercial sources and used without further purification unless otherwise noted. All reactions were performed under an inert atmosphere of nitrogen or argon. Chromatographic purification was conducted on prepacked silica gel cartridges using a flash chromatography system such as the CombiFlashRf+System (Teledyne ISCO). HPLC and LCMS analyses were conducted using a Shimadzu SCL-10A liquid chromatograph and a SPD UV–vis detector at 220 or 254 nm with the MS detection performed with either a Waters Micromass ZQ spectrometer or a Micromass Platform LC spectrometer. Unless otherwise reported, preparative reverse-phase HPLC purifications were performed using the following conditions: YMC S5 ODS 20 mm × 100 mm column with a binary solvent system where solvent A = 10% methanol, 90% water, 0.1% trifluoroacetic acid and solvent B = 90% methanol, 10% water, and 0.1% trifluoroacetic acid, flow rate = 20 mL/min, linear gradient time = 10 min, start % B = 20, final % B = 100. Fractions containing the product were concentrated in vacuo to remove solvent. The resulting product could be further neutralized with aqueous sodium bicarbonate, extracted into organic solvent, dried, and concentrated under reduced pressure. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on either a JEOL Eclipse 500 or a Bruker Avance 400 spectrometer and are reported in ppm relative to either residual protio solvent of the sample in which they were run or to TMS as internal standard. Coupling constants are provided in Hz with standard abbreviations for the spectral pattern designations.</div><div class="NLM_p last">HPLC analyses for purity were performed using the following two conditions for all final compounds and were determined to have an HPLC purity of ≥95% unless otherwise noted.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Method A</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% TFA (solvent A) and 95% acetonitrile, 5% water, and 0.05% TFA (solvent B), <i>t</i> = 0 min, 10% B, <i>t</i> = 12 min, 100% B (15 min) was employed on a Waters SunFire C<sub>18</sub> 3.5 μm, 4.6 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The column was maintained at ambient temperature.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Method B</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% TFA (solvent A) and 95% acetonitrile, 5% water, and 0.05% TFA (solvent B), <i>t</i> = 0 min, 10% B, <i>t</i> = 12 min, 100% B (15 min) was employed on a Waters XBridge Ph 3.5 μm, 4.6 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The column was maintained at ambient temperature.</div></div><div id="sec4_3_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-(3-(4-Fluorobenzamido)-2-methylphenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide, TFA (<b>5</b>). Step A. Ethyl 3-Hydroxycyclohexanecarboxylate</h3><div class="NLM_p last">To an EtOH (500 mL) solution of ethyl 3-hydroxybenzoate (50 g, 0.3 mol) was added 5% rhodium on alumina (7.5 g), and the mixture was stirred in an autoclave under 12 kg of hydrogen pressure at rt overnight. The reaction mixture was filtered through Celite and the volatiles removed to give ethyl 3-hydroxycyclohexanecarboxylate (50 g, 96%) as a liquid and a mixture of diastereomers. The material was used without further purification. Mass spectrum <i>m</i>/<i>z</i> 173 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.03–4.21 (m, 2.3H), 3.54–3.71 (m, 0.7H), 2.67–2.83 (m, 0.3H), 2.36 (m, 0.7H), 2.20 (m, 1H), 1.76–2.01 (m, 3H), 1.16–1.76 (m, 8H).</div></div><div id="sec4_3_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Step B. Ethyl 3-Oxocyclohexanecarboxylate (<b>26</b>)</h3><div class="NLM_p last">To a DCM (1.1 L, dry) solution of ethyl 3-hydroxycyclohexanecarboxylate (51 g, 0.3 mol) at 0 °C was added carefully portionwise Dess–Martin periodinane (251 g, 0.59 mol). After the addition was complete, the reaction mixture was allowed to slowly come to rt overnight. The reaction was basified by the addition of Na<sub>2</sub>CO<sub>3</sub> solution, the resulting solids were removed by filtration through Celite, and the filtrate was concentrated. The resulting residue was diluted with EtOAc, the organic layer washed with Na<sub>2</sub>CO<sub>3</sub> solution, water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give <b>26</b> (48 g, 95%) as a light yellow colored oil. The ester <b>26</b> had a very strong odor and should be handled in a fume hood. Mass spectrum <i>m</i>/<i>z</i> 171 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.16 (q, <i>J</i> = 7.1 Hz, 2H), 2.78 (s, 1H), 2.55 (d, <i>J</i> = 8.3 Hz, 2H), 2.28–2.43 (m, 2H), 2.03–2.16 (m, 2H), 1.68–1.90 (m, 2H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_3_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Step C. 4-Bromo-2-hydrazinylbenzoic Acid (<b>27</b>)</h3><div class="NLM_p last">A solution of sodium nitrite (2.4 g, 35.5 mmol) in water (12 mL) was added dropwise to a suspension of 2-amino-4-bromobenzoic acid (7.3 g, 33.8 mmol) in concentrated aqueous hydrochloric acid (34 mL) at −5 °C at such a rate that the temperature did not exceed 0 °C. The resulting suspension was stirred at −5 °C for 10 min and was then added dropwise to a rapidly stirred solution of tin(II) chloride (13.5 g, 71.0 mmol) in concentrated aqueous hydrochloric acid (10 mL) at −5 °C at such a rate that the temperature did not exceed 0 °C. The resulting suspension was warmed to rt and stirred for 1 h. The precipitate was collected by filtration, washed with water, and air-dried to afford <b>27</b> (7.8 g, 86%) as a light-colored solid. Mass spectrum <i>m</i>/<i>z</i> 231.0, 233.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Step D. 5-Bromo-2-(ethoxycarbonyl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic Acid (<b>28</b>)</h3><div class="NLM_p last">A stirred suspension of <b>27</b> (16.4 g, 58.1 mmol) in acetic acid (171 mL) was treated with <b>26</b> (9.9 g, 58.1 mmol) at rt. The mixture was stirred at reflux for 2.5 h. The mixture was cooled to rt and concentrated to afford a brown solid. The solid was suspended in ethyl acetate (20 mL) and the precipitate was collected by filtration, washed with ethyl acetate and air-dried to provide <b>28</b> (11.5 g) as a colorless solid. The filtrate was concentrated, the residue resuspended in ethyl acetate, and the precipitate collected by filtration to provide additional <b>28</b> (0.8 g, total 12.3 g, 58%). Mass spectrum <i>m</i>/<i>z</i> 366.0, 368.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.10 (br s, 1H), 11.06 (s, 1H), 7.50 (d, <i>J</i> = 8.13 Hz, 1H), 7.19 (d, <i>J</i> = 8.13 Hz, 1H), 4.07–4.15 (m, 2H), 3.08–3.19 (m, 1H), 2.99–3.08 (m, 1H), 2.89–2.99 (m, 2H), 2.79–2.89 (m, 1H), 2.09–2.22 (m, 1H), 1.75–1.89 (m, 1H), 1.20 (t, <i>J</i> = 7.14 Hz, 3H).</div></div><div id="sec4_3_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Step E. Ethyl 5-Bromo-8-carbamoyl-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2-carboxylate (<b>29</b>)</h3><div class="NLM_p last">A suspension of acid <b>28</b> (12.3 g, 33.5 mmol), EDC (7.7 g, 40.2 mmol), and 1-hydroxybenzotriazole hydrate (6.2 g, 40.2 mmol) in THF–DCM (4:1, 335 mL) was treated with aqueous ammonium hydroxide (7.83 mL, 201 mmol), and the resulting suspension was stirred at rt overnight. The mixture was concentrated and the residue was suspended in water. The precipitate was collected by filtration, washed with water and ethyl acetate, and air-dried to give <b>29</b> (8.9 g). The filtrate was concentrated, and the residue was suspended in methanol. A solid was collected by filtration, washed with methanol, and air-dried to afford additional <b>29</b> (0.4 g, total 9.3 g, 76%). Mass spectrum <i>m</i>/<i>z</i> 365.1, 367.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.08 (s, 1H) 8.02 (br s, 1H), 7.43 (d, <i>J</i> = 8.13 Hz, 1H), 7.39 (br s, 1H), 7.14 (d, <i>J</i> = 8.13 Hz, 1H), 4.02–4.17 (m, 2H), 3.07–3.18 (m, 1H), 2.97–3.06 (m, 1H), 2.86–2.98 (m, 2H), 2.77–2.86 (m, 1H), 2.09–2.19 (m, 1H), 1.72–1.86 (m, 1H), 1.20 (t, <i>J</i> = 7.14 Hz, 3H).</div></div><div id="sec4_3_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Step F. Ethyl 5-Bromo-8-carbamoyl-9<i>H</i>-carbazole-2-carboxylate (<b>30</b>)</h3><div class="NLM_p last">To a suspension of <b>29</b> (60 g, 164 mmol) in THF (400 mL) was added 4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile (78 g, 345 mmol) portionwise at rt. After 1 h, the reaction mixture was added to an aqueous NaOH solution (1 N NaOH (500 mL) and water (725 mL)), the resulting suspension filtered and washed with water. The resulting material was dried in vacuo at 50 °C to obtain <b>30</b> (51 g, 86%) as a yellow solid. LCMS <i>m</i>/<i>z</i> 360.9, 362.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.00 (s, 1H), 8.69 (d, <i>J</i> = 8.4 Hz, 1H), 8.50 (d, <i>J</i> = 0.9 Hz, 1H), 8.23 (br s, 1H), 7.92 (d, <i>J</i> = 8.1 Hz, 1H), 7.86 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.59 (br s, 1H), 7.50 (d, <i>J</i> = 8.1 Hz, 1H), 4.36 (q, <i>J</i> = 7.2 Hz, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_3_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Step G. 5-Bromo-8-carbamoyl-9<i>H</i>-carbazole-2-carboxylic Acid (<b>34</b>)</h3><div class="NLM_p last">A solution of <b>30</b> (7.2 g, 19.1 mmol) and LiOH monohydrate (1.4 g, 57.2 mmol) in THF/EtOH/H<sub>2</sub>O (3:1:1, 201 mL) was heated at reflux for 6 h. The reaction mixture was cooled to rt and concentrated. The resulting residue was suspended in water, and the pH was adjusted to ∼2–3 with 1 N aqueous HCl. The resulting precipitate was collected by filtration, washed with water, and dried to provide <b>34</b> (7 g, 99%) as an off-white solid. LCMS <i>m</i>/<i>z</i> 333, 335 (M + H)<sup>+</sup>, 316, 318 (M + H – NH<sub>3</sub>)<sup>+</sup>.</div></div><div id="sec4_3_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Step H. 4-Bromo-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide (<b>35</b>)</h3><div class="NLM_p last">A suspension of <b>34</b> (7.0 g, 18.9 mmol), EDC (5.1 g, 26.5 mmol), and 1-hydroxybenzotriazole hydrate (4.1 g, 26.5 mmol) in THF/DCM/DMF (378 mL, 4:1:1) was treated with 1-methylpiperazine (6.3 mL, 56.7 mmol). The mixture was stirred at rt overnight, then was concentrated under vacuum. The resulting residue was partitioned between DCM/MeOH (8:1) and saturated aqueous NaHCO<sub>3</sub>. The aqueous phase was extracted twice again with DCM/MeOH (8:1), and the combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The resulting residue was suspended in ethyl acetate and allowed to stand overnight, forming a precipitate which was collected by filtration, washed with ethyl acetate, and dried. The filtrates were concentrated under vacuum, and the residue was triturated with ethyl acetate–methanol to provide additional precipitate, which was collected by filtration and dried. The process was repeated to yield additional precipitate. The dried precipitates were combined to provide <b>35</b> (7.5 g, 96%) as a peach-colored solid. LCMS <i>m</i>/<i>z</i> 415, 417 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.57 (d, <i>J</i> = 8.1 Hz, 1H), 8.20 (br s, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 1H), 7.79 (s, 1H), 7.56 (br s, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 7.22 (d, <i>J</i> = 8.1 Hz, 1H), 3.70–3.30 (m, 4H), 2.39–2.20 (m, 4H), 2.16 (s, 3H).</div></div><div id="sec4_3_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Step I. 2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline</h3><div class="NLM_p last">A mixture of 3-bromo-2-methylaniline (4.0 g, 21.5 mmol), bis(pinacolato)diboron (6.5 g, 25.8 mmol), and potassium acetate (4.2 g, 43.0 mmol) in 1,4-dioxane (44.8 mL) and DMSO (9 mL) was bubbled with nitrogen for 10 min. PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (0.53 g, 0.64 mmol) was added, and the mixture was degassed for another 5 min, then was heated to reflux. After 2 h, the mixture was cooled to rt, filtered through Celite, and the solids were washed with ethyl acetate. The combined filtrates were washed sequentially with water and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The resulting residue was purified by chromatography (eluting with ethyl acetate–hexanes, 5:95, then 15:85) to provide 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline as an off-white solid (4.4 g, 88%).</div></div><div id="sec4_3_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Step J. 4-(3-Amino-2-methylphenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide (<b>7a</b>)</h3><div class="NLM_p last">A mixture of <b>35</b> (3.0 g, 7.2 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.4 g, 0.36 mmol), 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (9 mL, 18.1 mmol), and 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2 g, 8.7 mmol) in toluene–ethanol (4:1, 181 mL) under nitrogen was heated at 90 °C for 11 h. The mixture was cooled to rt and treated with water, saturated aqueous NaHCO<sub>3</sub>, and ethyl acetate. An insoluble gummy solid was formed. The supernatant phases were decanted, and the organic phase was separated and washed with brine. The gummy solid was dissolved in MeOH, combined with the ethyl acetate phase, and the combined solution was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was suspended in ethyl acetate, forming a precipitate which was collected by filtration, washed with ethyl acetate, and dried. Additional solid was isolated from the filtrates, and the combined solids were triturated with ethyl acetate to provide <b>7a</b> (2.45 g, 77%) as a white solid. LCMS <i>m</i>/<i>z</i> 442.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.65 (s, 1H), 8.19 (br s, 1H), 8.00 (d, <i>J</i> = 7.9 Hz, 1H), 7.75 (s, 1H), 7.51 (br s, 1H), 7.09–7.01 (m, 1H), 6.98–6.85 (m, 3H), 6.82–6.76 (m, 1H), 6.47 (d, <i>J</i> = 6.2 Hz, 1H), 5.02 (s, 2H), 3.74–3.22 (m, 4H), 2.29 (s, 4H), 2.18 (s, 3H), 1.71 (s, 3H).</div></div><div id="sec4_3_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Step K. 4-(3-(4-Fluorobenzamido)-2-methylphenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide, TFA (<b>5</b>)</h3><div class="NLM_p last">To a solution of <b>7a</b> (26 mg, 0.059 mmol) and DIEA (0.031 mL, 0.177 mmol) in THF (2 mL) was added 4-fluorobenzoyl chloride (0.014 mL, 0.118 mmol). The reaction mixture was stirred at rt overnight and concentrated. The resulting crude residue was purified by preparative HPLC to give a TFA salt of <b>5</b> (23 mg, 59%) as a white solid. LCMS <i>m</i>/<i>z</i> 564.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77 (s, 1H), 10.15 (s, 1H), 9.81 (br s, 1H), 8.26 (br s, 1H), 8.14–8.03 (m, 3H), 7.85 (s, 1H), 7.63–7.48 (m, 2H), 7.46–7.32 (m, 3H), 7.22 (d, <i>J</i> = 7.3 Hz, 1H), 7.08–6.99 (m, 3H), 3.32–2.99 (m, 7H), 2.82 (s, 3H), 1.91 (s, 3H).</div></div><div id="sec4_3_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 7-(2-Hydroxypropan-2yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4<i>H</i>)-yl))phenyl-9<i>H</i>-carbazole-1-carboxamide (<b>6</b>). Step A. 4-Bromo-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>31</b>)</h3><div class="NLM_p last">To a solution of <b>30</b> in THF (600 mL) at −75 °C was added dropwise 1.6 N methyllithium solution in hexane (529 mL, 847 mmol). The addition temperature was maintained below −60 °C. There was a heavy yellow suspension observed, requiring the addition of more THF (200 mL) to maintain stirring. The reaction mixture was stirred for 30 min at −75 °C, then quenched by the slow addition of MeOH (132 mL), followed by 6 N HCl (190 mL) to adjust the pH to 2–3. The reaction mixture was allowed to warm to rt and the layers were separated. The acidic aqueous layer was back extracted with EtOAc (300 mL), and both organic layers were combined, washed with saturated NaHCO<sub>3</sub> solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and treated with activated charcoal and stirred for 30 min at rt. The suspension was filtered through Celite, the filtrate concentrated, and the resulting residue was triturated with anhydrous ether (250 mL) and stirred for 1 h at rt. The resulting solid was filtered and dried to give <b>31</b> (40 g, 84%). LCMS <i>m</i>/<i>z</i> 331 (M + H – H<sub>2</sub>O)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (s, 1H), 8.48 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (br s, 1H), 7.93 (d, <i>J</i> = 1.1 Hz, 1H), 7.80 (d, <i>J</i> = 8.1 Hz, 1H), 7.57–7.44 (m, 1H), 7.42–7.32 (m, 2H), 5.07 (s, 1H), 1.50 (s, 6H).</div></div><div id="sec4_3_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Step B. 3-(3-Bromo-2-methylphenyl)quinazolin-4(3<i>H</i>)-one (<b>50</b>)</h3><div class="NLM_p last">A mixture of anthranilic acid (80 g, 583 mmol), 3-bromo-2-methylaniline (109 g, 583 mmol), and triethyl orthoformate (86 g, 583 mmol) in toluene (800 mL) was heated to 85 °C to distill off ethanol. After the distillation was complete, the reaction mixture was refluxed at 110 °C for 16 h with a Dean–Stark apparatus to collect water. After cooling to rt, the reaction mixture was concentrated and the resulting residue was dissolved in EtOAc (600 mL). The organic layer was washed with saturated NaHCO<sub>3</sub> solution, water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The resulting solid was triturated with anhydrous ether for 30 min at rt and collected by filtration to give <b>50</b> (115 g, 63%) as an off white solid. LCMS <i>m</i>/<i>z</i> 314.0, 316.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 7.97 (s, 1H), 7.94 (dd, <i>J</i> = 7.2, 1.7 Hz, 1H), 7.85–7.77 (m, 2H), 7.56 (ddd, <i>J</i> = 8.0, 6.4, 1.9 Hz, 1H), 7.38–7.33 (m, 1H), 7.33–7.29 (m, 1H), 2.37 (s, 3H).</div></div><div id="sec4_3_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Step C. 3-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (<b>51</b>)</h3><div class="NLM_p last">A mixture of <b>50</b> (60 g, 190 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (3.9 g, 4.8 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (53.2 g, 209 mmol), and potassium acetate (56.1 g, 571 mmol) in dioxane (500 mL) was heated to reflux for 1 h. The reaction mixture was cooled to rt and concentrated. The resulting dark residue was dissolved in EtOAc (400 mL), washed twice with water, the organic layer filtered through Celite and dried over Na<sub>2</sub>SO<sub>4</sub> with activated charcoal for 30 min at rt. The mixture was filtered through Celite, concentrated, and purified in three portions by chromatography (eluting with EtOAc/hexanes, 0–35% gradient) to obtain <b>51</b> (45 g, 65%). LCMS <i>m</i>/<i>z</i> 363.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (dq, <i>J</i> = 8.0, 0.6 Hz, 1H), 7.96 (s, 1H), 7.94 (dd, <i>J</i> = 7.2, 1.7 Hz, 1H), 7.86–7.74 (m, 2H), 7.56 (ddd, <i>J</i> = 8.0, 6.4, 1.9 Hz, 1H), 7.39–7.32 (m, 1H), 7.32–7.29 (m, 1H), 2.37 (s, 3H), 1.35 (s, 12H).</div></div><div id="sec4_3_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Step D. 7-(2-Hydroxypropan-2yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4<i>H</i>)-yl))phenyl-9<i>H</i>-carbazole-1-carboxamide (<b>6</b>)</h3><div class="NLM_p last">To a mixture of <b>31</b> (24 g, 69.1 mmol) and <b>51</b> (27.5 g, 76 mmol) in toluene (360 mL) and ethanol (120 mL) were added 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (104 mL, 208 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (3.99 g, 3.46 mmol). The reaction mixture was then heated to 75–80 °C for 16 h. After cooling to rt, the precipitated gray solid was collected by filtration, was suspended in THF (120 mL) and heated at 65 °C for 2 h. After cooling to rt, the dark solution was filtered through Celite to remove Pd material. The filtrate was divided into 3 equal portions and purified by chromatography (eluting with MeOH–DCM, 2–7% gradient) to give <b>6</b> (18 g, 52%) as a colorless solid and as a mixture of four atropisomers. CHN analysis, calcd for C<sub>31</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>·0.79H<sub>2</sub>O: C, 72.04, H, 5.38, N, 10.84, H<sub>2</sub>O, 2.76. Found: C, 72.27, H, 5.25, N, 10.88, H<sub>2</sub>O, 2.76; Pd 27 ppm. LCMS <i>m</i>/<i>z</i> 503.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO<i>-d</i><sub>6</sub>) δ 11.43 (s, 0.6H), 11.42 (s, 0.4H), 8.48 (s, 0.4H), 8.41 (s, 0.6H), 8.26 (dd, <i>J</i> = 8.04, 1.22 Hz, 0.4H), 8.23 (dd, <i>J</i> = 8.04, 1.22 Hz, 0.6H), 8.15 (br s, 2H), 8.00 (d, <i>J</i> = 7.79 Hz, 0.4H), 7.99 (d, <i>J</i> = 7.79 Hz, 0.6H), 7.88–7.92 (m, 1H), 7.86 (dd, <i>J</i> = 7.91, 1.10 Hz, 1H), 7.79 (d, <i>J</i> = 5.11 Hz, 0.6H), 7.77 (d, <i>J</i> = 5.36 Hz, 0.4H), 7.62–7.67 (m, 1H), 7.60–7.62 (m, 1H), 7.58 (t, <i>J</i> = 7.30 Hz, 1H), 7.48 (dd, <i>J</i> = 7.55, 1.22 Hz, 0.4H), 7.46 (dd, <i>J</i> = 7.43, 1.10 Hz, 0.6H), 7.12–7.14 (m, 0.4H), 7.11 (dd, <i>J</i> = 5.84, 1.70 Hz, 0.6H), 7.06 (d, <i>J</i> = 8.28 Hz, 0.6H), 7.03 (d, <i>J</i> = 7.79 Hz, 0.4H), 7.00 (d, <i>J</i> = 7.79 Hz, 0.6H), 6.85 (d, <i>J</i> = 8.52 Hz, 0.4H), 5.00 (s, 0.6H), 4.97 (s, 0.4H), 1.79 (s, 1.5H), 1.76 (s, 1.5H), 1.47 (d, <i>J</i> = 4.38 Hz, 3H), 1.46 (d, <i>J</i> = 1.22 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO<i>-d</i><sub>6</sub>) δ 169.00, 168.97, 159.80, 159.78, 148.89 (s, 2C), 147.94 (s, 2C), 147.34, 147.29, 141.51 (s, 2C), 140.36 (s, 2C), 139.01, 138.96, 137.81, 137.70, 137.42, 137.24, 134.75, 134.70, 134.00, 133.56, 130.21, 130.13, 128.19, 128.08, 127.52, 127.50, 127.43, 127.39, 127.18, 127.08, 126.48, 126.40, 124.13, 124.03, 121.88, 121.84, 121.80, 121.62, 120.42, 119.94, 119.07, 119.02, 118.48, 118.37, 116.88, 116.60, 114.97, 114.93, 108.01, 107.87, 70.94, 70.92, 32.39, 32.27, 32.12, 32.05, 14.55, 14.48. Numerous carbons were split due to the diastereomeric nature of the mixture of atropisomers.</div></div><div id="sec4_3_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-(3-(5-Fluoropicolinamido)-2-methylphenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide (<b>10</b>)</h3><div class="NLM_p last">A mixture of <b>7a</b> (100 mg, 0.2 mmol), 5-fluoropicolinic acid (43.1 mg, 0.31 mmol), and 1-hydroxy-7-azabenzotriazole (41.6 mg, 0.31 mmol) in acetonitrile (2 mL) was treated with diisopropylethylamine (0.053 mL, 0.31 mmol) and EDC (78 mg, 0.41 mmol). After 18 h at rt, the mixture was diluted with methanol and purified by preparative HPLC (Phenomenex AXIA C<sub>18</sub> 21.2 mm × 100 mm, 5–95% methanol–water containing 0.1% TFA, 10 min, 20 mL/min, 220 nm). The aqueous residue from partial concentration of the appropriate effluent fractions was made basic with saturated aqueous NaHCO<sub>3</sub> and extracted with ethyl acetate (3×). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to provide <b>10</b> as a light gray powder (111.5 mg, 92%). LCMS <i>m</i>/<i>z</i> 565.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.58 (d, <i>J</i> = 3.1 Hz, 1H), 8.31 (dd, <i>J</i> = 8.8, 4.8 Hz, 1H), 7.96–8.03 (m, 2H), 7.82 (td, <i>J</i> = 8.6, 2.6 Hz, 1H), 7.68 (d, <i>J</i> = 0.9 Hz, 1H), 7.45 (t, <i>J</i> = 7.9 Hz, 1H), 7.23 (dd, <i>J</i> = 7.5, 0.9 Hz, 1H), 7.09 (d, <i>J</i> = 7.9 Hz, 1H), 7.03–7.08 (m, 1H), 6.95–7.00 (m, 1H), 3.78 (br s, 2H), 3.49 (br s, 2H), 2.52 (br s, 2H), 2.40 (br s, 2H), 2.31 (s, 3H), 2.04 (s, 3H). Contains 0.33 equiv (5% by weight) residual ethyl acetate.</div></div><div id="sec4_3_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-(3-(4-Fluorobenzamido)-2-methylphenyl)-7-(isopropylamino)-9<i>H</i>-carbazole-1-carboxamide (<b>11</b>). Step A. Benzyl 5-Bromo-8-carbamoyl-9<i>H</i>-carbazol-2-ylcarbamate (<b>36</b>)</h3><div class="NLM_p last">To a suspension of <b>34</b> (4.6 g, 12.6 mmol) and 4 Å molecular sieves (4.6 g) in 1,4-dioxane (126 mL) at 50 °C were added Et<sub>3</sub>N (4.3 mL, 31 mmol) and diphenylphosphoryl azide (6.7 mL, 31 mmol). The mixture was stirred at 50 °C for 1.5 h at which point phenylmethanol (13 mL, 126 mmol) was added, and the reaction temperature was increased to 85 °C. After 18 h, the reaction mixture was cooled to rt, filtered through Celite, the solid washed with MeOH, EtOAc, and acetone. The filtrates were concentrated to afford crude <b>36</b> as a light brown syrup. The syrup was triturated with MeOH, the resulting solid collected by filtration, washed with MeOH, and dried. The resulting filtrates were concentrated, triturated with MeOH again, and the solid was collected by filtration. The pale solids were combined to give <b>36</b> (5.1 g, 91%). LCMS <i>m</i>/<i>z</i> 437.9, 439.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 1H), 9.98 (s, 1H), 8.43 (d, <i>J</i> = 8.6 Hz, 1H), 8.16 (br s, 1H), 8.06 (s, 1H), 7.76 (d, <i>J</i> = 8.3 Hz, 1H), 7.60–7.23 (m, 8H), 5.19 (s, 2H).</div></div><div id="sec4_3_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Step B. Benzyl 5-(3-Amino-2-methylphenyl)-8-carbamoyl-9<i>H</i>-carbazol-2-ylcarbamate</h3><div class="NLM_p last">A suspension of <b>36</b> (1 g, 2.3 mmol), (Ph<sub>3</sub>P)<sub>4</sub>Pd (0.13 g, 0.11 mmol), 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (2.8 mL, 5.7 mmol), and 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.64 g, 2.7 mmol) in toluene/EtOH (4/1) (57 mL) under nitrogen was heated at 90 °C for 10 h. After cooling to rt, the reaction mixture was filtered through Celite, which was washed with EtOAc. The filtrates were partitioned between EtOAc and water, the organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford a yellow colored solid. The crude product was triturated with MeOH to give benzyl 5-(3-amino-2-methylphenyl)-8-carbamoyl-9<i>H</i>-carbazol-2-ylcarbamate as an off-white solid (0.86 g in 82%). LCMS <i>m</i>/<i>z</i> 465.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 9.82 (s, 1H), 8.14 (br s, 1H), 7.97 (d, <i>J</i> = 1.3 Hz, 1H), 7.91 (d, <i>J</i> = 7.5 Hz, 1H), 7.47 (br s, 1H), 7.45–7.31 (m, 5H), 7.30–7.24 (m, 1H), 7.17 (d, <i>J</i> = 7.5 Hz, 1H), 6.97–6.86 (m, 3H), 6.67 (d, <i>J</i> = 8.8 Hz, 1H), 5.15 (s, 2H), 1.84 (s, 3H) (some exchangeable protons diffuse and not observed).</div></div><div id="sec4_3_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Step C. Benzyl 8-Carbamoyl-5-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazol-2-ylcarbamate</h3><div class="NLM_p last">To a mixture of benzyl 5-(3-amino-2-methylphenyl)-8-carbamoyl-9<i>H</i>-carbazol-2-ylcarbamate (700 mg, 1.5 mmol) and Hunig’s base (1 mL, 6 mmol) in THF (80 mL) at rt was added 4-fluorobenzoyl chloride (0.36 mL, 3 mmol). After 1 h the reaction mixture was concentrated, then partitioned between DCM, water, and sat. NaHCO<sub>3</sub>. The organic phases were separated, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The resulting residue was purified by chromatography (eluting with hexane/EtOAc, 70/30–50/50–30/70) to give benzyl 8-carbamoyl-5-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazol-2-ylcarbamate (721 mg, 82%) as an off-white foamy solid. LCMS <i>m</i>/<i>z</i> 587.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 10.13 (s, 1H), 9.82 (s, 1H), 8.08 (dd, <i>J</i> = 9.0, 5.5 Hz, 2H), 7.98 (d, <i>J</i> = 1.3 Hz, 1H), 7.93 (d, <i>J</i> = 7.7 Hz, 1H), 7.50–7.33 (m, 11H), 7.20 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 6.95 (d, <i>J</i> = 7.7 Hz, 2H), 6.79 (d, <i>J</i> = 8.8 Hz, 1H), 5.16 (s, 2H), 1.89 (s, 3H).</div></div><div id="sec4_3_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Step D. 7-Amino-4-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>9a</b>)</h3><div class="NLM_p last">A suspension of benzyl 8-carbamoyl-5-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazol-2-ylcarbamate (720 mg, 1.2 mmol) in hydrogen bromide in acetic acid (2.45 mL, 12.3 mmol) was stirred at rt for 1 h. To the above suspension was added EtOAc, water, and 1 M NaOH to give a basic aqueous layer (pH ≈ 9). The organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was then triturated with EtOAc to give 7-amino-4-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>9a</b>) (0.33 g, 59%) as a greenish-yellow solid. LCMS <i>m</i>/<i>z</i> 453.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.02 (s, 1H), 10.11 (s, 1H), 8.09 (dd, <i>J</i> = 8.8, 5.3 Hz, 3H), 7.78 (d, <i>J</i> = 7.9 Hz, 1H), 7.48–7.43 (m, 1H), 7.42–7.32 (m, 4H), 7.18 (dd, <i>J</i> = 7.5, 0.9 Hz, 1H), 6.89–6.75 (m, 2H), 6.60 (d, <i>J</i> = 8.8 Hz, 1H), 6.21 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 5.18 (s, 2H), 1.90 (s, 3H).</div></div><div id="sec4_3_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Step E. 4-(3-(4-Fluorobenzamido)-2-methylphenyl)-7-(isopropylamino)-9<i>H</i>-carbazole-1-carboxamide (<b>11</b>)</h3><div class="NLM_p last">A suspension of 7-amino-4-(3-(4-fluorobenzamido)-2-methylphenyl)-9<i>H</i>-carbazole-1-carboxamide (30 mg, 0.066 mmol), acetone (0.019 mL, 0.265 mmol), and sodium triacetoxyborohydride (35.1 mg, 0.166 mmol) in DCM/THF (3 mL, 2/1) was stirred at rt overnight. After 18 h, the reaction mixture was concentrated, dissolved in DMF, and purified by prep HPLC to give <b>11</b> (11 mg, 24%) as a pale solid. LCMS <i>m</i>/<i>z</i> 495.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.12–8.01 (m, 3H), 7.66 (d, <i>J</i> = 1.4 Hz, 1H), 7.55–7.50 (m, 1H), 7.46 (t, <i>J</i> = 7.8 Hz, 1H), 7.33–7.20 (m, 4H), 7.15 (d, <i>J</i> = 7.8 Hz, 1H), 6.97 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 3.80 (dt, <i>J</i> = 13.0, 6.5 Hz, 1H), 1.99 (s, 3H), 1.35 (dd, <i>J</i> = 6.2, 5.1 Hz, 6H).</div></div><div id="sec4_3_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-(2-Methyl-3-(1-oxoisoindolin-2-yl)phenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide (<b>12</b>). Step A. 2-(3-Bromo-2-methylphenyl)isoindolin-1-one (<b>39a</b>)</h3><div class="NLM_p last">To a solution of 3-bromo-2-methylaniline (2 g, 10.8 mmol) in DCM (25 mL) and TEA (3 mL, 21.5 mmol) at rt was slowly added a DCM (10 mL) solution of 2-(chloromethyl)benzoyl chloride (2 g, 10.8 mmol) over 1.5 h. The reaction mixture was then washed with water and brine and concentrated to give <i>N</i>-(3-bromo-2-methylphenyl)-2-(chloromethyl)benzamide as a tan solid. A 60% oil dispersion of NaH (0.86 g, 21.5 mmol) was washed twice with hexanes and suspended in tetrahydrofuran (25 mL). To this suspension was slowly added a THF (50 mL) solution of <i>N</i>-(3-bromo-2-methylphenyl)-2-(chloromethyl)benzamide. After the addition was complete the mixture was stirred at rt for 1 h. The reaction mixture was then diluted with DCM and quenched carefully with methanol, washed with water, brine, and concentrated to give <b>39a</b> (1.9 g, 60%) as a tan solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 301.9, 303.9.</div></div><div id="sec4_3_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Step B. 2-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoindolin-1-one (<b>40a</b>)</h3><div class="NLM_p last">Nitrogen was bubbled into a mixture of <b>39a</b> (1.5 g, 5 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.9 g, 7.4 mmol), and potassium acetate (1.5 g, 14.9 mmol) in dioxane (40 mL) for 10 min, followed by the addition of PdCl2(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (0.12 g, 0.15 mmol). The resulting mixture was heated to reflux for 4 h and diluted with ethyl acetate. The resulting mixture was filtered, the filtrate washed with water and again filtered. The resulting solution was concentrated and the residue purified by chromatography (eluting with EtOAc/hexane, 10–50% gradient) to give <b>40a</b> (1.2 g, 69%) as a light yellow sticky foam. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 350.1.</div></div><div id="sec4_3_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Step C. 4-(2-Methyl-3-(1-oxoisoindolin-2-yl)phenyl)-7-(4-methylpiperazine-1-carbonyl)-9<i>H</i>-carbazole-1-carboxamide (<b>12</b>)</h3><div class="NLM_p last">To a mixture of <b>35</b> (52 mg, 0.12 mmol) and <b>40a</b> (52 mg, 0.15 mmol) in toluene (3 mL) and ethanol (1 mL) were added 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.19 mL, 0.38 mmol) and then Pd(Ph<sub>3</sub>P)<sub>4</sub> (7.2 mg, 6.3 μmol). The reaction mixture was heated at 100 °C for 8 h and then diluted with ethyl acetate. The mixture was washed with water and the organic layer concentrated. The resulting residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/DCM, 50–100% gradient) to give <b>12</b> (44 mg), which was further purified by prep HPLC (Phenomenex Luna Axia, 5 μm, 21 mm × 100 mm; solvent A consisting of 10% MeOH–90% H<sub>2</sub>O–0.1% TFA; solvent B consisting of 90% MeOH–10% H<sub>2</sub>O–0.1% TFA; gradient, 0–100% B; gradient time, 10 min; flow rate, 30 mL/min; wavelength, 220 nm) to give <b>12</b> (30 mg, 44%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 558.2; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.68 (s, 1 H), 7.97 (d, <i>J</i> = 8.35 Hz, 1H), 7.70 (d, <i>J</i> = 7.47 Hz, 1H), 7.63 (t, <i>J</i> = 6.81 Hz, 1H), 7.51–7.58 (m, 3H), 7.46 (d, <i>J</i> = 3.95 Hz, 2H), 7.33–7.39 (m, 1H), 7.08–7.16 (m, 3H), 4.83 (s, 2H), 3.30–4.04 (m, 4H), 2.34–2.61 (m, 4H), 2.32 (s, 3H), 1.93 (s, 3H) (some exchangeable protons diffuse and not observed).</div></div><div id="sec4_3_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-oxoisoindolin-2-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>13</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (40 mg, 0.12 mmol), <b>40a</b> (40 mg, 0.12 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (6.7 mg, 5.8 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.14 mL, 0.28 mmol) in toluene (2 mL) and EtOH (0.5 mL) was heated at 90 °C for 16 h. After cooling to rt, the reaction mixture was diluted with DMF (1 mL), filtered, and purified by preparative HPLC. The product containing fractions were collected, basified with 1 N NaOH, and extracted twice with DCM. The combined organic phases were washed with water and concentrated. The resulting residue was purified further by chromatography (eluting with a gradient from 100% DCM to 0.8:7.2:92 ammonia–MeOH–DCM) to give <b>13</b> as a white solid (25 mg, 42%). Mass spectrum <i>m</i>/<i>z</i> 472.2 (M – OH)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.95 (d, <i>J</i> = 7.92 Hz, 1H), 7.89 (d, <i>J</i> = 7.48 Hz, 1H), 7.76 (d, <i>J</i> = 1.10 Hz, 1H), 7.65–7.73 (m, 2H), 7.48–7.61 (m, 3H), 7.41 (dd, <i>J</i> = 7.04, 1.76 Hz, 1H), 7.17 (dd, <i>J</i> = 8.36, 1.54 Hz, 1H), 7.04–7.10 (m, 2H), 4.96 (s, 2H), 1.92 (s, 3H), 1.61 (d, <i>J</i> = 3.74 Hz, 6H).</div></div><div id="sec4_3_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-(3-(6-Fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>14</b>). Step A. <i>N</i>-(3-Bromo-2-methylphenyl)-2-(bromomethyl)-5-fluorobenzamide</h3><div class="NLM_p last">To a solution of 2-(bromomethyl)-5-fluorobenzoic acid (3.1 g, 13.1 mmol) in DCM (50 mL) at rt were added 6 drops of DMF and oxalyl dichloride (1.7 g, 13.1 mmol). After 1 h, the reaction was concentrated, redissolved in DCM, and concentrated again. The resulting residue was redissolved in DCM (50 mL), and 3-bromo-2-methylaniline (1.7 g, 9.1 mmol) was added. After stirring for 1 h, Et<sub>3</sub>N (2.9 mL, 15.7 mmol) was added portionwise. The reaction mixture was diluted with DCM (100 mL) after 2 h, the organic layer washed with sat. NaHCO<sub>3</sub>, water, and concentrated. The resulting solid residue was triturated with DCM to give <i>N</i>-(3-bromo-2-methylphenyl)-2-(bromomethyl)-5-fluorobenzamide (1.4 g). The mother liquor was purified by chromatography (eluting with ethyl acetate/hexane, 0–70% gradient) to give additional material (2.5 g total, 48%) suitable for the subsequent reaction.</div></div><div id="sec4_3_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Step B. 2-(3-Bromo-2-methylphenyl)-6-fluoroisoindolin-1-one (<b>39b</b>)</h3><div class="NLM_p last">A mixture of <i>N</i>-(3-bromo-2-methylphenyl)-2-(bromomethyl)-5-fluorobenzamide (2.5 g, 6.3 mmol) and sodium <i>tert</i>-butoxide (0.91 g, 9.5 mmol) in THF (80 mL) was stirred at rt for 30 min. The reaction mixture was quenched with water, extracted with DCM twice, the combined organic phases were washed with water and concentrated. The resulting residue was purified by chromatography (eluting with hexane/ethyl acetate) to give <b>39b</b> (1.18 g, 59%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 319.9, 321.9.</div></div><div id="sec4_3_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Step C. 6-Fluoro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoindolin-1-one (<b>40b</b>)</h3><div class="NLM_p last">A solution of <b>39b</b> (1.3 g, 4.1 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.6 g, 6.1 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (0.17 g, 0.2 mmol), and potassium acetate (1.2 g, 12.2 mmol) in dioxane (20 mL) was heated at 90 °C overnight. The reaction mixture was diluted with DCM, washed with water, the organic layer separated, and the aqueous layer was extracted twice more with DCM. The combined organic extracts were concentrated and the crude material was purified by chromatography (eluting with EtOAc/hexane, 0–50% gradient) to give <b>40b</b> (1.35 g, 86%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 368.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82 (dd, <i>J</i> = 6.93, 1.87 Hz, 1H), 7.63 (dd, <i>J</i> = 7.59, 2.31 Hz, 1H), 7.47 (dd, <i>J</i> = 8.25, 4.29 Hz, 1H), 7.27–7.34 (m, 3H), 4.65 (s, 2H), 2.41 (s, 3H), 1.32–1.37 (m, 12H).</div></div><div id="sec4_3_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Step D. 4-(3-(6-Fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>14</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (30 mg, 0.09 mmol), <b>40b</b> (41 mg, 0.11 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (5 mg, 4.3 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.13 mL, 0.26 mmol) in toluene (3 mL) and ethanol (1 mL) was heated at 100 °C for 9 h. The reaction mixture was cooled to rt, partitioned between water and ethyl acetate, and the organics concentrated to give a yellow solid. The crude material was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/DCM, 10–30% gradient) to give <b>14</b> (28 mg, 59%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H – H<sub>2</sub>0)<sup>+</sup> = 490.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.60 (s, 1H), 7.70 (d, <i>J</i> = 1.10 Hz, 1H), 7.63–7.68 (m, 2H), 7.52 (dd, <i>J</i> = 8.36, 4.40 Hz, 1H), 7.44–7.48 (m, 2H), 7.31–7.41 (m, 2H), 7.21 (dd, <i>J</i> = 8.36, 1.76 Hz, 1H), 7.06–7.11 (m, 2H), 4.82 (s, 2H), 2.01 (s, 1H), 1.97 (s, 3H), 1.66 (s, 6H) (some exchangeable protons diffuse and not observed).</div></div><div id="sec4_3_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>15</b>). Step A. 7-(2-Hydroxypropan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>33</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (5 g, 14.4 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (4.4 g, 17.3 mmol), potassium acetate (4.2 g, 43.2 mmol), and PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (0.59 g, 0.72 mmol) was equally divided into two large pressure reaction vials, suspended in dioxane (30 mL), sealed, and heated at 110 °C for 4.5 h. The two reaction mixtures were then combined, diluted with ethyl acetate, washed with water, filtered through Celite, and concentrated. The resulting black residue was purified by chromatography (eluting with EtOAc/hexane, 50–100% gradient) to give <b>33</b> (3.9 g, 67%). LCMS <i>m</i>/<i>z</i> 376.9 (M + H – OH)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.55 (br s, 1H), 8.92 (d, <i>J</i> = 8.6 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.59–7.52 (m, 2H), 7.43 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 1.49 (s, 12H) (some exchangeable protons diffuse and not observed).</div></div><div id="sec4_3_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Step B. 3,4-Dihydroisoquinolin-l(2<i>H</i>)-one (<b>46</b>)</h3><div class="NLM_p last">A solution of 2,3-dihydro-1<i>H</i>-inden-1-one (1 g, 7.6 mmol) in DCM (10 mL) was treated with methanesulfonic acid (10 mL) and cooled to 0 °C. Sodium azide (0. 98 g, 15.1 mmol) was added, and the mixture was stirred at 0 °C for 2 h, then at rt overnight. The mixture was made basic with 20% aqueous sodium hydroxide and extracted with DCM. The organic phase was washed with water, dried, and concentrated. The resulting residue was purified by chromatography (eluting with hexane–EtOAc) to provide 3,4-dihydroisoquinolin-l (2<i>H</i>)-one <b>46</b> as a colorless oil (162 mg, 15%). Mass spectrum <i>m</i>/<i>z</i> 148.1 (M + H)<sup>+</sup>. 1H NMR (400 MHz, CD3OD) δ 7.93 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 7.44–7.52 (m, 1H), 7.35 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 3.50 (t, <i>J</i> = 6.6 Hz, 2H), 2.98 (t, <i>J</i> = 6.7 Hz, 2H).</div></div><div id="sec4_3_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Step C. 2-(3-Bromo-2-methylphenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>47</b>)</h3><div class="NLM_p last">A mixture of 1,3-dibromo-2-methylbenzene (340 mg, 1.36 mmol), <b>46</b> (100 mg, 0.68 mmol), and potassium carbonate (94 mg, 0.68 mmol) in DMSO (2 mL) was purged with nitrogen, treated with copper(I) iodide (26 mg, 0.14 mmol), and heated at 150 °C for 3.5 h. The mixture was combined with that from a second identical reaction using 1, 3-dibromo-2-methylbenzene (2.6 g, 10.4 mmol) and 3, 4-dihydroisoquinolin-l (2<i>H</i>)-one (508 mg, 3.4 mmol), diluted with DCM, and filtered through Celite. The filtrate was washed with 5% aqueous ammonium hydroxide, dried, and concentrated. The residue was purified by chromatography (eluting with hexane–EtOAc) to provide <b>47</b> as a yellow solid (142 mg, 11%). Mass spectrum <i>m</i>/<i>z</i> 315.9, 317.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (dd, <i>J</i> = 7.70, 1.10 Hz, 1H), 7. 55 (dd, <i>J</i> = 7. 92, 1.10 Hz, 1H), 7.46–7.51 (m, 1H), 7.37–7.42 (m, 1H), 7.24–7.28 (m, 1H), 7.17–7.21 (m, 1H), 7.09–7.16 (m, 1H), 3.95 (ddd, <i>J</i> = 12.21, 10.12, 4.73 Hz, 1H), 3.73 (ddd, <i>J</i> = 11.94, 6.33, 5.28 Hz, 1H), 3.26 (ddd, <i>J</i> = 15.74, 10.23, 5.28 Hz, 1H), 3.06–3.14 (m, 1H), 2.36 (s, 3H).</div></div><div id="sec4_3_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Step D. 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>15</b>)</h3><div class="NLM_p last">A mixture of <b>33</b> (40 mg, 0.1 mmol), <b>47</b> (38 mg, 0.12 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (5.9 mg, 5 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.13 mL, 0.25 mmol) was heated at 90 °C for 16 h. The reaction mixture was diluted with DCM, washed with water, separated, and the organic phase was concentrated. The resulting residue was purified twice by chromatography and then purified further by prep HPLC to give <b>15</b> (21 mg, 39%) as a white solid. Mass spectrum <i>m</i>/<i>z</i> 504.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.47–10.59 (m, 1H), 8.13–8.22 (m, 1H), 7.60–7.71 (m, 2H), 7.35–7.53 (m, 4H), 7.28–7.35 (m, 2H), 7.10–7.15 (m, 1H), 6.86–7.07 (m, 1H), 4.06–4.16 (m, 1H), 3.79–3.89 (m, 1H), 3.22–3.34 (m, 1H), 3.08–3.19 (m, 1H), 1.99–2.05 (m, 3H), 1.61–1.67 (m, 6H) (some exchangeable protons diffuse and not observed).</div></div><div id="sec4_3_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-oxoisoquinolin-2(1<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>16</b>). Step A. 2-(3-Bromo-2-methylphenyl)isoquinoline-1,3(2<i>H</i>,4<i>H</i>)-dione</h3><div class="NLM_p last">A mixture of 3-bromo-2-methylaniline (1 g, 5.4 mmol) and isochroman-1,3-dione (0.87 g, 5.4 mmol) in acetic acid (15 mL) was heated overnight at 100 °C. The solution was cooled to rt, concentrated, and purified by chromatography (eluting with EtOAc/hexane, 20–100% gradient) to give 2-(3-bromo-2-methylphenyl)isoquinoline-1,3(2<i>H</i>,4<i>H</i>)-dione (630 mg, 36%) as a tan solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 330.1, 332.1.</div></div><div id="sec4_3_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Step B. 2-(3-Bromo-2-methylphenyl)-3-hydroxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one</h3><div class="NLM_p last">A suspension of 2-(3-bromo-2-methylphenyl)isoquinoline-1,3(2<i>H</i>,4<i>H</i>)-dione (630 mg, 1.9 mmol) in methanol (100 mL) at rt was treated with NaBH<sub>4</sub> (caplets) (217 mg, 5.7 mmol). After 2 h, additional NaBH<sub>4</sub> (120 mg) was added. After 4 h, the reaction mixture was concentrated and partitioned between DCM and water. The organic layer was concentrated to give 2-(3-bromo-2-methylphenyl)-3-hydroxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (600 mg, 95%) as a light-yellow foam suitable for the subsequent reaction. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 332.1, 334.1.</div></div><div id="sec4_3_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Step C. 2-(3-Bromo-2-methylphenyl)isoquinolin-1(2<i>H</i>)-one (<b>43</b>)</h3><div class="NLM_p last">A solution of 2-(3-bromo-2-methylphenyl)-3-hydroxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (600 mg, 1.81 mmol) in DCM (30 mL) was treated with TFA (1.4 mL, 18.1 mmol). After 2 h, the reaction mixture was concentrated. The resulting residue was dissolved in DCM, washed with aqueous sodium bicarbonate and water and the organic layer concentrated. The residue was purified by chromatography (eluting with EtOAc/hexane, 20–60% gradient) to give <b>43</b> (380 mg, 67%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 314.0, 316.0.</div></div><div id="sec4_3_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Step D. 2-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoquinolin-1(2<i>H</i>)-one (<b>44</b>)</h3><div class="NLM_p last">A mixture of <b>43</b> (360 mg, 1.2 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (320 mg, 1.3 mmol), potassium acetate (337 mg, 3.4 mmol), and PdCl2(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (47 mg, 0.06 mmol) in dioxane (7 mL) was heated at 100 °C for 16 h. The reaction mixture was diluted with ethyl acetate, washed with water and the organic layer filtered through Celite and concentrated. The black colored residue was purified by chromatography (eluting with EtOAc/hexane, 10–60% gradient) to give <b>44</b> (280 mg, 68%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 362.2.</div></div><div id="sec4_3_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Step E. 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-oxoisoquinolin-2(1<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>16</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (50 mg, 0.14 mmol) and <b>44</b> (68 mg, 0.19 mmol) in toluene (3 mL) and ethanol (1 mL) was treated with 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.22 mL, 0.43 mmol) and Pd(Ph<sub>3</sub>P)<sub>4</sub> (8.3 mg, 7.2 μmol) and heated at 100 °C for 7 h. The reaction mixture was diluted with ethyl acetate, washed with water and the organic layer concentrated. The resulting residue was purified by chromatography (eluting with EtOAc), followed by further chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/DCM, 10–50% gradient) to give <b>16</b> (18 mg, 44%) as a white solid and as a mixture of atropisomers. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 502.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.53–10.64 (m, 1H), 8.52 (d, <i>J</i> = 8.14 Hz, 1H), 7.41–7.75 (m, 7H), 7.30–7.33 (m, 1H), 7.16–7.21 (m, 2H), 7.04–7.13 (m, 1H), 6.95 (d, <i>J</i> = 8.36 Hz, 1H), 6.64 (dd, <i>J</i> = 14.08, 7.48 Hz, 1H), 1.89 (d, <i>J</i> = 7.92 Hz, 3H), 1.66 (d, <i>J</i> = 2.86 Hz, 6H) (some exchangeable protons diffuse and not observed). Analytical HPLC showed 87–90% purity.</div></div><div id="sec4_3_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-(3-(5-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>17</b>). Step A. 3-(3-Bromo-2-methylphenyl)-5-fluoroquinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">A mixture of 5-fluoro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazine-2,4-dione (250 mg, 1.38 mmol), 3-bromo-2-methylaniline (257 mg, 1.38 mmol), and trimethoxymethane (439 mg, 4.14 mmol) in THF (2 mL) was heated at 100 °C for 15 h. The reaction mixture was concentrated and purified by chromatography (eluting with EtOAc/hexane, 10–40% gradient) to yield a yellow solid that was triturated with hexanes to give 3-(3-bromo-2-methylphenyl)-5-fluoroquinazolin-4(3<i>H</i>)-one (200 mg, 44%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 333.1, 335.1.</div></div><div id="sec4_3_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Step B. 5-Fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">A mixture of 3-(3-bromo-2-methylphenyl)-5-fluoroquinazolin-4(3<i>H</i>)-one (200 mg, 0.6 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (230 mg, 0.9 mmol), potassium acetate (177 mg, 1.8 mmol), and PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (25 mg, 0.03 mmol) in dioxane (4 mL) was heated at 100 °C for 3 h. The reaction mixture was diluted with ethyl acetate, the organics were washed with water, filtered through Celite, and concentrated. The resulting black residue was purified by chromatography (eluting with EtOAc/hexane, 20–40% gradient) to give 5-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-quinazolin-4(3<i>H</i>)-one (170 mg, 75%) as a white foam. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 381.3.</div></div><div id="sec4_3_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Step C. 4-(3-(5-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>17</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (35 mg, 0.1 mmol), 5-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (50 mg, 0.13 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (5.8 mg, 5 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.15 mL, 0.3 mmol) in toluene (3 mL) and ethanol (1 mL) was heated at 110 °C for 9 h. The reaction mixture was diluted with ethyl acetate, the organics were washed with water and concentrated. The resulting residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/97:2.7:0.3 DCM:MeOH:NH<sub>4</sub>OH, 0–100% gradient) to give <b>17</b> (39 mg, 71%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 521.3, (M + H – H<sub>2</sub>O)<sup>+</sup> 503.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.57 (d, <i>J</i> = 15.18 Hz, 1H), 8.11 (d, <i>J</i> = 6.38 Hz, 1H), 8.03 (ddd, <i>J</i> = 8.42, 5.45, 3.08 Hz, 1H), 7.78–7.84 (m, 1H), 7.70 (d, <i>J</i> = 1.76 Hz, 1H), 7.66 (dd, <i>J</i> = 7.92, 3.74 Hz, 1H), 7.41–7.58 (m, 5H), 7.25 (br s, 1H), 7.12–7.16 (m,1H), 6.89–7.08 (m, 1H), 1.90 (d, <i>J</i> = 12.10 Hz, 3H), 1.63–1.66 (m, 6H) (some exchangeable protons diffuse and not observed). <sup>1</sup>H NMR shows a mixture of atropisomers.</div></div><div id="sec4_3_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-(3-(6-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18</b>). Step A. 6-Fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">The title compound was synthesized following the same procedures as described for the syntheses of <b>50</b> and <b>51</b> in 51% yield for the two steps (1.25 g). LCMS <i>m</i>/<i>z</i> 381.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (dd, <i>J</i> = 8.4, 2.9 Hz, 1H), 7.94 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 7.92 (s, 1H), 7.80 (dd, <i>J</i> = 9.0, 4.8 Hz, 1H), 7.57–7.50 (m, 1H), 7.38–7.32 (m, 1H), 7.32–7.28 (m, 1H), 2.35 (s, 3H), 1.35 (s, 12H).</div></div><div id="sec4_3_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Step B. 4-(3-(6-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (35 mg, 0.1 mmol), 6-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (50 mg, 0.13 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (6 mg, 5 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.15 mL, 0.3 mmol) in toluene (3 mL) and ethanol (1 mL) was heated at 110 °C for 8 h. The reaction mixture was diluted with ethyl acetate, washed with water, and concentrated. The resulting residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/97:2.7:0.3 DCM:MeOH:NH<sub>4</sub>OH, 0–70% gradient) to give <b>18</b> (36 mg, 65%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 521.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.57 (d, <i>J</i> = 15.19 Hz, 1H), 8.11 (d, <i>J</i> = 6.38 Hz, 1H), 8.03 (ddd, <i>J</i> = 8.42, 5.45, 2.86 Hz, 1H), 7.78–7.84 (m, 1H), 7.70 (d, <i>J</i> = 1.76 Hz, 1H), 7.66 (dd, <i>J</i> = 7.70, 3.52 Hz, 1H), 7.40–7.59 (m, 5H), 7.14 (d, <i>J</i> = 7.48 Hz, 1H), 6.86–7.08 (m, 1H), 1.90 (d, <i>J</i> = 12.10 Hz, 3H), 1.82 (d, <i>J</i> = 13.42 Hz, 1H), 1.62–1.68 (m, 6H) (some exchangeable protons diffuse and not observed). <sup>1</sup>H NMR shows a mixture of atropisomers.</div></div><div id="sec4_3_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 4-(3-(7-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>19</b>). Step A. 7-Fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">The title compound was synthesized following the same procedures as described for the syntheses of <b>50</b> and <b>51</b> in 44% yield for the two steps (1.6 g). LCMS <i>m</i>/<i>z</i> 381.0 (M + H) <sup>+</sup>.</div></div><div id="sec4_3_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Step B. 4-(3-(7-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>19</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (35 mg, 0.1 mmol), 7-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (50 mg, 0.13 mmol), 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.15 mL, 0.3 mmol), and Pd(Ph<sub>3</sub>P)<sub>4</sub> (6 mg, 5 μmol) in a mixture of toluene (3 mL) and ethanol (1 mL) was heated at 110 °C for 15 h. The mixture was cooled to rt, diluted with ethyl acetate, and washed with water. The organics were concentrated and the residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/97:2.7:0.3 DCM:MeOH:NH<sub>4</sub>OH, 0–100% gradient) to give <b>19</b> (40 mg, 70%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 521.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.57 (d, <i>J</i> = 14.97 Hz, 1H), 8.41 (ddd, <i>J</i> = 9.02, 5.94, 3.08 Hz, 1H), 8.15 (d, <i>J</i> = 6.16 Hz, 1H), 7.68–7.71 (m, 1H), 7.65 (dd, <i>J</i> = 7.70, 1.76 Hz, 1H), 7.41–7.56 (m, 4H), 7.22–7.31 (m, 2H), 6.87–7.16 (m, 2H), 5.90 (br s, 2H), 1.90 (d, <i>J</i> = 11.66 Hz, 3H), 1.82 (d, <i>J</i> = 12.10 Hz, 1H), 1.63–1.67 (m, 6H). <sup>1</sup>H NMR shows a mixture of atropisomers.</div></div><div id="sec4_3_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 4-(3-(8-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>20</b>). Step A. 8-Fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">The title compound was synthesized following the same procedures as described for the syntheses of <b>50</b> and <b>51</b> in 34% yield for the two steps (0.55 g). LCMS <i>m</i>/<i>z</i> 381.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16 (d, <i>J</i> = 7.5 Hz, 1H), 8.00 (s, 1H), 7.95 (d, <i>J</i> = 7.3 Hz, 1H), 7.60–7.46 (m, 2H), 7.40–7.28 (m, 2H), 2.37 (s, 3H), 1.36 (s, 12H).</div></div><div id="sec4_3_10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Step B. 4-(3-(8-Fluoro-4-oxoquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>20</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (43 mg, 0.12 mmol), 8-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (61 mg, 0.16 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (7 mg, 6 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.19 mL, 0.37 mmol) in a mixture of toluene (3 mL) and ethanol (1 mL) was heated at 110 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water, and concentrated. The resulting residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/97:2.7:0.3 DCM:MeOH:NH<sub>4</sub>OH, 0–100% gradient) to give <b>20</b> (50 mg, 71%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 521.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.59 (m, 1H), 8.18 (d, <i>J</i> = 7.26 Hz, 2H), 7.71 (dd, <i>J</i> = 10.01, 0.99 Hz, 1H), 7.65 (t, <i>J</i> = 7.70 Hz, 1H), 7.41–7.59 (m, 5H), 7.20–7.29 (m, 1H), 7.07 (dd, <i>J</i> = 17.83, 7.70 Hz, 1H), 6.87–7.15 (m, 1H), 2.00 (d, <i>J</i> = 14.97 Hz, 1H), 1.89 (d, <i>J</i> = 12.54 Hz, 3H), 1.64 (s, 6H) (some exchangeable protons diffuse and not observed). <sup>1</sup>H NMR shows a mixture of atropisomers.</div></div><div id="sec4_3_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 7-(Hydroxymethyl)-4-(2-methyl-3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>21</b>). Step A. 4-Bromo-7-(hydroxymethyl)-9<i>H</i>-carbazole-1-carboxamide (<b>32</b>)</h3><div class="NLM_p last">To a cloudy solution of <b>30</b> (0.5 g, 1.38 mmol) in THF (28 mL) at 0 °C was added lithium aluminum hydride (3.46 mL, 3.46 mmol, 1 M in THF). The reaction was brought to rt, stirred for 2 h, and quenched with water. The reaction mixture was brought to pH ≈ 8–9 with the addition of 1 N HCl, then partitioned between EtOAc and water. The organic phase was washed with sat. NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford <b>32</b> (0.37 g, 84%) as a light pink solid. LCMS <i>m</i>/<i>z</i> 318.9, 320.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.67 (s, 1H), 8.52 (d, <i>J</i> = 8.3 Hz, 1H), 8.20 (br s, 1H), 7.82 (d, <i>J</i> = 8.3 Hz, 1H), 7.77 (s, 1H), 7.56 (br s, 1H), 7.41 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (d, <i>J</i> = 8.3 Hz, 1H), 5.29 (t, <i>J</i> = 5.7 Hz, 1H), 4.66 (d, <i>J</i> = 5.7 Hz, 2H).</div></div><div id="sec4_3_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Step B. 7-(Hydroxymethyl)-4-(2-methyl-3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>21</b>)</h3><div class="NLM_p last">A mixture of <b>32</b> (40 mg, 0.12 mmol), <b>51</b> (45 mg, 0.12 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (7 mg, 6.3 μmol), and 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.16 mL, 0.3 mmol) in THF (2 mL) was degassed with nitrogen and heated at 90 °C for 16 h. The reaction mixture was diluted with DCM, washed with saturated NaHCO<sub>3</sub>, and concentrated. The resulting residue was purified by chromatography (eluting with 0–100% ethyl acetate/hexane) to give <b>21</b> (22 mg, 36%) as a light yellow solid. LCMS <i>m</i>/<i>z</i> 474.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.29–8.39 (m, 2H), 7.95 (dd, <i>J</i> = 7.81, 6.05 Hz, 1H), 7.85–7.92 (m, 1H), 7.76–7.82 (m, 1H), 7.48–7.65 (m, 5H), 7.23 (d, <i>J</i> = 8.14 Hz, 1H), 7.06–7.13 (m, 1H), 6.98–7.06 (m, 1H), 4.70–4.76 (m, 2H), 1.82 (s, 3H). <sup>1</sup>H NMR shows a mixture of atropisomers.</div></div><div id="sec4_3_12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 7-(2-Hydroxypropan-2-yl)-4-(3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>22</b>). Step A. 3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">The title compound was synthesized following the same procedures as described for the syntheses of <b>50</b> and <b>51</b> in 34% yield for the two steps (0.8 g). LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 349.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 8.13 (s, 1H), 7.94–7.90 (m, 1H), 7.86–7.75 (m, 3H), 7.58–7.50 (m, 3H), 1.35 (s, 11H).</div></div><div id="sec4_3_12_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Step B. 7-(2-Hydroxypropan-2-yl)-4-(3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-9H-carbazole-1-carboxamide (<b>22</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (40 mg, 0.12 mmol), 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazolin-4(3<i>H</i>)-one (52 mg, 0.15 mmol), 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (0.17 mL, 0.35 mmol), and Pd(Ph<sub>3</sub>P)<sub>4</sub> (6.7 mg, 5.8 μmol) in a mixture of toluene (3 mL) and ethanol (1 mL) was heated at 110 °C for 8 h. The reaction mixture was diluted with ethyl acetate, and the organics were washed with water and then concentrated. The resulting yellow residue was purified by chromatography (eluting with 90:9:1 DCM:MeOH:NH<sub>4</sub>OH/97:2.7:0.3 DCM:MeOH:NH<sub>4</sub>OH, 0–100% gradient) to give <b>22</b> (48 mg, 81%) as a white solid. LCMS <i>m</i>/<i>z</i> (M + H – H<sub>2</sub>O)<sup>+</sup> 471.0, (M + H)<sup>+</sup> 489.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.62 (s, 1H), 8.40 (dd, <i>J</i> = 8.03, 0.77 Hz, 1H), 8.24 (s, 1H), 7.71–7.84 (m, 4H), 7.69 (d, <i>J</i> = 1.54 Hz, 2H), 7.54–7.64 (m, 4H), 7.20 (dd, <i>J</i> = 8.47, 1.65 Hz, 1H), 7.13 (d, <i>J</i> = 7.92 Hz, 1H), 6.00 (br s, 2H), 1.87 (s, 1H), 1.65 (s, 6H).</div></div><div id="sec4_3_13_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 4-(2-Fluoro-3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>23</b>). Step A. 3-(3-Bromo-2-fluorophenyl)quinazolin-4(3<i>H</i>)-one</h3><div class="NLM_p last">A mixture of 3-bromo-2-fluoroaniline (1 g, 5.3 mmol), 2-aminobenzoic acid (866 mg, 6.3 mmol), and triethoxymethane (1.5 mL, 9 mmol) in toluene (25 mL) was heated to 110 °C for 20 h. The reaction mixture was then cooled to rt and concentrated. The resulting residue was dissolved in EtOAc, washed with 1 M HCl, sat. NaHCO<sub>3</sub>, and brine. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by chromatography (eluting with EtOAc/hexane, 0–50% gradient) to give 3-(3-bromo-2-fluorophenyl)quinazolin-4(3<i>H</i>)-one (675 mg, 38%) as an off-white solid. LCMS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 318.9. <sup>1</sup>H NMR NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 8.22 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.96–7.88 (m, 2H), 7.78 (d, <i>J</i> = 8.1 Hz, 1H), 7.76–7.70 (m, 1H), 7.64 (t, <i>J</i> = 7.6 Hz, 1H), 7.39 (td, <i>J</i> = 8.1, 1.0 Hz, 1H).</div></div><div id="sec4_3_13_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Step B. 4-(2-Fluoro-3-(4-oxoquinazolin-3(4<i>H</i>)-yl)phenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>23</b>)</h3><div class="NLM_p last">A mixture of <b>33</b> (297 mg, 0.75 mmol), 3-(3-bromo-2-fluorophenyl)quinazolin-4(3<i>H</i>)-one (200 mg, 0.63 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (1.097 mL, 2.193 mmol) in toluene (7 mL) and ethanol (7 mL) was sonicated and degassed with nitrogen for 5 min. To this mixture was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (36 mg, 0.031 mmol), and the reaction was heated to 85 °C for 18 h. The reaction mixture was then concentrated, and brine and EtOAc were added. The organic phase was extracted, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting dark solid was purified by chromatography (eluting with MeOH/DCM, 0–10% gradient) to afford <b>23</b>, which was further purified by preparative HPLC (Phenomenex Luna Axia, 5 μm, 30 mm × 100 mm, solvent A consisting of 10% CH<sub>3</sub>CN–90% H<sub>2</sub>O–0.1% TFA; solvent B consisting of 90% CH<sub>3</sub>CN–10% H<sub>2</sub>O–0.1% TFA; gradient, 30–100% B; gradient time, 10 min; flow rate, 30 mL/min; wavelength, 254 nm) to give <b>23</b> (209 mg, 65%) as an off-white solid. LCMS (EI) <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 507.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 8.54 (br s, 1H), 8.27–8.14 (m, 2H), 8.00 (d, <i>J</i> = 7.7 Hz, 1H), 7.96–7.84 (m, 3H), 7.81–7.71 (m, 2H), 7.66–7.58 (m, 2H), 7.51 (br s, 1H), 7.31 (br s, 1H), 7.19–7.08 (m, 2H), 5.00 (s, 1H), 1.47 (s, 6H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Human Recombinant BTK Enzyme Assay</h3><div class="NLM_p last">To V-bottom 384-well plates were added test compounds, human recombinant BTK (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM (<i>K</i><sub>m</sub><sup>app</sup>)), and assay buffer (20 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, 0.015% Brij 35 surfactant, and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubation at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product (excitation, 488 nm; emission, 530 nm). Inhibition data were calculated by comparison to control reactions with no enzyme (for 100% inhibition) and controls with no inhibitor (for 0% inhibition). Dose–response curves were generated to determine the concentration required for inhibiting 50% of BTK activity (IC<sub>50</sub>). Compounds were dissolved at 10 mM in DMSO and evaluated at 11 concentrations.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Human Recombinant LCK Enzyme Assay</h3><div class="NLM_p last">Recombinant GST-LCK (PSS) was combined with a fluorescent substrate FITC-AHA-EGIYLFKKK-NH<sub>2</sub>, ATP, and varying concentrations of inhibitors in a 384-well plate (Thermo Scientific). The final reaction volume (0.030 mL) contained 100 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, 0.015% Brij-35, 0.4 mM DTT, 6 μM ATP (<i>K</i><sub>m</sub><sup>app</sup>), 3 μM FITC-AHA-EGIYLFKKK-NH<sub>2</sub>, 0.5 nM GST-LCK, 1.6% DMSO, and varying concentrations of inhibitors (from 2 μM to 33 pM). Compound stock solutions (10 mM) were prepared in dimethyl sulfoxide (DMSO). Kinase reactions were incubated at room temperature for 1 h and terminated by adding 60 μL of 35 mM EDTA buffer to each sample. Reaction solutions were analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product (excitation, 488 nm; emission, 530 nm). IC<sub>50</sub> values were derived by nonlinear regression analysis of the concentration response data.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> BCR-Stimulated Calcium Flux in Ramos B Cells</h3><div class="NLM_p last">Human Ramos (RA1) B cells (ATCC CRL-1596) at a density of 2 × 10<sup>6</sup> cells/mL in RPMI minus phenol red (Invitrogen 11835-030) and 50 mM HEPES (Invitrogen 15630-130) containing 0.1% BSA (Sigma A8577) were added to one-half volume of calcium loading buffer (BD bulk kit for probenecid sensitive assays, no. 640177) and incubated at room temperature in the dark for 1 h. Dye-loaded cells were pelleted (Beckmann GS-CKR, 1200 rpm, room temperature, 5 min) and resuspended at room temperature in RPMI minus phenol red with 50 mM HEPES and 10% FBS to a density of 1 × 10<sup>6</sup> cells/mL. 150 μL aliquots (150 000 cells/well) were plated into 96-well poly-<span class="smallcaps smallerCapital">d</span>-lysine coated assay plates (BD 35 4640) and briefly centrifuged (Beckmann GS-CKR 800 rpm, 5 min, without brake). Next, 50 μL compound dilutions in 0.4% DMSO/RPMI minus phenol red + 50 mM HEPES + 10% FBS were added to the wells and the plate was incubated at room temperature in the dark for 1 h. The assay plate was briefly centrifuged as above prior to measuring calcium levels. Using the FLIPR1 (Molecular Devices), cells were stimulated by adding goat anti-human IgM (Invitrogen AHI0601) to 2.5 μg/mL. Changes in intracellular calcium concentrations were measured for 180 s, and percent inhibition was determined relative to peak calcium levels seen in the presence of stimulation only.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Immune Complex-Stimulated TNFα Production in Peripheral Blood Mononuclear Cells (PBMCs)</h3><div class="NLM_p last">Human peripheral blood mononuclear cells in media containing 10% FBS and various concentrations of test compound were stimulated for 7 h at 37 °C with immune complexes prepared from goat anti-human IgG (Jackson ImmunoResearch, catalog no. 109-005-003) and human IgG (Jackson ImmunoResearch, catalog no. 009-000-003), both of which were purified to remove endotoxin prior to immune complex generation. TNFα levels were measured by ELISA (TNF-α, OptEIA, BD Biosciences, catalog no. 5551212).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Whole Blood Assays of BCR-Stimulated CD69 Expression on B Cells</h3><div class="NLM_p last">To measure BCR-stimulated B cells, heparinized human whole blood was added with various concentrations of test compound and stimulated with 30 μg/mL AffiniPure F(ab′)2 fragment goat anti-human IgM (Jackson 109-006-1299, endotoxin cleared) and 10 ng/mL human IL-4 (Peprotech 200-04) for 18 h at 37 °C with agitation. The cells were stained with FITC-conjugated mouse anti-human CD20 (BD Pharmingen 555622) and PE-conjugated mouse anti-human CD69 monoclonal antibody (BD Pharmingen 555531), lysed, and fixed, then washed. The amount of CD69 expression was quantitated by the mean fluorescence intensity (MFI) after gating on the CD20-positive B cell population as measured by FACS analysis. B cells in mouse whole blood were stimulated in an similar way, using AffinPure F(ab′)2 fragment goat anti-mouse IgG + IgM (Jackson catalog no. 115-006-068) at 100 μg/mL to stimulate, and staining with allophycocyanin (APC) rat anti-mouse CD19 antibody (BD Biosciences 550992) to identify the B cells and CD69 quantitation with FITC-conjugated anti-mouse CD69 monoclonal antibody (BD Biosciences, no. 553236).</div></div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> In Vivo Studies</h3><div class="NLM_p last">All animal procedures were conducted with the approval of the Bristol-Myers Squibb Animal Care and Use Committee and Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA; registration number 1089/RO/bc/2007/CPCSEA). Mice (Harlan Laboratories, Indianapolis, IN, USA, and The Netherlands) were housed under a 12-h/12-h light/dark cycle and provided customary access to fresh drinking water and rodent chow diet ad libitum.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Pharmacokinetic (PK) Analysis</h3><div class="NLM_p last">Unless noted otherwise, in the in vivo studies described below, compound <b>6</b> was administered in a polyethylene glycol 400 (PEG-400)/water/ethanol (70:20:10, v/v/v) solution.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Single-Dose PK in Mice</h3><div class="NLM_p last">Two groups of animals (<i>N</i> = 9 per group, 19–26 g) were fasted overnight and received compound <b>6</b> either as an intravenous (iv) bolus dose (2 mg/kg) via the tail vein or by oral gavage (5 mg/kg). Blood samples (∼0.2 mL) were obtained by retro-orbital bleeding at 0.05 (or 0.25 for oral), 0.5, 1, 3, 6, 8, and 24 h postdose. For iv dosing, mice were divided into three groups; one group was bled at 0.05, 0.5, and 6 h, and the second group was bled at 0.25, 3, and 8 h, while the third group was bled at 1 and 24 h. For po dosing, mice were also divided into three groups; one group was bled at 0.25, 1, and 6 h, and the second group was bled at 0.5, 3, and 8 h, while the third group was bled at 24 h, resulting in a composite PK profiles (3 mice per time point). Blood samples were allowed to coagulate and centrifuged at 4 °C (1500–2000<i>g</i>) to obtain serum. Serum samples were stored at −20 °C until analysis by LC/MS/MS.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Single-Dose PK in Rats</h3><div class="NLM_p">Male Sprague–Dawley rats (255–298 g) were used in the PK studies of <b>6</b>. The iv doses were administered to nonfasted rats; oral doses were administered to fasted rats, which were allowed food 4 h postdose. Blood samples (∼0.3 mL) were collected from the jugular vein into K<sub>3</sub>EDTA-containing tubes and then centrifuged at 4 °C (1500–2000<i>g</i>) to obtain plasma, which was stored at −20 °C until analysis by LC/MS/MS.</div><div class="NLM_p last">To investigate the oral bioavailability of compound <b>6</b> after crystalline microsuspension doses, rats received the compound by oral gavage (1, 5, and 20 mg/kg), T99.5% 10 mM citrate buffer, pH 4, 0.02% DOSS, Methocel A4M. Serial blood samples were obtained after oral dosing at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 h postdose. Plasma samples, obtained by centrifugation at 4 °C (1500–2000<i>g</i>), were stored at −20 °C until analysis.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Single-Dose PK in Dogs</h3><div class="NLM_p last">The PK of compound <b>6</b> was evaluated in male beagle dogs following iv infusion (2 mg/kg over 10 min) via a femoral vein or by oral administration (2 mg/kg). The studies were conducted in a crossover design (<i>N</i> = 3), with 1 week washout period between the iv and oral studies. The iv doses were administered to nonfasted dogs; oral doses were administered to fasted dogs, which were allowed food 4 h postdose. Serial blood samples were collected at 0.167 (iv only), 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24, and 48 h postdose, followed by centrifugation at 4 °C (1500–2000<i>g</i>) to obtain plasma. All samples were stored at −20 °C until analysis by LC/MS/MS.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Single-Dose PK in Monkeys</h3><div class="NLM_p last">Compound <b>6</b> was evaluated in male cynomolgus monkeys, following iv infusion (2 mg/kg over 10 min) via a femoral vein port or by oral administration (2 mg/kg) (4.6–6.2 kg). The studies were conducted in a crossover design (<i>N</i> = 3), with 1 week washout period between the iv and oral studies. The iv doses were administered to nonfasted monkeys; oral doses were administered to fasted monkeys, which were allowed food 4 h postdose. Serial blood samples were collected at 0.167 (iv only), 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24, and 48 h postdose, followed by centrifugation at 4 °C (1500–2000<i>g</i>) to obtain plasma. All samples were stored at −20 °C until analysis by LC/MS/MS.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Primary Anti-KLH Antibody Responses in Mice</h3><div class="NLM_p last">Female BALB/c mice (8–12 weeks old, Harlan) were immunized intraperitoneally (ip) with 250 μg of KLH (Pierce, Rockford, IL) in PBS on day 0. Mice in appropriate groups were dosed daily by oral gavage with vehicle (EtOH:TPGS:PEG300, 5:5:90) or test compound. Blood was collected on days 7 and 14 postimmunization. Serum was separated and analyzed for anti-KLH IgM titers (day 7) and anti-KLH IgG titers (day 14) by ELISA. Briefly, 96-well plates were coated with KLH in PBS, blocked, and serial dilutions of test serum samples were added. Captured anti-KLH antibodies were detected using horseradish peroxidase-conjugated antibody specific for mouse IgM or IgG (Southern Biotechnology Associates, Birmingham, AL) and the TMB peroxidase substrate system (Kirkegaard and Perry Laboratories, Gaithersburg, MD). Optical densities of developed plates were quantitated in a SpectraMax Plus ELISA plate reader (Molecular Devices, Sunnyvale, CA). Serum from BALB/c mice collected on day 7 (IgM) or on day 14 (IgG) after immunization with KLH was pooled and used as a standard comparator in each respective assay. The data are expressed by relating the test sample titers to the standard comparator titer which was assigned a value of 1.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Collagen-Induced Arthritis in Mice</h3><div class="NLM_p">DBA/1 male mice (8–10 weeks of age; Harlan) were immunized subcutaneously at the base of the tail on day 0 and again on day 21 with 200 μg of bovine type II collagen admixed with reconstituted Sigma Adjuvant System (SAS; Sigma-Aldrich). For “preventative” dosing, mice were dosed daily (beginning on day 0) by oral gavage with vehicle (EtOH:TPGS:PEG300; 5:5:90) or compound <b>6</b>. For “pseudo-established” dosing, the start of dosing was delayed until the day 21 booster immunization. Following the booster immunization, mice were monitored 3 times per week for the development and severity of paw inflammation. Each paw was visually scored by the following scheme: +0 = normal; +1 = one (or more) joints inflamed on digits; +2 = mild-moderate inflammation of plantar surface of paw and paw thickness modestly increased; +3 = moderate-severe inflammation of plantar surface of paw and paw thickness significantly increased; +4 = ankylosis of ankle joint (significantly reduced hock joint motion on flexion/extension). Unblinded clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group.</div><div class="NLM_p last">For histological evaluation, rear paws were fixed, decalcified, and embedded in paraffin. Sections were cut in the sagittal plane, stained in H&E, and evaluated microscopically without knowledge of treatment group. Lesions were scored on a severity scale of 0 (normal) to 4 in two separate categories, inflammation (cellular infiltration and pannus formation) and bone resorption. Bone morphology and bone mineral density of hind paws excised post-mortem were analyzed by microcomputed tomography (micro-CT) after fixation in 10% neutral buffered formalin. Age-matched naive (disease-free) paws were used as a control for comparative micro-CT analysis. The analysis was conducted in a blinded format.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Microcomputed Tomography Imaging and Histopathology</h3><div class="NLM_p last">Bone morphology was evaluated by micro-CT using the Scanco VivaCT40 (Scanco Medical AG, Zurich, Switzerland). Imaging parameters included approximately 500 slices (21 μm thick) acquired with 250 projections, 500 ms integration time, 55 kVp photon energy, and 145 μA of current. Region of interest (ROI) focused on the hind/mid foot sections (talus to proximal end of the first metatarsal bone). Threshold settings were optimized using histomorphometric methods. Bone mineral density (BMD) and bone surface area (BSA) were evaluated using a hydroxylapatite calibration phantom and Scanco proprietary software. The analysis was conducted in a blinded format.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Collagen Antibody-Induced Arthritis in Mice</h3><div class="NLM_p last">Female BALB/c mice (8–10 weeks of age; Harlan) were injected ip with a mixture of four monoclonal anti-mouse type II collagen antibodies (1 mg of each). Daily oral dosing was immediately started with vehicle (EtOH:TPGS:PEG300, 5:5:90), compound <b>6</b> (10 or 30 mg/kg), or dexamethasone (1 mg/kg). Three days later, the mice were injected ip with 1.25 mg/kg LPS (<i>E. coli</i> O111:B4; Sigma). Thereafter, mice were monitored 3×/week for the development and severity of paw inflammation. Each paw was visually scored by the following scheme: +0 = normal; +1 = one (or more) joints inflamed on digits; +2 = mild–moderate inflammation of plantar surface of paw and paw thickness modestly increased; +3 = moderate–severe inflammation of plantar surface of paw and paw thickness significantly increased; +4 = ankylosis of ankle joint (significantly reduced hock joint motion on flexion/extension). Unblinded clinical paw scores for all four paws were summed for each mouse, and the mean ± SEM was calculated for each treatment group.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> X-ray Crystallography</h3><div class="NLM_p last">A baculovirus construct of His-TEV-hBTK (E396-S659) was used to generate protein for X-ray crystallography as previously reported.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For protein/compound complex formation, 4 μL of compound <b>23</b> (50 mM DMSO stock) was added to 1.5 mL of hBTK at 0.35 mg/mL and incubated at room temperature for 3 h and then concentrated to 5.25 mg/mL prior to set up drops. Crystals were grown at room temperature using hanging drop vapor diffusion method. The drop consisted of 3 μL of protein solution and 1 μL of reservoir solution containing 31% (w/v) methyl ether PEG 5000, 1% (w/v) PEG 8000, 0.2 M Tris-HCl, pH 8.5. Macroseeding was performed to initiate crystal growth. The crystals appeared within a few days and continued to grow for 2–3 weeks. Crystals were flash-cooled in liquid nitrogen for data collection with 25% glycerol and 75% reservoir solution as cryoprotectant. Diffraction data were collected by Shamrock Structures, Inc. at IMCA-CAT, beamline 17ID at the Advanced Photon Source. hBTK/compound <b>23</b> cocrystals belonged to the space group <i>p</i>2<sub>1</sub>: <i>a</i> = 63.5 Å, <i>b</i> = 45.5 Å, <i>c</i> = 98.4 Å, α = λ = 90.0°, β = 94.0°. The 1.97 Å resolution structure was determined by molecular replacement using a previously determined in house BTK structure (unpublished results). The structure of hBTK + compound <b>23</b> has been deposited to RCSB with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00722">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26503" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26503" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00722" class="ext-link">10.1021/acs.jmedchem.6b00722</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and the associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00722/suppl_file/jm6b00722_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00722/suppl_file/jm6b00722_si_001.csv">jm6b00722_si_001.csv (1.61 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for compound <b>23</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00722" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George V. De Lucca</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5c2c0cad7c2c08bc1c0c9d0c6c6c4e5c7c8d68bc6cac8"><span class="__cf_email__" data-cfemail="4f282a203d282a612b2a233a2c2c2e0f2d223c612c2022">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph A. Tino</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa9095899f8a92d48e939495ba989789d4999597"><span class="__cf_email__" data-cfemail="2842475b4d5840065c414647684a455b064b4745">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qing Shi</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingjie Liu</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas G. Batt</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Myra Beaudoin Bertrand</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rick Rampulla</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lorell Discenza</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Dai</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Obermeier</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodney Vickery</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingru Zhang</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Yang</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Punit Marathe</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew J. Tebben</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodi K. Muckelbauer</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">ChiehYing J. Chang</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huiping Zhang</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Gillooly</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy Taylor</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Pattoli</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey Skala</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel W. Kukral</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Salter-Cid</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aberra Fura</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel C. Barrish</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">†Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i94" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i94"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i95" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i95"> Abbreviations Used</h2><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">antigen presenting cell</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">DOSS</td><td class="NLM_def"><p class="first last">dioctylsodium sulfosuccinate</p></td></tr><tr><td class="NLM_term">BCS</td><td class="NLM_def"><p class="first last">biopharmaceutics classification system</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Volkamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rippmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulle, S.</span><span> </span><span class="NLM_article-title">Pocketome of human kinases: Prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1021/ci500624s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500624s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2MvjsVSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=538-549&author=A.+Volkamerauthor=S.+Eidauthor=S.+Turkauthor=S.+Jaegerauthor=F.+Rippmannauthor=S.+Fulle&title=Pocketome+of+human+kinases%3A+Prioritizing+the+ATP+binding+sites+of+%28yet%29+untapped+protein+kinases+for+drug+discovery&doi=10.1021%2Fci500624s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery</span></div><div class="casAuthors">Volkamer Andrea; Eid Sameh; Turk Samo; Jaeger Sabrina; Fulle Simone; Rippmann Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases are involved in a variety of diseases including cancer, inflammation, and autoimmune disorders.  Although the development of new kinase inhibitors is a major focus in pharmaceutical research, a large number of kinases remained so far unexplored in drug discovery projects.  The selection and assessment of targets is an essential but challenging area.  Today, a few thousands of experimentally determined kinase structures are available, covering about half of the human kinome.  This large structural source allows guiding the target selection via structure-based druggability prediction approaches such as DoGSiteScorer.  Here, a thorough analysis of the ATP pockets of the entire human kinome in the DFG-in state is presented in order to prioritize novel kinase structures for drug discovery projects.  For this, all human kinase X-ray structures available in the PDB were collected, and homology models were generated for the missing part of the kinome.  DoGSiteScorer was used to calculate geometrical and physicochemical properties of the ATP pockets and to predict the potential of each kinase to be druggable.  The results indicate that about 75% of the kinome are in principle druggable.  Top ranking structures comprise kinases that are primary targets of known approved drugs but additionally point to so far less explored kinases.  The presented analysis provides new insights into the druggability of ATP binding pockets of the entire kinome.  We anticipate this comprehensive druggability assessment of protein kinases to be helpful for the community to prioritize so far untapped kinases for drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXYhJ2uLp2lX6HPRus0rAafW6udTcc2ea8gFYkdfS50rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvjsVSksw%253D%253D&md5=85c8e48d59f1acea82d1019da51b47e1</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1021%2Fci500624s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500624s%26sid%3Dliteratum%253Aachs%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DEid%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DJaeger%26aufirst%3DS.%26aulast%3DRippmann%26aufirst%3DF.%26aulast%3DFulle%26aufirst%3DS.%26atitle%3DPocketome%2520of%2520human%2520kinases%253A%2520Prioritizing%2520the%2520ATP%2520binding%2520sites%2520of%2520%2528yet%2529%2520untapped%2520protein%2520kinases%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D538%26epage%3D549%26doi%3D10.1021%2Fci500624s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stransky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span> </span><span class="NLM_article-title">Targeting cancer with kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1780</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1172/JCI76094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1172%2FJCI76094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=25932675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2MjpvFGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=1780-1789&author=S.+Grossauthor=R.+Rahalauthor=N.+Stranskyauthor=C.+Lengauerauthor=K.+P.+Hoeflich&title=Targeting+cancer+with+kinase+inhibitors&doi=10.1172%2FJCI76094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with kinase inhibitors</span></div><div class="casAuthors">Gross Stefan; Rahal Rami; Stransky Nicolas; Lengauer Christoph; Hoeflich Klaus P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1780-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases.  Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation.  In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors.  We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic.  Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyaX6QAuw1pbFU0A1HOshhfW6udTcc2eYlRlg0Ge5vmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjpvFGitA%253D%253D&md5=b35d25dcf88d08a43ca3a0945c048111</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1172%2FJCI76094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI76094%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DS.%26aulast%3DRahal%26aufirst%3DR.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26atitle%3DTargeting%2520cancer%2520with%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D1780%26epage%3D1789%26doi%3D10.1172%2FJCI76094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Quantitative proteomics of kinase inhibitor targets and mechanisms</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1021/cb5008794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=201-212&author=H.+Daub&title=Quantitative+proteomics+of+kinase+inhibitor+targets+and+mechanisms&doi=10.1021%2Fcb5008794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fcb5008794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008794%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DQuantitative%2520proteomics%2520of%2520kinase%2520inhibitor%2520targets%2520and%2520mechanisms%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D201%26epage%3D212%26doi%3D10.1021%2Fcb5008794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0ljhgar2iClz3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lh30ulDeblCWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jongstra-Bilen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cybulsky, M. I.</span><span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaven, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2576</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span><span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lh30ulDeblCWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsukada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0lh30ulDeblCWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11534</span><span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mease, P. J.</span><span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0lgtsA9B5hSXTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Goldstein, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debenedette, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbaugh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, T. H.</span><span> </span><span class="NLM_article-title">Induction of costimulatory molecules B7–1 and B7–2 in murine B cells: the CBA/N mouse reveals a role for Bruton’s tyrosine kinase in CD40-mediated B7 induction</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1016/0161-5890(96)00005-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2F0161-5890%2896%2900005-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8700170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK28Xks1ShsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1996&pages=541-552&author=M.+D.+Goldsteinauthor=M.+A.+Debenedetteauthor=D.+Hollenbaughauthor=T.+H.+Watts&title=Induction+of+costimulatory+molecules+B7%E2%80%931+and+B7%E2%80%932+in+murine+B+cells%3A+the+CBA%2FN+mouse+reveals+a+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+CD40-mediated+B7+induction&doi=10.1016%2F0161-5890%2896%2900005-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of costimulatory molecules B7-1 and B7-2 in murine B cells: the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction</span></div><div class="casAuthors">Goldstein, Marni D.; Debenedette, Mark A.; Hollenbaugh, Diane; Watts, Tania H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">541-552</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding of CD40 ligand on activated T cells to CD40 on resting B cells induces the expression of costimulatory mols. B7-1 (CD80) and B7-2 (CD86).  The induction of B7 mols. by CD40 ligand-CD40 interaction represents a crit. step in rendering B cells competent for antigen presentation.  The CBA/N mouse has a defect in CD40 signalling which has been attributed to a mutation of Bruton's tyrosine kinase.  We have compared the ability of murine CD40 ligand to induce B7-1 and B7-2 expression on B cells isolated from CBA/N and wild-type CBA/J mice.  We find that the CBA/N defect partially impairs both B7-1 and B7-2 induction via CD40.  Subsequent expts. investigated the roles of different second messenger systems in B7-1 and B7-2 induction in normal B cells.  In M12 B lymphomas either CD40 crosslinking or cAMP treatment can induce B7 mols.  Here we report that treatment with dibutyryl-cAMP also induces B7 mols. in normal B cells provided that they have been preactivated by CD40 crosslinking.  We also find that PMA and ionomycin treatment of B cells induces B7-2 but not B7-1 expression.  Our data therefore show roles for BTK, cAMP and PMA/ionomycin in B7 induction, as well as providing further evidence for differential regulation of B7-1 and B7-2 induction in B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNEdhcqOYWrVg90H21EOLACvtfcHk0lgtsA9B5hSXTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xks1ShsL8%253D&md5=90032ff733f6264a80241f131cb70b4d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0161-5890%2896%2900005-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0161-5890%252896%252900005-3%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DM.%2BD.%26aulast%3DDebenedette%26aufirst%3DM.%2BA.%26aulast%3DHollenbaugh%26aufirst%3DD.%26aulast%3DWatts%26aufirst%3DT.%2BH.%26atitle%3DInduction%2520of%2520costimulatory%2520molecules%2520B7%25E2%2580%25931%2520and%2520B7%25E2%2580%25932%2520in%2520murine%2520B%2520cells%253A%2520the%2520CBA%252FN%2520mouse%2520reveals%2520a%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520CD40-mediated%2520B7%2520induction%26jtitle%3DMol.%2520Immunol.%26date%3D1996%26volume%3D33%26spage%3D541%26epage%3D552%26doi%3D10.1016%2F0161-5890%2896%2900005-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0lgtsA9B5hSXTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinberg, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smathers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, A. D.</span><span> </span><span class="NLM_article-title">Ability of the XID gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+XID+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eYOeZ2asiMF47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520XID%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivassan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivassanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lhPryBIPx0RwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivassan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rankin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathialagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homer, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III.</span><span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">4540</span><span class="NLM_x">–</span> <span class="NLM_lpage">4550</span><span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0li2Z0xH75CEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Puck, J. M.</span><span> </span><span class="NLM_article-title">Molecular and genetic basis of X-linked immunodeficiency disorders</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/BF01541340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2FBF01541340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8195317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=81-89&author=J.+M.+Puck&title=Molecular+and+genetic+basis+of+X-linked+immunodeficiency+disorders&doi=10.1007%2FBF01541340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and genetic basis of X-linked immunodeficiency disorders</span></div><div class="casAuthors">Puck, Jennifer M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-9</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review with 51 refs.  Topics discussed include X-linked hyper-IgM syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, and immunodeficiency genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dSBJ76uLHLVg90H21EOLACvtfcHk0li2Z0xH75CEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D&md5=c9c2d448576c949acc62b4926389b46b</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1007%2FBF01541340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01541340%26sid%3Dliteratum%253Aachs%26aulast%3DPuck%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520and%2520genetic%2520basis%2520of%2520X-linked%2520immunodeficiency%2520disorders%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D14%26spage%3D81%26epage%3D89%26doi%3D10.1007%2FBF01541340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredius, R. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike-Overzet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, F. J. T.</span><span> </span><span class="NLM_article-title">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/14728222.2011.585971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1517%2F14728222.2011.585971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21635151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=1003-1021&author=R.+W.+Hendriksauthor=R.+G.+M.+Brediusauthor=K.+Pike-Overzetauthor=F.+J.+T.+Staal&title=Biology+and+novel+treatment+options+for+XLA%2C+the+most+common+monogenetic+immunodeficiency+in+man&doi=10.1517%2F14728222.2011.585971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span></div><div class="casAuthors">Hendriks, Rudi W.; Bredius, Robbert G. M.; Pike-Overzet, Karin; Staal, Frank J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1003-1021</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency in man, and is caused by a single genetic defect.  Inactivating mutations in the Bruton's tyrosine kinase (BTK) gene are invariably the cause of XLA,.  XLA is characterized by a differentiation arrest at the pre-B cell stage, the absence of Igs and recurrent bacterial infections, making it an insidious disease that gradually disables the patient, and can result in death due to chronic lung disease.  Current treatment involves prophylactic antibiotics and Ig infusions, which are non-curative.  This disease is a good candidate for curative hematopoietic stem cell (HSC)-based gene therapy, which could correct the B cell and myeloid deficiencies.  Areas covered: This paper reviews the basic biol. of BTK in B cell development, the clin. features of XLA, and the possibilities of gene therapy for XLA, covering the literature from 1995 to 2010.  Expert opinion: Work from various labs. demonstrates the feasibility of using gene-cor. HSCs to complement the immune defects of Btk-deficiency in mice.  We propose that it is timely to start clin. programs to develop stem cell based therapy for XLA, using gene-cor. autologous HSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeANh_LlclL7Vg90H21EOLACvtfcHk0li2Z0xH75CEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D&md5=24f073dee412df4b5ec3beb5dc982b0e</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.585971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.585971%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DBredius%26aufirst%3DR.%2BG.%2BM.%26aulast%3DPike-Overzet%26aufirst%3DK.%26aulast%3DStaal%26aufirst%3DF.%2BJ.%2BT.%26atitle%3DBiology%2520and%2520novel%2520treatment%2520options%2520for%2520XLA%252C%2520the%2520most%2520common%2520monogenetic%2520immunodeficiency%2520in%2520man%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D1003%26epage%3D1021%26doi%3D10.1517%2F14728222.2011.585971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, J. A.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia: an analysis of 96 patients</span> <span class="citation_source-journal">Medicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1097/00005792-198505000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1097%2F00005792-198505000-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1985&pages=145-156&author=H.+M.+Ledermanauthor=J.+A.+Winkelstein&title=X-linked+agammaglobulinemia%3A+an+analysis+of+96+patients&doi=10.1097%2F00005792-198505000-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1097%2F00005792-198505000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-198505000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26atitle%3DX-linked%2520agammaglobulinemia%253A%2520an%2520analysis%2520of%252096%2520patients%26jtitle%3DMedicine%26date%3D1985%26volume%3D64%26spage%3D145%26epage%3D156%26doi%3D10.1097%2F00005792-198505000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0lhNJfhbEobZEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lhNJfhbEobZEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhNJfhbEobZEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burger, J. A.</span><span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1007/s11899-013-0188-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2Fs11899-013-0188-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24357428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=44-49&author=J.+A.+Burger&title=Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+in+Clinical+Trials&doi=10.1007%2Fs11899-013-0188-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in clinical trials</span></div><div class="casAuthors">Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors.  Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders.  The BTK inhibitor ibrutinib (PCI-32765, brand name: Imbruvica) demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM).  Therefore, ibrutinib was granted a 'breakthrough therapy' designation for these indications and was recently approved for the treatment of relapsed MCL by the U.S.  Food and Drug Administration.  Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059.  In CLL and MCL, ibrutinib characteristically induces redistribution of malignant B cells from tissue sites into the peripheral blood, along with rapid resolution of enlarged lymph nodes and a surge in lymphocytosis.  With continuous ibrutinib therapy, growth- and survival-inhibitory activities of ibrutinib result in the normalization of lymphocyte counts and remissions in a majority of patients.  This review discusses the clinical advances with BTK inhibitor therapy, as well as its pathophysiological basis, and outlines perspectives for future use of BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqhvp3dQ4UIub6AVA-44PTfW6udTcc2eYG-ZxgufRQybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D&md5=2e6e9639a96e00f2669027ab74f8c7c4</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-013-0188-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-013-0188-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D44%26epage%3D49%26doi%3D10.1007%2Fs11899-013-0188-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Akinleye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0lictZK2Qt3-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0lictZK2Qt3-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel oral BTK inhibitor, inhibits human immune cell activation: New drug candidate to treat B-cell associated autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-eular.2783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1136%2Fannrheumdis-2014-eular.2783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=355-356&author=J.+K.+Parkauthor=J.+A.+Parkauthor=Y.+J.+Leeauthor=J.+Songauthor=J.+I.+Ohauthor=Y.-M.+Leeauthor=K.+H.+Suhauthor=J.+Sonauthor=E.+B.+Lee&title=HM71224%2C+a+novel+oral+BTK+inhibitor%2C+inhibits+human+immune+cell+activation%3A+New+drug+candidate+to+treat+B-cell+associated+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2014-eular.2783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-eular.2783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-eular.2783%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520oral%2520BTK%2520inhibitor%252C%2520inhibits%2520human%2520immune%2520cell%2520activation%253A%2520New%2520drug%2520candidate%2520to%2520treat%2520B-cell%2520associated%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2014%26volume%3D73%26spage%3D355%26epage%3D356%26doi%3D10.1136%2Fannrheumdis-2014-eular.2783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lit-2ntAfRVsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Evans, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witowski, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounsbury, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lit-2ntAfRVsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0ljbrLabCRomEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: pyridazinone analogs with improved metabolic stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+highly+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+pyridazinone+analogs+with+improved+metabolic+stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0ljbrLabCRomEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520pyridazinone%2520analogs%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krikorian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boga, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhassan, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu-Pham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manusueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang-Hoover, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knemeyer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible selective BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=A.+De+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Horvakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Manusuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+selective+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DDe%2BMan%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHorvak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DManusueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520selective%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Y.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0ljFsapWSnrUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; De Lucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Carbazole carboxamide compounds useful as kinase inhibitors</span>. U.S. Patent US 20100160303 A1, 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Liu%2C+Q.%3B+Batt%2C+D.+G.%3B+De+Lucca%2C+G.+V.%3B+Shi%2C+Q.%3B+Tebben%2C+A.+J.+Carbazole+carboxamide+compounds+useful+as+kinase+inhibitors.+U.S.+Patent+US+20100160303+A1%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DCarbazole%2520carboxamide%2520compounds%2520useful%2520as%2520kinase%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span> <span class="citation_source-journal">Drug Met. Dispersion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span><span class="refDoi"> DOI: 10.1124/dmd.111.040840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fdmd.111.040840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21742900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+C.+A.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor&doi=10.1124%2Fdmd.111.040840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor</span></div><div class="casAuthors">Liu, Lichuan; Halladay, Jason S.; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John C., Jr.; Liao, X. Charlene; Lubach, Joseph W.; Deese, Alan; Sowell, C. Gregory; Currie, Kevin S.; Young, Wendy B.; Khojasteh, S. Cyrus; Hop, Cornelis E. C. A.; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1840-1849</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(R)-N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide (GDC-0834) is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.  In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human.  The formation of M1 appeared to be NADPH-independent in human liver microsomes.  M1 was found in only minor to moderate quantities in plasma from preclin. species dosed with GDC-0834.  Human clearance predictions using various methodologies resulted in ests. ranging from low to high.  In addn., GDC-0834 exhibited low clearance in PXB chimeric mice with humanized liver.  Uncertainty in human pharmacokinetic prediction and high interest in a BTK inhibitor for clin. evaluation prompted an investigational new drug strategy, in which GDC-0834 was rapidly advanced to a single-dose human clin. trial.  GDC-0834 plasma concns. in humans were below the limit of quantitation (<1 ng/mL) in most samples from the cohorts dosed orally at 35 and 105 mg.  In contrast, substantial plasma concns. of M1 were obsd.  In human plasma and urine, only M1 and its sequential metabolites were identified.  The formation kinetics of M1 was evaluated in rat, dog, monkey, and human liver microsomes in the absence of NADPH.  The max. rate of M1 formation (Vmax) was substantially higher in human compared with that in other species.  In contrast, the Michaelis-Menten const. (Km) was comparable among species.  Intrinsic clearance (Vmax/Km) of GDC-0834 from M1 formation in human was 23- to 169-fold higher than obsd. in rat, dog, and monkey.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_v1aPr50jkLVg90H21EOLACvtfcHk0ljFsapWSnrUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE&md5=976adc37c4d621924276d174318a1a84</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040840%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Met.%2520Dispersion%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849%26doi%3D10.1124%2Fdmd.111.040840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Plitnick, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzyk, D. J.</span><span> </span><span class="NLM_article-title">The T-dependent antibody response to keyhole limpet hemocyanin in rodents</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">598</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1007/978-1-60761-401-2_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2F978-1-60761-401-2_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19967512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=598&publication_year=2010&pages=159-171&author=L.+M.+Plitnickauthor=D.+J.+Herzyk&title=The+T-dependent+antibody+response+to+keyhole+limpet+hemocyanin+in+rodents&doi=10.1007%2F978-1-60761-401-2_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The T-dependent antibody response to keyhole limpet hemocyanin in rodents</span></div><div class="casAuthors">Plitnick, Lisa M.; Herzyk, Danuta J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">598</span>
        (<span class="NLM_cas:issue">Immunotoxicity Testing</span>),
    <span class="NLM_cas:pages">159-171</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Central to the evaluation of potential immunotoxicants is the concept that measurement of multiple parameters is required for the detn. of toxicity toward the immune system.  A carefully considered integration of endpoints involved in the immune response should be used to det. an immunotoxic effect.  A functional evaluation, specifically the rodent T-cell-dependent antibody response (TDAR) model developed for regulated immunotoxicity evaluations, has been established to detect potential immunotoxicity, esp. immunosuppression, caused by chems. and novel pharmaceuticals in development.  This chapter provides an overview and detailed procedures involved in the TDAR assay that measures the immune response (i.e., antibody prodn.) to an introduced antigen (i.e., keyhole limpet hemocyanin (KLH)) in rats or mice treated with a chem. (e.g., a known immunotoxicant and/or a new drug candidate).  The TDAR model of competent immune function requires the participation of multiple effector cells such as antigen presenting cells, T lymphocytes, and B lymphocytes to produce the final product, the antigen-specific antibody response.  Thus, alterations in the level of antibody prodn. to the specific antigen may reflect effects on any or all of the cell populations involved in TDAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJiPrwzNO6bVg90H21EOLACvtfcHk0lgoTr_hnMnXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymtbs%253D&md5=033e19ab74af5b29b7514899bd17c661</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-401-2_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-401-2_11%26sid%3Dliteratum%253Aachs%26aulast%3DPlitnick%26aufirst%3DL.%2BM.%26aulast%3DHerzyk%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520T-dependent%2520antibody%2520response%2520to%2520keyhole%2520limpet%2520hemocyanin%2520in%2520rodents%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2010%26volume%3D598%26spage%3D159%26epage%3D171%26doi%3D10.1007%2F978-1-60761-401-2_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgoTr_hnMnXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nandakumar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäcklund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">R544</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span><span class="refDoi"> DOI: 10.1186/ar1217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1186%2Far1217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=R544-550&author=K.+S.+Nandakumarauthor=J.+B%C3%A4cklundauthor=M.+Vestbergauthor=R.+Holmdahl&title=Collagen+type+II+%28CII%29-specific+antibodies+induce+arthritis+in+the+absence+of+T+or+B+cells+but+the+arthritis+progression+is+enhanced+by+CII-reactive+T+cells&doi=10.1186%2Far1217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1186%2Far1217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far1217%26sid%3Dliteratum%253Aachs%26aulast%3DNandakumar%26aufirst%3DK.%2BS.%26aulast%3DB%25C3%25A4cklund%26aufirst%3DJ.%26aulast%3DVestberg%26aufirst%3DM.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DCollagen%2520type%2520II%2520%2528CII%2529-specific%2520antibodies%2520induce%2520arthritis%2520in%2520the%2520absence%2520of%2520T%2520or%2520B%2520cells%2520but%2520the%2520arthritis%2520progression%2520is%2520enhanced%2520by%2520CII-reactive%2520T%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2004%26volume%3D6%26spage%3DR544%26epage%3D550%26doi%3D10.1186%2Far1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kagari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimozato, T.</span><span> </span><span class="NLM_article-title">Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">4318</span><span class="NLM_x">–</span> <span class="NLM_lpage">4324</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.8.4318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.170.8.4318" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=4318-4324&author=T.+Kagariauthor=D.+Tanakaauthor=H.+Doiauthor=T.+Shimozato&title=Essential+role+of+Fc+gamma+receptors+in+anti-type+II+collagen+antibody-induced+arthritis&doi=10.4049%2Fjimmunol.170.8.4318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.8.4318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.8.4318%26sid%3Dliteratum%253Aachs%26aulast%3DKagari%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DD.%26aulast%3DDoi%26aufirst%3DH.%26aulast%3DShimozato%26aufirst%3DT.%26atitle%3DEssential%2520role%2520of%2520Fc%2520gamma%2520receptors%2520in%2520anti-type%2520II%2520collagen%2520antibody-induced%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D4318%26epage%3D4324%26doi%3D10.4049%2Fjimmunol.170.8.4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Street, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiblin, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, M. S.</span><span> </span><span class="NLM_article-title">Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1529</span><span class="NLM_x">–</span> <span class="NLM_lpage">1538</span><span class="refDoi"> DOI: 10.1021/jm00063a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00063a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1529-1538&author=L.+J.+Streetauthor=R.+Bakerauthor=J.+L.+Castroauthor=M.+S.+Chambersauthor=A.+R.+Guiblinauthor=S.+C.+Hobbsauthor=V.+G.+Matassaauthor=A.+J.+Reeveauthor=M.+S.+Beer&title=Synthesis+and+serotonergic+activity+of+5-%28oxadiazolyl%29tryptamines%3A+potent+agonists+for+5-HT1D+receptors&doi=10.1021%2Fjm00063a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00063a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00063a003%26sid%3Dliteratum%253Aachs%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DCastro%26aufirst%3DJ.%2BL.%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DGuiblin%26aufirst%3DA.%2BR.%26aulast%3DHobbs%26aufirst%3DS.%2BC.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DReeve%26aufirst%3DA.%2BJ.%26aulast%3DBeer%26aufirst%3DM.%2BS.%26atitle%3DSynthesis%2520and%2520serotonergic%2520activity%2520of%25205-%2528oxadiazolyl%2529tryptamines%253A%2520potent%2520agonists%2520for%25205-HT1D%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1529%26epage%3D1538%26doi%3D10.1021%2Fjm00063a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kamata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotake, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niijima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugumi, H. A.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1248/cpb.52.1071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1248%2Fcpb.52.1071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=1071-1081&author=J.+Kamataauthor=T.+Okadaauthor=Y.+Kotakeauthor=J.+Niijimaauthor=K.+Nakamuraauthor=T.+Uenakaauthor=A.+Yamaguchiauthor=K.+Tsukaharaauthor=T.+Nagasuauthor=N.+Koyanagiauthor=K.+Kitohauthor=K.+Yoshimatsuauthor=H.+Yoshinoauthor=H.+A.+Sugumi&title=Synthesis+and+evaluation+of+novel+pyrimido-acridone%2C+-phenoxadine%2C+and+-carbazole+as+topoisomerase+II+inhibitors&doi=10.1248%2Fcpb.52.1071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.1071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.1071%26sid%3Dliteratum%253Aachs%26aulast%3DKamata%26aufirst%3DJ.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DNiijima%26aufirst%3DJ.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DTsukahara%26aufirst%3DK.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DSugumi%26aufirst%3DH.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520pyrimido-acridone%252C%2520-phenoxadine%252C%2520and%2520-carbazole%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D1071%26epage%3D1081%26doi%3D10.1248%2Fcpb.52.1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lucca, G. V.</span><span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2206</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0ljORyvRiiJ9LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieltyka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elvebak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span> </span><span class="NLM_article-title">An integrated bioanalytical platform for supporting high-throughput serum protein binding screening</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3601</span><div class="note"><p class="first last">(protein binding)</p></div><span class="refDoi"> DOI: 10.1002/rcm.4817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Frcm.4817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21080511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=3593-3601&author=J.+Zhangauthor=W.+Z.+Shouauthor=M.+Vathauthor=K.+Kieltykaauthor=J.+Maloneyauthor=L.+Elvebakauthor=J.+Stewartauthor=J.+Herbstauthor=H.+N.+Weller&title=An+integrated+bioanalytical+platform+for+supporting+high-throughput+serum+protein+binding+screening&doi=10.1002%2Frcm.4817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated bioanalytical platform for supporting high-throughput serum protein binding screening</span></div><div class="casAuthors">Zhang, Jun; Shou, Wilson Z.; Vath, Marianne; Kieltyka, Kasia; Maloney, Jennifer; Elvebak, Larry; Stewart, Jeremy; Herbst, John; Weller, Harold N.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3593-3601</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Quantification of small mols. using liq. chromatog./tandem mass spectrometry (LC/MS/MS) on a triple quadrupole mass spectrometer has become a common practice in bioanal. support of in vitro adsorption, distribution, metab. and excretion (ADME) screening.  The bioanal. process involves primarily three indispensable steps: MS/MS optimization for a large no. of new chem. compds. undergoing various screening assays in early drug discovery, high-throughput sample anal. with LC/MS/MS for those chem. diverse compds. using the optimized MS/MS conditions, and post-acquisition data review and reporting.  To improve overall efficiency of ADME bioanal., an integrated system was proposed featuring an automated and unattended MS/MS optimization, a staggered parallel LC/MS/MS for high-throughput sample anal., and a sophisticated software tool for LC/MS/MS raw data review as well as biol. data calcn. and reporting.  The integrated platform has been used in bioanal. support of a serum protein binding screening assay with high speed, high capacity, and good robustness.  In this new platform, a unique sample diln. scheme was also introduced.  With this diln. design, the total no. of anal. samples was reduced; therefore, the total operation time was reduced and the overall throughput was further improved.  The performance of the protein binding screening assay was monitored with two controls representing high and low binding properties and an acceptable inter-assay consistency was achieved.  This platform has been successfully used for the detn. of serum protein binding in multiple species for more than 4000 compds.  Copyright © 2010 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mXcL-JCF37Vg90H21EOLACvtfcHk0ljORyvRiiJ9LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb7M&md5=476a8b2315eddc9f9a1cc56895480dbc</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1002%2Frcm.4817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4817%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DElvebak%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26atitle%3DAn%2520integrated%2520bioanalytical%2520platform%2520for%2520supporting%2520high-throughput%2520serum%2520protein%2520binding%2520screening%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2010%26volume%3D24%26spage%3D3593%26epage%3D3601%26doi%3D10.1002%2Frcm.4817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zvyaga, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuppugalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorndike, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1698</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><div class="note"><p class="first last">(HLM CYP)</p></div><span class="refDoi"> DOI: 10.1124/dmd.112.045575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fdmd.112.045575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22648560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1698-1711&author=T.+A.+Zvyagaauthor=S.-Y.+Changauthor=C.+Chenauthor=Z.+Yangauthor=R.+Vuppugallaauthor=J.+Hurleyauthor=D.+Thorndikeauthor=A.+Wagnerauthor=A.+Chimalakondaauthor=A.+D.+Rodrigues&title=Evaluation+of+six+proton+pump+inhibitors+as+inhibitors+of+various+human+cytochromes+P450%3A+focus+on+cytochrome+P450+2C19&doi=10.1124%2Fdmd.112.045575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19</span></div><div class="casAuthors">Zvyaga, Tatyana; Chang, Shu-Ying; Chen, Cliff; Yang, Zheng; Vuppugalla, Ragini; Hurley, Jeremy; Thorndike, Denise; Wagner, Andrew; Chimalakonda, Anjaneya; Rodrigues, A. David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1698-1711</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole, dexlansoprazole, pantoprazole, and rabeprazole, were shown to be weak inhibitors of cytochromes P 450 (CYP3A4, -2B6, -2D6, -2C9, -2C8, and -1A2) in human liver microsomes.  In most cases, IC50 values were > 40 μM, except for dexlansoprazole and lansoprazole with CYP1A2 (IC50 = ∼8 μM) and esomeprazole with CYP2C8 (IC50 = 31 μM).  With the exception of CYP2C19 inhibition by omeprazole and esomeprazole (IC50 ratio, 2.5 to 5.9), there was no evidence for a marked time-dependent shift in IC50 (IC50 ratio, ≤2) after a 30-min preincubation with NADPH.  In the absence of preincubation, lansoprazole (IC50 = 0.73 μM) and esomeprazole (IC50 = 3.7 μM) were the most potent CYP2C19 inhibitors, followed by dexlansoprazole and omeprazole (IC50 = ∼7.0 μM).  Rabeprazole and pantoprazole (IC50 = ≥25 μM) were the weakest.  A similar ranking was obtained with recombinant CYP2C19.  Despite the IC50 ranking, after consideration of blood plasma levels (static and dynamic), protein binding, and metab.-dependent inhibition, it is concluded that omeprazole and esomeprazole are the most potent CYP2C19 inhibitors.  This was confirmed after the incubation of the individual PPIs with human primary hepatocytes (in the presence of human serum) and by monitoring their impact on diazepam N-demethylase activity at a low concn. of diazepam (2 μM).  Data described herein are consistent with reports that PPIs are mostly weak inhibitors of cytochromes P 450 in vivo.  However, 2 members of the PPI class (esomeprazole and omeprazole) are more likely to serve as clin. relevant inhibitors of CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Il9jjcdDvrVg90H21EOLACvtfcHk0ljr7urELwlnHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShtbjK&md5=4f2d29cbfbda06e4181f6e869ed37c3d</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045575%26sid%3Dliteratum%253Aachs%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DChang%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DThorndike%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DEvaluation%2520of%2520six%2520proton%2520pump%2520inhibitors%2520as%2520inhibitors%2520of%2520various%2520human%2520cytochromes%2520P450%253A%2520focus%2520on%2520cytochrome%2520P450%25202C19%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1698%26epage%3D1711%26doi%3D10.1124%2Fdmd.112.045575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paiva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H.</span><span> </span><span class="NLM_article-title">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography–tandem mass spectrometry</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2755</span><span class="NLM_x">–</span> <span class="NLM_lpage">2762</span><div class="note"><p class="first last">(Caco-2)</p></div><span class="refDoi"> DOI: 10.1002/jps.23194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Fjps.23194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22611052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=2755-2762&author=X.+Caiauthor=A.+Walkerauthor=C.+Chengauthor=A.+Paivaauthor=Y.+Liauthor=J.+Kolbauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Approach+to+improve+compound+recovery+in+a+high-throughput+Caco-2+permeability+assay+supported+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fjps.23194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Cai, Xianmei; Walker, Aaron; Cheng, Charles; Paiva, Anthony; Li, Ying; Kolb, Janet; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2755-2762</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The Caco-2 cell culture system is widely employed as an in vitro model for prediction of intestinal absorption of test compds. in early drug discovery.  Poor recovery is a commonly encountered issue in Caco-2 assay, which can lead to difficulty in data interpretation and underestimation of the apparent permeability of affected compds.  In this study, we systematically investigated the potential sources of compd. loss in our automated, high-throughput Caco-2 assay, sample storage, and anal. processes, and as a result found the nonspecific binding to various plastic surfaces to be the major cause of poor compd. recovery.  To minimize the nonspecific binding, we implemented a simple and practical approach in our assay automation by preloading collection plates with org. solvent contg. internal std. prior to transferring incubations samples.  The implementation of this new method has been shown to significantly increase recovery in many compds. previously identified as having poor recovery in the Caco-2 permeability assay.  With improved recovery, permeability results were obtained for many compds. that were previously not detected in the basolateral samples.  In addn. to recovery improvement, this new approach also simplified sample prepn. for liq. chromatog.-tandem mass spectrometric anal. and therefore achieved time and cost savings for the bioanalyst. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3d7jZyPfxPLVg90H21EOLACvtfcHk0ljr7urELwlnHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D&md5=16cfacab071344c98a95dc8c6f4483af</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fjps.23194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23194%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DApproach%2520to%2520improve%2520compound%2520recovery%2520in%2520a%2520high-throughput%2520Caco-2%2520permeability%2520assay%2520supported%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D2755%26epage%3D2762%26doi%3D10.1002%2Fjps.23194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25d"><span><span class="NLM_label">(d) </span> PAMPA Evolution. <a href="http://www.pion-inc.com/Products/PAMPA_Evolution/en" class="extLink">http://www.pion-inc.com/Products/PAMPA_Evolution/en</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PAMPA+Evolution.+http%3A%2F%2Fwww.pion-inc.com%2FProducts%2FPAMPA_Evolution%2Fen."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kieltyka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baglieri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. Z.</span><span> </span><span class="NLM_article-title">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span><div class="note"><p class="first last">(liver microsome metabolic stability).</p></div><span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+high-throughput+bioanalytical+platform+using+automated+infusion+for+tandem+mass+spectrometric+method+optimization+and+its+application+in+a+metabolic+stability+screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25eR"><div class="casContent"><span class="casTitleNuber">25e</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0ljr7urELwlnHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit25e&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520high-throughput%2520bioanalytical%2520platform%2520using%2520automated%2520infusion%2520for%2520tandem%2520mass%2520spectrometric%2520method%2520optimization%2520and%2520its%2520application%2520in%2520a%2520metabolic%2520stability%2520screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c','cit25d','cit25e']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2195-2203. <a href="https://doi.org/10.1021/acsmedchemlett.0c00335" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDriving%252BPotency%252Bwith%252BRotationally%252BStable%252BAtropisomers%25253A%252BDiscovery%252Bof%252BPyridopyrimidinedione-Carbazole%252BInhibitors%252Bof%252BBTK%26aulast%3DSrivastava%26aufirst%3DAnurag%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D16092020%26date%3D22092020%26date%3D16092020%26volume%3D11%26issue%3D11%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6561-6574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Aminoquinoline-3-carboxamide%252BDerivatives%252Bas%252BPotent%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DYao%26aufirst%3DXia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D12072019%26date%3D01072019%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven M. Mennen, Carolina Alhambra, C. Liana Allen, Mario Barberis, Simon Berritt, Thomas A. Brandt, Andrew D. Campbell, Jesús Castañón, Alan H. Cherney, Melodie Christensen, David B. Damon, J. Eugenio de Diego, Susana García-Cerrada, Pablo García-Losada, Rubén Haro, Jacob Janey, David C. Leitch, Ling Li, Fangfang Liu, Paul C. Lobben, David W. C. MacMillan, Javier Magano, Emma McInturff, Sebastien Monfette, Ronald J. Post, Danielle Schultz, Barbara J. Sitter, Jason M. Stevens, Iulia I. Strambeanu, Jack Twilton, Ke Wang, <span class="NLM_string-name hlFld-ContribAuthor">Matthew A. Zajac</span>. </span><span class="cited-content_cbyCitation_article-title">The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (6)
                                     , 1213-1242. <a href="https://doi.org/10.1021/acs.oprd.9b00140" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00140%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DThe%252BEvolution%252Bof%252BHigh-Throughput%252BExperimentation%252Bin%252BPharmaceutical%252BDevelopment%252Band%252BPerspectives%252Bon%252Bthe%252BFuture%26aulast%3DMennen%26aufirst%3DSteven%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D31052019%26date%3D07052019%26volume%3D23%26issue%3D6%26spage%3D1213%26epage%3D1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter-Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3228-3250. <a href="https://doi.org/10.1021/acs.jmedchem.9b00167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBranebrutinib%252B%252528BMS-986195%252529%25253A%252BA%252BStrategy%252Bfor%252BIdentifying%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252BProviding%252BRapid%252Bin%252BVivo%252BInactivation%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%26aulast%3DWatterson%26aufirst%3DScott%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27012019%26date%3D29032019%26date%3D20032019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John R. Coombs, Rebecca A. Green, Frederick Roberts, Eric M. Simmons, Jason M. Stevens, <span class="NLM_string-name hlFld-ContribAuthor">Steven R. Wisniewski</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Base-Metal Catalysis: Development of a Screening Platform for Nickel-Catalyzed Borylations of Aryl (Pseudo)halides with B2(OH)4. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     , 157-166. <a href="https://doi.org/10.1021/acs.organomet.8b00307" title="DOI URL">https://doi.org/10.1021/acs.organomet.8b00307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.8b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.8b00307%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DAdvances%252Bin%252BBase-Metal%252BCatalysis%25253A%252BDevelopment%252Bof%252Ba%252BScreening%252BPlatform%252Bfor%252BNickel-Catalyzed%252BBorylations%252Bof%252BAryl%252B%252528Pseudo%252529halides%252Bwith%252BB2%252528OH%2525294%26aulast%3DCoombs%26aufirst%3DJohn%2BR.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11052018%26date%3D14082018%26volume%3D38%26issue%3D1%26spage%3D157%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven R. Wisniewski, Ronald Carrasquillo-Flores, Federico Lora Gonzalez, Antonio Ramirez, Matthew Casey, Maxime Soumeillant, Thomas M. Razler, <span class="NLM_string-name hlFld-ContribAuthor">Brendan Mack</span>. </span><span class="cited-content_cbyCitation_article-title">Adventures in Atropisomerism: Development of a Robust, Diastereoselective, Lithium-Catalyzed Atropisomer-Forming Active Pharmaceutical Ingredient Step. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (10)
                                     , 1426-1431. <a href="https://doi.org/10.1021/acs.oprd.8b00246" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00246%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAdventures%252Bin%252BAtropisomerism%25253A%252BDevelopment%252Bof%252Ba%252BRobust%25252C%252BDiastereoselective%25252C%252BLithium-Catalyzed%252BAtropisomer-Forming%252BActive%252BPharmaceutical%252BIngredient%252BStep%26aulast%3DWisniewski%26aufirst%3DSteven%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01082018%26date%3D03102018%26date%3D11092018%26volume%3D22%26issue%3D10%26spage%3D1426%26epage%3D1431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gregory Beutner, Ronald Carrasquillo, Peng Geng, Yi Hsiao, Eric C. Huang, Jacob Janey, Kishta Katipally, Sergei Kolotuchin, Thomas La Porte, Andrew Lee, Paul Lobben, Federico Lora-Gonzalez, Brendan Mack, Boguslaw Mudryk, Yuping Qiu, Xinhua Qian, Antonio Ramirez, Thomas M. Razler, Thorsten Rosner, Zhongping Shi, Eric Simmons, Jason Stevens, Jianji Wang, Carolyn Wei, Steven R. Wisniewski, <span class="NLM_string-name hlFld-ContribAuthor">Ye Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Adventures in Atropisomerism: Total Synthesis of a Complex Active Pharmaceutical Ingredient with Two Chirality Axes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (13)
                                     , 3736-3740. <a href="https://doi.org/10.1021/acs.orglett.8b01218" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01218%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAdventures%252Bin%252BAtropisomerism%25253A%252BTotal%252BSynthesis%252Bof%252Ba%252BComplex%252BActive%252BPharmaceutical%252BIngredient%252Bwith%252BTwo%252BChirality%252BAxes%26aulast%3DBeutner%26aufirst%3DGregory%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17042018%26date%3D17062018%26volume%3D20%26issue%3D13%26spage%3D3736%26epage%3D3740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">James  Barbosa</span>, <span class="hlFld-ContribAuthor ">Peter  Blomgren</span>, <span class="hlFld-ContribAuthor ">Meire C.  Bremer</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wei  Deng</span>, <span class="hlFld-ContribAuthor ">Liming  Dong</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Steve  Gallion</span>, <span class="hlFld-ContribAuthor ">Jonathon  Hau</span>, <span class="hlFld-ContribAuthor ">Huiyong  Hu</span>, <span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jeffrey E.  Kropf</span>, <span class="hlFld-ContribAuthor ">Seung H.  Lee</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Lubach</span>, <span class="hlFld-ContribAuthor ">Jen  Macaluso</span>, <span class="hlFld-ContribAuthor ">Pat  Maciejewski</span>, <span class="hlFld-ContribAuthor ">Scott A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Julie  DiPaolo</span>, <span class="hlFld-ContribAuthor ">Karin  Reif</span>, <span class="hlFld-ContribAuthor ">Heleen  Scheerens</span>, <span class="hlFld-ContribAuthor ">Aaron  Schmitt</span>, <span class="hlFld-ContribAuthor ">Harvey  Wong</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Xiong</span>, <span class="hlFld-ContribAuthor ">Jianjun  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongdong  Zhao</span>, <span class="hlFld-ContribAuthor ">Fusheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, and <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 608-613. <a href="https://doi.org/10.1021/acsmedchemlett.7b00103" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00103%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BTricyclic%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BImproved%252BDruglike%252BProperties%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08032017%26date%3D03052017%26date%3D16052017%26date%3D08062017%26date%3D03052017%26volume%3D8%26issue%3D6%26spage%3D608%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">George V.  De Lucca</span>, <span class="hlFld-ContribAuthor ">Qing  Shi</span>, <span class="hlFld-ContribAuthor ">Charles M.  Langevine</span>, <span class="hlFld-ContribAuthor ">Qingjie  Liu</span>, <span class="hlFld-ContribAuthor ">Douglas G.  Batt</span>, <span class="hlFld-ContribAuthor ">Myra  Beaudoin Bertrand</span>, <span class="hlFld-ContribAuthor ">Hua  Gong</span>, <span class="hlFld-ContribAuthor ">Jun  Dai</span>, <span class="hlFld-ContribAuthor ">Shiuhang  Yip</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Dawn  Sun</span>, <span class="hlFld-ContribAuthor ">Dauh-Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">Chunlei  Wang</span>, <span class="hlFld-ContribAuthor ">Yingru  Zhang</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Traeger</span>, <span class="hlFld-ContribAuthor ">Mark A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">Stacey  Skala</span>, <span class="hlFld-ContribAuthor ">Lihong  Cheng</span>, <span class="hlFld-ContribAuthor ">Mary T.  Obermeier</span>, <span class="hlFld-ContribAuthor ">Rodney  Vickery</span>, <span class="hlFld-ContribAuthor ">Lorell N.  Discenza</span>, <span class="hlFld-ContribAuthor ">Celia J.  D’Arienzo</span>, <span class="hlFld-ContribAuthor ">Yifan  Zhang</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Heimrich</span>, <span class="hlFld-ContribAuthor ">Kathleen M.  Gillooly</span>, <span class="hlFld-ContribAuthor ">Tracy L.  Taylor</span>, <span class="hlFld-ContribAuthor ">Claudine  Pulicicchio</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Michael A.  Galella</span>, <span class="hlFld-ContribAuthor ">Andy J.  Tebben</span>, <span class="hlFld-ContribAuthor ">Jodi K.  Muckelbauer</span>, <span class="hlFld-ContribAuthor ">ChiehYing  Chang</span>, <span class="hlFld-ContribAuthor ">Richard  Rampulla</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Luisa  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">James R.  Burke</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 9173-9200. <a href="https://doi.org/10.1021/acs.jmedchem.6b01088" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-Fluoro-5-%252528R%252529-%2525283-%252528S%252529-%2525288-fluoro-1-methyl-2%25252C4-dioxo-1%25252C2-dihydroquinazolin-3%2525284H%252529-yl%252529-2-methylphenyl%252529-2-%252528S%252529-%2525282-hydroxypropan-2-yl%252529-2%25252C3%25252C4%25252C9-tetrahydro-1H-carbazole-8-carboxamide%252B%252528BMS-986142%252529%25253A%252BA%252BReversible%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BConformationally%252BConstrained%252Bby%252BTwo%252BLocked%252BAtropisomers%26aulast%3DWatterson%26aufirst%3DScott%2BH.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21072016%26date%3D19092016%26date%3D13102016%26date%3D01092016%26volume%3D59%26issue%3D19%26spage%3D9173%26epage%3D9200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba S.A.  ElZahabi</span>, <span class="hlFld-ContribAuthor ">Mohamed S.  Nafie</span>, <span class="hlFld-ContribAuthor ">Dina  Osman</span>, <span class="hlFld-ContribAuthor ">Nehal H.  Elghazawy</span>, <span class="hlFld-ContribAuthor ">Dalia H.  Soliman</span>, <span class="hlFld-ContribAuthor ">Abdelghany Ali H.  EL-Helby</span>, <span class="hlFld-ContribAuthor ">Reem K.  Arafa</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113609. <a href="https://doi.org/10.1016/j.ejmech.2021.113609" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113609%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnew%252Bquinazolin-4-one%252Bderivatives%252Bas%252Bapoptotic%252Benhancers%252Band%252Bautophagy%252Binhibitors%252Bwith%252Bpotent%252Bantitumor%252Bactivity%26aulast%3DElZahabi%26aufirst%3DHeba%2BS.A.%26date%3D2021%26volume%3D222%26spage%3D113609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy J.  Hagen</span>, <span class="hlFld-ContribAuthor ">Travis R.  Helgren</span>. </span><span class="cited-content_cbyCitation_article-title">Chirality and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-45. <a href="https://doi.org/10.1002/0471266949.bmc016.pub3" title="DOI URL">https://doi.org/10.1002/0471266949.bmc016.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc016.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc016.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DChirality%252Band%252BDrug%252BDiscovery%26aulast%3DHagen%26aufirst%3DTimothy%2BJ.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D45%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113094. <a href="https://doi.org/10.1016/j.ejmech.2020.113094" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113094%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C4%25252C6-Trisubstituted%252Bimidazo%25255B4%25252C5-c%25255Dpyridines%252Bas%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2021%26volume%3D211%26spage%3D113094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian M.  Catlett</span>, <span class="hlFld-ContribAuthor ">Miroslawa  Nowak</span>, <span class="hlFld-ContribAuthor ">Sudeep  Kundu</span>, <span class="hlFld-ContribAuthor ">Naiyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Ang  Liu</span>, <span class="hlFld-ContribAuthor ">Bing  He</span>, <span class="hlFld-ContribAuthor ">Ihab G.  Girgis</span>, <span class="hlFld-ContribAuthor ">Dennis M.  Grasela</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2020,</strong> <em>86 </em>
                                    (9)
                                     , 1849-1859. <a href="https://doi.org/10.1111/bcp.14290" title="DOI URL">https://doi.org/10.1111/bcp.14290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14290%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacokinetics%252Band%252Bpharmacodynamics%252Bof%252Bbranebrutinib%252B%252528BMS%2525E2%252580%252590986195%252529%25252C%252Ba%252Bcovalent%25252C%252Birreversible%252Binhibitor%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%25253A%252BRandomised%252Bphase%252BI%25252C%252Bplacebo%2525E2%252580%252590controlled%252Btrial%252Bin%252Bhealthy%252Bparticipants%26aulast%3DCatlett%26aufirst%3DIan%2BM.%26date%3D2020%26date%3D2020%26volume%3D86%26issue%3D9%26spage%3D1849%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. L.  Ong</span>, <span class="hlFld-ContribAuthor ">J. D.  Vasta</span>, <span class="hlFld-ContribAuthor ">L.  Monereau</span>, <span class="hlFld-ContribAuthor ">G.  Locke</span>, <span class="hlFld-ContribAuthor ">H.  Ribeiro</span>, <span class="hlFld-ContribAuthor ">M. A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">S.  Skala</span>, <span class="hlFld-ContribAuthor ">J. R.  Burke</span>, <span class="hlFld-ContribAuthor ">S. H.  Watterson</span>, <span class="hlFld-ContribAuthor ">J. A.  Tino</span>, <span class="hlFld-ContribAuthor ">P. L.  Meisenheimer</span>, <span class="hlFld-ContribAuthor ">B.  Arey</span>, <span class="hlFld-ContribAuthor ">J.  Lippy</span>, <span class="hlFld-ContribAuthor ">L.  Zhang</span>, <span class="hlFld-ContribAuthor ">M. B.  Robers</span>, <span class="hlFld-ContribAuthor ">A.  Tebben</span>, <span class="hlFld-ContribAuthor ">C.  Chaudhry</span>. </span><span class="cited-content_cbyCitation_article-title">A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 176-185. <a href="https://doi.org/10.1177/2472555219884881" title="DOI URL">https://doi.org/10.1177/2472555219884881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219884881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219884881%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DA%252BHigh-Throughput%252BBRET%252BCellular%252BTarget%252BEngagement%252BAssay%252BLinks%252BBiochemical%252Bto%252BCellular%252BActivity%252Bfor%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DOng%26aufirst%3DL.%2BL.%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D176%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Wenjun  Xie</span>, <span class="hlFld-ContribAuthor ">Xintong  Wang</span>, <span class="hlFld-ContribAuthor ">Zongze  Huang</span>, <span class="hlFld-ContribAuthor ">Xiling  Bian</span>, <span class="hlFld-ContribAuthor ">KeWei  Wang</span>, <span class="hlFld-ContribAuthor ">Qi  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical conversion of nicotinamide into type I positive allosteric modulator of α7 nAChRs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (15)
                                     , 1928-1933. <a href="https://doi.org/10.1016/j.bmcl.2019.05.046" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.05.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.05.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DChemical%252Bconversion%252Bof%252Bnicotinamide%252Binto%252Btype%252BI%252Bpositive%252Ballosteric%252Bmodulator%252Bof%252B%2525CE%2525B17%252BnAChRs%26aulast%3DLi%26aufirst%3DXin%26date%3D2019%26volume%3D29%26issue%3D15%26spage%3D1928%26epage%3D1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyu  Li</span>, <span class="hlFld-ContribAuthor ">Binyu  Shi</span>, <span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Huizhu  Yang</span>, <span class="hlFld-ContribAuthor ">Jiurong  Li</span>, <span class="hlFld-ContribAuthor ">Lianjian  Wang</span>, <span class="hlFld-ContribAuthor ">Siying  He</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 294-299. <a href="https://doi.org/10.1039/C8MD00413G" title="DOI URL">https://doi.org/10.1039/C8MD00413G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00413G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00413G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2-phenyl%252Bpyrimidine%252Bderivatives%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DLi%26aufirst%3DXinyu%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D294%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Liu</span>, <span class="hlFld-ContribAuthor ">Douglas G.  Batt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Lippy</span>, <span class="hlFld-ContribAuthor ">Mark A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">Neha  Surti</span>, <span class="hlFld-ContribAuthor ">Songmei  Xu</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">James R.  Burke</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3080-3084. <a href="https://doi.org/10.1016/j.bmcl.2018.07.041" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConversion%252Bof%252Bcarbazole%252Bcarboxamide%252Bbased%252Breversible%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binto%252Bpotent%25252C%252Bselective%252Birreversible%252Binhibitors%252Bin%252Bthe%252Bcarbazole%25252C%252Btetrahydrocarbazole%25252C%252Band%252Ba%252Bnew%252B2%25252C3-dimethylindole%252Bseries%26aulast%3DLiu%26aufirst%3DQingjie%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3080%26epage%3D3084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Li</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>, <span class="hlFld-ContribAuthor ">Zhipei  Gao</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (4)
                                     , 1244. <a href="https://doi.org/10.3390/ijms19041244" title="DOI URL">https://doi.org/10.3390/ijms19041244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19041244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19041244%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BModeling%252BStudies%252Bon%252BCarbazole%252BCarboxamide%252BBased%252BBTK%252BInhibitors%252BUsing%252BDocking%252Band%252BStructure-Based%252B3D-QSAR%26aulast%3DLi%26aufirst%3DRui%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D4%26spage%3D1244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Mingli  Tang</span>, <span class="hlFld-ContribAuthor ">Taijing  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoxin  Chen</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 7 H -pyrrolo[2,3- d ]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 96-112. <a href="https://doi.org/10.1016/j.ejmech.2017.12.079" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.079%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252Bselective%252BBtk%252Binhibitors%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2018%26volume%3D145%26spage%3D96%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter W.  Glunz</span>. </span><span class="cited-content_cbyCitation_article-title">Recent encounters with atropisomerism in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (2)
                                     , 53-60. <a href="https://doi.org/10.1016/j.bmcl.2017.11.050" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.11.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.11.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bencounters%252Bwith%252Batropisomerism%252Bin%252Bdrug%252Bdiscovery%26aulast%3DGlunz%26aufirst%3DPeter%2BW.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D53%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Agathe C.A.  D'Hollander</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Westwood</span>. </span><span class="cited-content_cbyCitation_article-title">Assessment of the regioselectivity in the condensation reaction of unsymmetrical o -phthaldialdehydes with alanine. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (2)
                                     , 224-239. <a href="https://doi.org/10.1016/j.tet.2017.11.035" title="DOI URL">https://doi.org/10.1016/j.tet.2017.11.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2017.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2017.11.035%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAssessment%252Bof%252Bthe%252Bregioselectivity%252Bin%252Bthe%252Bcondensation%252Breaction%252Bof%252Bunsymmetrical%252Bo%252B-phthaldialdehydes%252Bwith%252Balanine%26aulast%3DD%2527Hollander%26aufirst%3DAgathe%2BC.A.%26date%3D2018%26volume%3D74%26issue%3D2%26spage%3D224%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James  Kempson</span>, <span class="hlFld-ContribAuthor ">Damaso  Ovalle</span>, <span class="hlFld-ContribAuthor ">Junqing  Guo</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>, <span class="hlFld-ContribAuthor ">Shuqun  Lin</span>, <span class="hlFld-ContribAuthor ">Steven H.  Spergel</span>, <span class="hlFld-ContribAuthor ">James J.-W.  Duan</span>, <span class="hlFld-ContribAuthor ">Bin  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhonghui  Lu</span>, <span class="hlFld-ContribAuthor ">Jagabandhu  Das</span>, <span class="hlFld-ContribAuthor ">Bingwei V.  Yang</span>, <span class="hlFld-ContribAuthor ">John  Hynes</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">John  Tokarski</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Javed  Khan</span>, <span class="hlFld-ContribAuthor ">Gary  Schieven</span>, <span class="hlFld-ContribAuthor ">Yuval  Blatt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of highly potent, selective, covalent inhibitors of JAK3. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (20)
                                     , 4622-4625. <a href="https://doi.org/10.1016/j.bmcl.2017.09.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Bcovalent%252Binhibitors%252Bof%252BJAK3%26aulast%3DKempson%26aufirst%3DJames%26date%3D2017%26volume%3D27%26issue%3D20%26spage%3D4622%26epage%3D4625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdul Ashik  Khan</span>, <span class="hlFld-ContribAuthor ">Kanchan  Mitra</span>, <span class="hlFld-ContribAuthor ">Abhijit  Mandal</span>, <span class="hlFld-ContribAuthor ">Nabajyoti  Baildya</span>, <span class="hlFld-ContribAuthor ">Mohabul A.  Mondal</span>. </span><span class="cited-content_cbyCitation_article-title">Yttrium nitrate catalyzed synthesis, photophysical study, and TD-DFT calculation of 2,3-dihydroquinazolin-4(1H)-ones. </span><span class="cited-content_cbyCitation_journal-name">Heteroatom Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (4)
                                     , e21379. <a href="https://doi.org/10.1002/hc.21379" title="DOI URL">https://doi.org/10.1002/hc.21379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hc.21379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhc.21379%26sid%3Dliteratum%253Aachs%26jtitle%3DHeteroatom%2520Chemistry%26atitle%3DYttrium%252Bnitrate%252Bcatalyzed%252Bsynthesis%25252C%252Bphotophysical%252Bstudy%25252C%252Band%252BTD-DFT%252Bcalculation%252Bof%252B2%25252C3-dihydroquinazolin-4%2525281H%252529-ones%26aulast%3DKhan%26aufirst%3DAbdul%2BAshik%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D4%26spage%3De21379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Tao</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free One-pot Synthesis of Functionalized Carbazoles. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (7)
                                     , 2282-2287. <a href="https://doi.org/10.1002/slct.201700128" title="DOI URL">https://doi.org/10.1002/slct.201700128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201700128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201700128%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DMetal-free%252BOne-pot%252BSynthesis%252Bof%252BFunctionalized%252BCarbazoles%26aulast%3DTao%26aufirst%3DSheng%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D7%26spage%3D2282%26epage%3D2287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Dai</span>, <span class="hlFld-ContribAuthor ">Chunlei  Wang</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Traeger</span>, <span class="hlFld-ContribAuthor ">Lorell  Discenza</span>, <span class="hlFld-ContribAuthor ">Mary T.  Obermeier</span>, <span class="hlFld-ContribAuthor ">Adrienne A.  Tymiak</span>, <span class="hlFld-ContribAuthor ">Yingru  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2017,</strong> <em>1487 </em>, 116-128. <a href="https://doi.org/10.1016/j.chroma.2017.01.016" title="DOI URL">https://doi.org/10.1016/j.chroma.2017.01.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2017.01.016%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DThe%252Brole%252Bof%252Bchromatographic%252Band%252Bchiroptical%252Bspectroscopic%252Btechniques%252Band%252Bmethodologies%252Bin%252Bsupport%252Bof%252Bdrug%252Bdiscovery%252Bfor%252Batropisomeric%252Bdrug%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DDai%26aufirst%3DJun%26date%3D2017%26volume%3D1487%26spage%3D116%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BTK irreversible inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Initial lead <b>5</b> and optimized compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial optimization of carbazole core series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A, B) Compound <b>23</b> X-ray crystal structure bound to BTK kinase domain: (A) electron density mapping of <b>23</b>; (B) binding of <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>), including waters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Efficacy of <b>6</b> (5, 20, and 45 mg/kg) vs vehicle in a mouse neoantigen (KLH) antibody response model. (B) Plasma exposures of <b>6</b> in satellite animals. Female BALB/c mice (8–12 weeks old, Harlan) were immunized ip with 250 μg of KLH in PBS on day 0. Mice were dosed daily by oral gavage with vehicle (EtOH:TPGS:PEG300, 5:5:90) or compound <b>6</b> at doses of 5, 20, or 45 mg/kg. Blood was collected on days 7 and 14 postimmunization. Serum was separated and analyzed for anti-KLH IgM titers (day 7) and anti-KLH IgG titers (day 14) by ELISA. (A) Day 7 IgM (gray bars) and day 14 IgG (dark bars) anti-KLH titers ((∗) <i>p</i> < 0.05 vs vehicle, ANOVA with Dunnett’s post-test). (B) Serum drug levels from day 1 satellite mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of <b>6</b> (10, 20, and 30 mg/kg) vs vehicle in a mouse collagen induced arthritis (CIA) inflammation model. DBA/1 male mice were immunized subcutaneously at the base of the tail on day 0 and again on day 21 with 200 μg of bovine type II collagen admixed with reconstituted Sigma Adjuvant System (SAS; Sigma-Aldrich). Mice were dosed daily by oral gavage with vehicle (EtOH:TPGS:PEG300, 5:5:90) or compound <b>6</b> starting on day 0. Mice were monitored 3 times per week for the development and severity of paw inflammation. Clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group: (∗) <i>p</i> < 0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0007.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Bone and inflammation efficacy of <b>6</b> (10, 20, and 30 mg/kg) vs vehicle in a mouse CIA model. Histological evaluation of rear paws from the CIA study. Lesions were scored on a severity scale of 0 (normal) to 4 in two separate categories, inflammation (cellular infiltration and pannus formation), and bone resorption. Results represent the mean ± SEM: (∗∗) <i>p</i> < 0.01 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0008.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representative microcomputed tomography (micro-CT) images of the hind paws of CIA mice treated with <b>6</b> (10, 20, and 30 mg/kg). Hind paws were excised post-mortem and analyzed by micro-CT after fixation in 10% neutral buffered formalin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0009.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Efficacy of <b>6</b> (10 and 30 mg/kg) vs vehicle and dexamethasone (Dex) in a mouse anti-collagen antibody-induced arthritis (CAIA) inflammation model. Mice (<i>N</i> = 8–10 per group) were injected intraperitoneally (ip) with a mixture of four monoclonal antimouse type II collagen antibodies (1 mg of each). Daily oral dosing was immediately started with vehicle (EtOH:TPGS:PEG300, 5:5:90), compound <b>6</b> (10 or 30 mg/kg), or dexamethasone (dex, 1 mg/kg). Three days later, the mice were injected ip with 1.25 mg/kg LPS (<i>E. coli</i> O111:B4; Sigma). Thereafter, mice were monitored 3×/week for the development and severity of paw inflammation. Clinical scores are shown as mean ± SEM: (∗) <i>p</i> < 0.05 vs vehicle group, <i>n</i> = 8–10/group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Bicyclic Amide Replacements<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) Suzuki coupling conditions: Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 50–75%.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>31</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH, 110 °C, 3 h, 58%; (b) NH<sub>4</sub>OH, EDC, HOBt, THF/DCM, rt, 16 h, 76%; (c) DDQ, THF, 0 °C to rt, 86%; (d) MeLi, −60 °C, THF, 84%; (e) LAH, THF, 0 °C, 64%; (f) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bis(1,3,2-dioxaborolane), PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 70–85%.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediates <b>35</b> and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LiOH, THF/ethanol/H<sub>2</sub>O, reflux, 6 h, 96%; (b) 1-methylpiperazine, EDC, HOBt, THF/DCM, rt, 16 h, 96%; (c) (i) diphenylphosphoryl azide, Et<sub>3</sub>N, dioxane, 50 °C, 1.5 h, (ii) benzyl alcohol, 85 °C, 18 h, 91%.</p></p></figure><figure data-id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>5</b>, <b>11</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 77%; (b) 4-F-benzoic acid, EDC, HOAt, DIEA, ACN, rt, 16 h, 92%; (c) 4-fluoropicolinic acid, EDC, HOAt, DIEA, ACN, rt, 18 h, 96%; (d) Pd(Ph<sub>3</sub>P)<sub>4</sub>, 2 M K<sub>3</sub>PO<sub>4</sub>, toluene/ethanol (3/1), 100 °C, 16 h, 60%.</p></p></figure><figure data-id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Boronic Ester Intermediates <b>40a</b> and <b>40b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>3</sub>N, DCM, rt, 2 h, 48%; (b) KOtBu, THF, rt, 1 h, 75%; (c) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 86%.</p></p></figure><figure data-id="sch6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0016.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Intermediates <b>44</b> and <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH, 110 °C, 16 h, 36%; (b) NaBH<sub>4</sub>, MeOH, rt, 6 h, 95%; (c) TFA, DCM, rt, 2 h, 67%; (d) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 67%; (e) CuI, K<sub>2</sub>CO<sub>3</sub>, DMSO, 150 °C, 1.5 h, 15%.</p></p></figure><figure data-id="sch7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0017.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Boronic Ester Intermediates <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triethyl orthoformate, toluene, 110 °C, 16 h, 36–75%; (b) PdCl<sub>2</sub>–dppf, KOAc, dioxane, 100 °C, 16 h, 67–95%.</p></p></figure><figure data-id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/medium/jm-2016-007228_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0010.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Two axes of hindered rotation of compound <b>6</b> and (B) chiral HPLC trace showing four atropisomers. In (A), arrows show bonds with hindered rotation leading to atropisomers. In (B), chromatographic conditions were the following: Chiralpak IB column, 4.6 mm × 250 mm, 5 μm, 35/65 MeOH/CO<sub>2</sub>, 100 bar back-pressure, 4 mL/min, column 0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00722/20160901/images/large/jm-2016-007228_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00722&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Volkamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rippmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulle, S.</span><span> </span><span class="NLM_article-title">Pocketome of human kinases: Prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1021/ci500624s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500624s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2MvjsVSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=538-549&author=A.+Volkamerauthor=S.+Eidauthor=S.+Turkauthor=S.+Jaegerauthor=F.+Rippmannauthor=S.+Fulle&title=Pocketome+of+human+kinases%3A+Prioritizing+the+ATP+binding+sites+of+%28yet%29+untapped+protein+kinases+for+drug+discovery&doi=10.1021%2Fci500624s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery</span></div><div class="casAuthors">Volkamer Andrea; Eid Sameh; Turk Samo; Jaeger Sabrina; Fulle Simone; Rippmann Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases are involved in a variety of diseases including cancer, inflammation, and autoimmune disorders.  Although the development of new kinase inhibitors is a major focus in pharmaceutical research, a large number of kinases remained so far unexplored in drug discovery projects.  The selection and assessment of targets is an essential but challenging area.  Today, a few thousands of experimentally determined kinase structures are available, covering about half of the human kinome.  This large structural source allows guiding the target selection via structure-based druggability prediction approaches such as DoGSiteScorer.  Here, a thorough analysis of the ATP pockets of the entire human kinome in the DFG-in state is presented in order to prioritize novel kinase structures for drug discovery projects.  For this, all human kinase X-ray structures available in the PDB were collected, and homology models were generated for the missing part of the kinome.  DoGSiteScorer was used to calculate geometrical and physicochemical properties of the ATP pockets and to predict the potential of each kinase to be druggable.  The results indicate that about 75% of the kinome are in principle druggable.  Top ranking structures comprise kinases that are primary targets of known approved drugs but additionally point to so far less explored kinases.  The presented analysis provides new insights into the druggability of ATP binding pockets of the entire kinome.  We anticipate this comprehensive druggability assessment of protein kinases to be helpful for the community to prioritize so far untapped kinases for drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXYhJ2uLp2lX6HPRus0rAafW6udTcc2ea2O2B3Je4eO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvjsVSksw%253D%253D&md5=85c8e48d59f1acea82d1019da51b47e1</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1021%2Fci500624s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500624s%26sid%3Dliteratum%253Aachs%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DEid%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DJaeger%26aufirst%3DS.%26aulast%3DRippmann%26aufirst%3DF.%26aulast%3DFulle%26aufirst%3DS.%26atitle%3DPocketome%2520of%2520human%2520kinases%253A%2520Prioritizing%2520the%2520ATP%2520binding%2520sites%2520of%2520%2528yet%2529%2520untapped%2520protein%2520kinases%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D538%26epage%3D549%26doi%3D10.1021%2Fci500624s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stransky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span> </span><span class="NLM_article-title">Targeting cancer with kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1780</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1172/JCI76094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1172%2FJCI76094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=25932675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2MjpvFGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=1780-1789&author=S.+Grossauthor=R.+Rahalauthor=N.+Stranskyauthor=C.+Lengauerauthor=K.+P.+Hoeflich&title=Targeting+cancer+with+kinase+inhibitors&doi=10.1172%2FJCI76094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with kinase inhibitors</span></div><div class="casAuthors">Gross Stefan; Rahal Rami; Stransky Nicolas; Lengauer Christoph; Hoeflich Klaus P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1780-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases.  Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation.  In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors.  We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic.  Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyaX6QAuw1pbFU0A1HOshhfW6udTcc2eZGVFoNCgIby7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjpvFGitA%253D%253D&md5=b35d25dcf88d08a43ca3a0945c048111</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1172%2FJCI76094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI76094%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DS.%26aulast%3DRahal%26aufirst%3DR.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26atitle%3DTargeting%2520cancer%2520with%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D1780%26epage%3D1789%26doi%3D10.1172%2FJCI76094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Quantitative proteomics of kinase inhibitor targets and mechanisms</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1021/cb5008794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=201-212&author=H.+Daub&title=Quantitative+proteomics+of+kinase+inhibitor+targets+and+mechanisms&doi=10.1021%2Fcb5008794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fcb5008794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008794%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DQuantitative%2520proteomics%2520of%2520kinase%2520inhibitor%2520targets%2520and%2520mechanisms%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D201%26epage%3D212%26doi%3D10.1021%2Fcb5008794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lijnJn0lgch1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lijnJn0lgch1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jongstra-Bilen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cybulsky, M. I.</span><span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaven, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2576</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span><span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lgPUhPskiX00A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsukada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0lgPUhPskiX00A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11534</span><span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mease, P. J.</span><span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0lin4dxlXW2u2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Goldstein, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debenedette, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbaugh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, T. H.</span><span> </span><span class="NLM_article-title">Induction of costimulatory molecules B7–1 and B7–2 in murine B cells: the CBA/N mouse reveals a role for Bruton’s tyrosine kinase in CD40-mediated B7 induction</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1016/0161-5890(96)00005-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2F0161-5890%2896%2900005-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8700170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK28Xks1ShsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1996&pages=541-552&author=M.+D.+Goldsteinauthor=M.+A.+Debenedetteauthor=D.+Hollenbaughauthor=T.+H.+Watts&title=Induction+of+costimulatory+molecules+B7%E2%80%931+and+B7%E2%80%932+in+murine+B+cells%3A+the+CBA%2FN+mouse+reveals+a+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+CD40-mediated+B7+induction&doi=10.1016%2F0161-5890%2896%2900005-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of costimulatory molecules B7-1 and B7-2 in murine B cells: the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction</span></div><div class="casAuthors">Goldstein, Marni D.; Debenedette, Mark A.; Hollenbaugh, Diane; Watts, Tania H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">541-552</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding of CD40 ligand on activated T cells to CD40 on resting B cells induces the expression of costimulatory mols. B7-1 (CD80) and B7-2 (CD86).  The induction of B7 mols. by CD40 ligand-CD40 interaction represents a crit. step in rendering B cells competent for antigen presentation.  The CBA/N mouse has a defect in CD40 signalling which has been attributed to a mutation of Bruton's tyrosine kinase.  We have compared the ability of murine CD40 ligand to induce B7-1 and B7-2 expression on B cells isolated from CBA/N and wild-type CBA/J mice.  We find that the CBA/N defect partially impairs both B7-1 and B7-2 induction via CD40.  Subsequent expts. investigated the roles of different second messenger systems in B7-1 and B7-2 induction in normal B cells.  In M12 B lymphomas either CD40 crosslinking or cAMP treatment can induce B7 mols.  Here we report that treatment with dibutyryl-cAMP also induces B7 mols. in normal B cells provided that they have been preactivated by CD40 crosslinking.  We also find that PMA and ionomycin treatment of B cells induces B7-2 but not B7-1 expression.  Our data therefore show roles for BTK, cAMP and PMA/ionomycin in B7 induction, as well as providing further evidence for differential regulation of B7-1 and B7-2 induction in B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNEdhcqOYWrVg90H21EOLACvtfcHk0lin4dxlXW2u2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xks1ShsL8%253D&md5=90032ff733f6264a80241f131cb70b4d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0161-5890%2896%2900005-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0161-5890%252896%252900005-3%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DM.%2BD.%26aulast%3DDebenedette%26aufirst%3DM.%2BA.%26aulast%3DHollenbaugh%26aufirst%3DD.%26aulast%3DWatts%26aufirst%3DT.%2BH.%26atitle%3DInduction%2520of%2520costimulatory%2520molecules%2520B7%25E2%2580%25931%2520and%2520B7%25E2%2580%25932%2520in%2520murine%2520B%2520cells%253A%2520the%2520CBA%252FN%2520mouse%2520reveals%2520a%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520CD40-mediated%2520B7%2520induction%26jtitle%3DMol.%2520Immunol.%26date%3D1996%26volume%3D33%26spage%3D541%26epage%3D552%26doi%3D10.1016%2F0161-5890%2896%2900005-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0lin4dxlXW2u2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinberg, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smathers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, A. D.</span><span> </span><span class="NLM_article-title">Ability of the XID gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+XID+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eaW8ckkK4wmG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520XID%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivassan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivassanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lj7dFNOUvPb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivassan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rankin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathialagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homer, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III.</span><span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">4540</span><span class="NLM_x">–</span> <span class="NLM_lpage">4550</span><span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lj7dFNOUvPb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Puck, J. M.</span><span> </span><span class="NLM_article-title">Molecular and genetic basis of X-linked immunodeficiency disorders</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/BF01541340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2FBF01541340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=8195317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=81-89&author=J.+M.+Puck&title=Molecular+and+genetic+basis+of+X-linked+immunodeficiency+disorders&doi=10.1007%2FBF01541340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and genetic basis of X-linked immunodeficiency disorders</span></div><div class="casAuthors">Puck, Jennifer M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-9</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review with 51 refs.  Topics discussed include X-linked hyper-IgM syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, and immunodeficiency genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dSBJ76uLHLVg90H21EOLACvtfcHk0lgmAwKvULOogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D&md5=c9c2d448576c949acc62b4926389b46b</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1007%2FBF01541340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01541340%26sid%3Dliteratum%253Aachs%26aulast%3DPuck%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520and%2520genetic%2520basis%2520of%2520X-linked%2520immunodeficiency%2520disorders%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D14%26spage%3D81%26epage%3D89%26doi%3D10.1007%2FBF01541340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredius, R. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike-Overzet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, F. J. T.</span><span> </span><span class="NLM_article-title">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/14728222.2011.585971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1517%2F14728222.2011.585971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21635151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=1003-1021&author=R.+W.+Hendriksauthor=R.+G.+M.+Brediusauthor=K.+Pike-Overzetauthor=F.+J.+T.+Staal&title=Biology+and+novel+treatment+options+for+XLA%2C+the+most+common+monogenetic+immunodeficiency+in+man&doi=10.1517%2F14728222.2011.585971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span></div><div class="casAuthors">Hendriks, Rudi W.; Bredius, Robbert G. M.; Pike-Overzet, Karin; Staal, Frank J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1003-1021</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency in man, and is caused by a single genetic defect.  Inactivating mutations in the Bruton's tyrosine kinase (BTK) gene are invariably the cause of XLA,.  XLA is characterized by a differentiation arrest at the pre-B cell stage, the absence of Igs and recurrent bacterial infections, making it an insidious disease that gradually disables the patient, and can result in death due to chronic lung disease.  Current treatment involves prophylactic antibiotics and Ig infusions, which are non-curative.  This disease is a good candidate for curative hematopoietic stem cell (HSC)-based gene therapy, which could correct the B cell and myeloid deficiencies.  Areas covered: This paper reviews the basic biol. of BTK in B cell development, the clin. features of XLA, and the possibilities of gene therapy for XLA, covering the literature from 1995 to 2010.  Expert opinion: Work from various labs. demonstrates the feasibility of using gene-cor. HSCs to complement the immune defects of Btk-deficiency in mice.  We propose that it is timely to start clin. programs to develop stem cell based therapy for XLA, using gene-cor. autologous HSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeANh_LlclL7Vg90H21EOLACvtfcHk0lgmAwKvULOogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D&md5=24f073dee412df4b5ec3beb5dc982b0e</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.585971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.585971%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DBredius%26aufirst%3DR.%2BG.%2BM.%26aulast%3DPike-Overzet%26aufirst%3DK.%26aulast%3DStaal%26aufirst%3DF.%2BJ.%2BT.%26atitle%3DBiology%2520and%2520novel%2520treatment%2520options%2520for%2520XLA%252C%2520the%2520most%2520common%2520monogenetic%2520immunodeficiency%2520in%2520man%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D1003%26epage%3D1021%26doi%3D10.1517%2F14728222.2011.585971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, J. A.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia: an analysis of 96 patients</span> <span class="citation_source-journal">Medicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1097/00005792-198505000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1097%2F00005792-198505000-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1985&pages=145-156&author=H.+M.+Ledermanauthor=J.+A.+Winkelstein&title=X-linked+agammaglobulinemia%3A+an+analysis+of+96+patients&doi=10.1097%2F00005792-198505000-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1097%2F00005792-198505000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-198505000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26atitle%3DX-linked%2520agammaglobulinemia%253A%2520an%2520analysis%2520of%252096%2520patients%26jtitle%3DMedicine%26date%3D1985%26volume%3D64%26spage%3D145%26epage%3D156%26doi%3D10.1097%2F00005792-198505000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0lgmAwKvULOogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0ljl2J5UZ_ESpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0ljl2J5UZ_ESpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burger, J. A.</span><span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1007/s11899-013-0188-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2Fs11899-013-0188-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24357428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=44-49&author=J.+A.+Burger&title=Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+in+Clinical+Trials&doi=10.1007%2Fs11899-013-0188-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in clinical trials</span></div><div class="casAuthors">Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors.  Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders.  The BTK inhibitor ibrutinib (PCI-32765, brand name: Imbruvica) demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM).  Therefore, ibrutinib was granted a 'breakthrough therapy' designation for these indications and was recently approved for the treatment of relapsed MCL by the U.S.  Food and Drug Administration.  Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059.  In CLL and MCL, ibrutinib characteristically induces redistribution of malignant B cells from tissue sites into the peripheral blood, along with rapid resolution of enlarged lymph nodes and a surge in lymphocytosis.  With continuous ibrutinib therapy, growth- and survival-inhibitory activities of ibrutinib result in the normalization of lymphocyte counts and remissions in a majority of patients.  This review discusses the clinical advances with BTK inhibitor therapy, as well as its pathophysiological basis, and outlines perspectives for future use of BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqhvp3dQ4UIub6AVA-44PTfW6udTcc2eYKuBbznyLagrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D&md5=2e6e9639a96e00f2669027ab74f8c7c4</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-013-0188-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-013-0188-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D44%26epage%3D49%26doi%3D10.1007%2Fs11899-013-0188-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Akinleye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0ljghN7MaZSC4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0ljghN7MaZSC4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel oral BTK inhibitor, inhibits human immune cell activation: New drug candidate to treat B-cell associated autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-eular.2783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1136%2Fannrheumdis-2014-eular.2783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=355-356&author=J.+K.+Parkauthor=J.+A.+Parkauthor=Y.+J.+Leeauthor=J.+Songauthor=J.+I.+Ohauthor=Y.-M.+Leeauthor=K.+H.+Suhauthor=J.+Sonauthor=E.+B.+Lee&title=HM71224%2C+a+novel+oral+BTK+inhibitor%2C+inhibits+human+immune+cell+activation%3A+New+drug+candidate+to+treat+B-cell+associated+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2014-eular.2783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-eular.2783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-eular.2783%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520oral%2520BTK%2520inhibitor%252C%2520inhibits%2520human%2520immune%2520cell%2520activation%253A%2520New%2520drug%2520candidate%2520to%2520treat%2520B-cell%2520associated%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2014%26volume%3D73%26spage%3D355%26epage%3D356%26doi%3D10.1136%2Fannrheumdis-2014-eular.2783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lhtBZQ28RexIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Evans, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witowski, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounsbury, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lhtBZQ28RexIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lj_gZpEesWgpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: pyridazinone analogs with improved metabolic stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+highly+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+pyridazinone+analogs+with+improved+metabolic+stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0lj_gZpEesWgpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520pyridazinone%2520analogs%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krikorian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boga, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhassan, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu-Pham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manusueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang-Hoover, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knemeyer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible selective BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=A.+De+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Horvakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Manusuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+selective+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DDe%2BMan%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHorvak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DManusueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520selective%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Y.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lhL6VXSUEus7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; De Lucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Carbazole carboxamide compounds useful as kinase inhibitors</span>. U.S. Patent US 20100160303 A1, 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Liu%2C+Q.%3B+Batt%2C+D.+G.%3B+De+Lucca%2C+G.+V.%3B+Shi%2C+Q.%3B+Tebben%2C+A.+J.+Carbazole+carboxamide+compounds+useful+as+kinase+inhibitors.+U.S.+Patent+US+20100160303+A1%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DCarbazole%2520carboxamide%2520compounds%2520useful%2520as%2520kinase%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span> <span class="citation_source-journal">Drug Met. Dispersion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span><span class="refDoi"> DOI: 10.1124/dmd.111.040840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fdmd.111.040840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21742900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+C.+A.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor&doi=10.1124%2Fdmd.111.040840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor</span></div><div class="casAuthors">Liu, Lichuan; Halladay, Jason S.; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John C., Jr.; Liao, X. Charlene; Lubach, Joseph W.; Deese, Alan; Sowell, C. Gregory; Currie, Kevin S.; Young, Wendy B.; Khojasteh, S. Cyrus; Hop, Cornelis E. C. A.; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1840-1849</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(R)-N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide (GDC-0834) is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.  In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human.  The formation of M1 appeared to be NADPH-independent in human liver microsomes.  M1 was found in only minor to moderate quantities in plasma from preclin. species dosed with GDC-0834.  Human clearance predictions using various methodologies resulted in ests. ranging from low to high.  In addn., GDC-0834 exhibited low clearance in PXB chimeric mice with humanized liver.  Uncertainty in human pharmacokinetic prediction and high interest in a BTK inhibitor for clin. evaluation prompted an investigational new drug strategy, in which GDC-0834 was rapidly advanced to a single-dose human clin. trial.  GDC-0834 plasma concns. in humans were below the limit of quantitation (<1 ng/mL) in most samples from the cohorts dosed orally at 35 and 105 mg.  In contrast, substantial plasma concns. of M1 were obsd.  In human plasma and urine, only M1 and its sequential metabolites were identified.  The formation kinetics of M1 was evaluated in rat, dog, monkey, and human liver microsomes in the absence of NADPH.  The max. rate of M1 formation (Vmax) was substantially higher in human compared with that in other species.  In contrast, the Michaelis-Menten const. (Km) was comparable among species.  Intrinsic clearance (Vmax/Km) of GDC-0834 from M1 formation in human was 23- to 169-fold higher than obsd. in rat, dog, and monkey.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_v1aPr50jkLVg90H21EOLACvtfcHk0lgeUBwPfaVvOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE&md5=976adc37c4d621924276d174318a1a84</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040840%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Met.%2520Dispersion%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849%26doi%3D10.1124%2Fdmd.111.040840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Plitnick, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzyk, D. J.</span><span> </span><span class="NLM_article-title">The T-dependent antibody response to keyhole limpet hemocyanin in rodents</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">598</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1007/978-1-60761-401-2_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1007%2F978-1-60761-401-2_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19967512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=598&publication_year=2010&pages=159-171&author=L.+M.+Plitnickauthor=D.+J.+Herzyk&title=The+T-dependent+antibody+response+to+keyhole+limpet+hemocyanin+in+rodents&doi=10.1007%2F978-1-60761-401-2_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The T-dependent antibody response to keyhole limpet hemocyanin in rodents</span></div><div class="casAuthors">Plitnick, Lisa M.; Herzyk, Danuta J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">598</span>
        (<span class="NLM_cas:issue">Immunotoxicity Testing</span>),
    <span class="NLM_cas:pages">159-171</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Central to the evaluation of potential immunotoxicants is the concept that measurement of multiple parameters is required for the detn. of toxicity toward the immune system.  A carefully considered integration of endpoints involved in the immune response should be used to det. an immunotoxic effect.  A functional evaluation, specifically the rodent T-cell-dependent antibody response (TDAR) model developed for regulated immunotoxicity evaluations, has been established to detect potential immunotoxicity, esp. immunosuppression, caused by chems. and novel pharmaceuticals in development.  This chapter provides an overview and detailed procedures involved in the TDAR assay that measures the immune response (i.e., antibody prodn.) to an introduced antigen (i.e., keyhole limpet hemocyanin (KLH)) in rats or mice treated with a chem. (e.g., a known immunotoxicant and/or a new drug candidate).  The TDAR model of competent immune function requires the participation of multiple effector cells such as antigen presenting cells, T lymphocytes, and B lymphocytes to produce the final product, the antigen-specific antibody response.  Thus, alterations in the level of antibody prodn. to the specific antigen may reflect effects on any or all of the cell populations involved in TDAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJiPrwzNO6bVg90H21EOLACvtfcHk0lgeUBwPfaVvOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymtbs%253D&md5=033e19ab74af5b29b7514899bd17c661</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-401-2_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-401-2_11%26sid%3Dliteratum%253Aachs%26aulast%3DPlitnick%26aufirst%3DL.%2BM.%26aulast%3DHerzyk%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520T-dependent%2520antibody%2520response%2520to%2520keyhole%2520limpet%2520hemocyanin%2520in%2520rodents%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2010%26volume%3D598%26spage%3D159%26epage%3D171%26doi%3D10.1007%2F978-1-60761-401-2_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lh1iV02SCY0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nandakumar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäcklund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">R544</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span><span class="refDoi"> DOI: 10.1186/ar1217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1186%2Far1217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=R544-550&author=K.+S.+Nandakumarauthor=J.+B%C3%A4cklundauthor=M.+Vestbergauthor=R.+Holmdahl&title=Collagen+type+II+%28CII%29-specific+antibodies+induce+arthritis+in+the+absence+of+T+or+B+cells+but+the+arthritis+progression+is+enhanced+by+CII-reactive+T+cells&doi=10.1186%2Far1217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1186%2Far1217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far1217%26sid%3Dliteratum%253Aachs%26aulast%3DNandakumar%26aufirst%3DK.%2BS.%26aulast%3DB%25C3%25A4cklund%26aufirst%3DJ.%26aulast%3DVestberg%26aufirst%3DM.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DCollagen%2520type%2520II%2520%2528CII%2529-specific%2520antibodies%2520induce%2520arthritis%2520in%2520the%2520absence%2520of%2520T%2520or%2520B%2520cells%2520but%2520the%2520arthritis%2520progression%2520is%2520enhanced%2520by%2520CII-reactive%2520T%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2004%26volume%3D6%26spage%3DR544%26epage%3D550%26doi%3D10.1186%2Far1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kagari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimozato, T.</span><span> </span><span class="NLM_article-title">Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">4318</span><span class="NLM_x">–</span> <span class="NLM_lpage">4324</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.8.4318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.4049%2Fjimmunol.170.8.4318" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=4318-4324&author=T.+Kagariauthor=D.+Tanakaauthor=H.+Doiauthor=T.+Shimozato&title=Essential+role+of+Fc+gamma+receptors+in+anti-type+II+collagen+antibody-induced+arthritis&doi=10.4049%2Fjimmunol.170.8.4318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.8.4318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.8.4318%26sid%3Dliteratum%253Aachs%26aulast%3DKagari%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DD.%26aulast%3DDoi%26aufirst%3DH.%26aulast%3DShimozato%26aufirst%3DT.%26atitle%3DEssential%2520role%2520of%2520Fc%2520gamma%2520receptors%2520in%2520anti-type%2520II%2520collagen%2520antibody-induced%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D4318%26epage%3D4324%26doi%3D10.4049%2Fjimmunol.170.8.4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Street, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiblin, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, M. S.</span><span> </span><span class="NLM_article-title">Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1529</span><span class="NLM_x">–</span> <span class="NLM_lpage">1538</span><span class="refDoi"> DOI: 10.1021/jm00063a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00063a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1529-1538&author=L.+J.+Streetauthor=R.+Bakerauthor=J.+L.+Castroauthor=M.+S.+Chambersauthor=A.+R.+Guiblinauthor=S.+C.+Hobbsauthor=V.+G.+Matassaauthor=A.+J.+Reeveauthor=M.+S.+Beer&title=Synthesis+and+serotonergic+activity+of+5-%28oxadiazolyl%29tryptamines%3A+potent+agonists+for+5-HT1D+receptors&doi=10.1021%2Fjm00063a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00063a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00063a003%26sid%3Dliteratum%253Aachs%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DCastro%26aufirst%3DJ.%2BL.%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DGuiblin%26aufirst%3DA.%2BR.%26aulast%3DHobbs%26aufirst%3DS.%2BC.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DReeve%26aufirst%3DA.%2BJ.%26aulast%3DBeer%26aufirst%3DM.%2BS.%26atitle%3DSynthesis%2520and%2520serotonergic%2520activity%2520of%25205-%2528oxadiazolyl%2529tryptamines%253A%2520potent%2520agonists%2520for%25205-HT1D%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1529%26epage%3D1538%26doi%3D10.1021%2Fjm00063a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kamata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotake, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niijima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugumi, H. A.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1248/cpb.52.1071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1248%2Fcpb.52.1071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=1071-1081&author=J.+Kamataauthor=T.+Okadaauthor=Y.+Kotakeauthor=J.+Niijimaauthor=K.+Nakamuraauthor=T.+Uenakaauthor=A.+Yamaguchiauthor=K.+Tsukaharaauthor=T.+Nagasuauthor=N.+Koyanagiauthor=K.+Kitohauthor=K.+Yoshimatsuauthor=H.+Yoshinoauthor=H.+A.+Sugumi&title=Synthesis+and+evaluation+of+novel+pyrimido-acridone%2C+-phenoxadine%2C+and+-carbazole+as+topoisomerase+II+inhibitors&doi=10.1248%2Fcpb.52.1071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.1071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.1071%26sid%3Dliteratum%253Aachs%26aulast%3DKamata%26aufirst%3DJ.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DNiijima%26aufirst%3DJ.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DTsukahara%26aufirst%3DK.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DSugumi%26aufirst%3DH.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520pyrimido-acridone%252C%2520-phenoxadine%252C%2520and%2520-carbazole%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D1071%26epage%3D1081%26doi%3D10.1248%2Fcpb.52.1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lucca, G. V.</span><span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2206</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0li46KojpL2O3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieltyka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elvebak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span> </span><span class="NLM_article-title">An integrated bioanalytical platform for supporting high-throughput serum protein binding screening</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3601</span><div class="note"><p class="first last">(protein binding)</p></div><span class="refDoi"> DOI: 10.1002/rcm.4817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Frcm.4817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=21080511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=3593-3601&author=J.+Zhangauthor=W.+Z.+Shouauthor=M.+Vathauthor=K.+Kieltykaauthor=J.+Maloneyauthor=L.+Elvebakauthor=J.+Stewartauthor=J.+Herbstauthor=H.+N.+Weller&title=An+integrated+bioanalytical+platform+for+supporting+high-throughput+serum+protein+binding+screening&doi=10.1002%2Frcm.4817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated bioanalytical platform for supporting high-throughput serum protein binding screening</span></div><div class="casAuthors">Zhang, Jun; Shou, Wilson Z.; Vath, Marianne; Kieltyka, Kasia; Maloney, Jennifer; Elvebak, Larry; Stewart, Jeremy; Herbst, John; Weller, Harold N.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3593-3601</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Quantification of small mols. using liq. chromatog./tandem mass spectrometry (LC/MS/MS) on a triple quadrupole mass spectrometer has become a common practice in bioanal. support of in vitro adsorption, distribution, metab. and excretion (ADME) screening.  The bioanal. process involves primarily three indispensable steps: MS/MS optimization for a large no. of new chem. compds. undergoing various screening assays in early drug discovery, high-throughput sample anal. with LC/MS/MS for those chem. diverse compds. using the optimized MS/MS conditions, and post-acquisition data review and reporting.  To improve overall efficiency of ADME bioanal., an integrated system was proposed featuring an automated and unattended MS/MS optimization, a staggered parallel LC/MS/MS for high-throughput sample anal., and a sophisticated software tool for LC/MS/MS raw data review as well as biol. data calcn. and reporting.  The integrated platform has been used in bioanal. support of a serum protein binding screening assay with high speed, high capacity, and good robustness.  In this new platform, a unique sample diln. scheme was also introduced.  With this diln. design, the total no. of anal. samples was reduced; therefore, the total operation time was reduced and the overall throughput was further improved.  The performance of the protein binding screening assay was monitored with two controls representing high and low binding properties and an acceptable inter-assay consistency was achieved.  This platform has been successfully used for the detn. of serum protein binding in multiple species for more than 4000 compds.  Copyright © 2010 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mXcL-JCF37Vg90H21EOLACvtfcHk0li46KojpL2O3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb7M&md5=476a8b2315eddc9f9a1cc56895480dbc</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1002%2Frcm.4817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4817%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DElvebak%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26atitle%3DAn%2520integrated%2520bioanalytical%2520platform%2520for%2520supporting%2520high-throughput%2520serum%2520protein%2520binding%2520screening%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2010%26volume%3D24%26spage%3D3593%26epage%3D3601%26doi%3D10.1002%2Frcm.4817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zvyaga, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuppugalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorndike, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1698</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><div class="note"><p class="first last">(HLM CYP)</p></div><span class="refDoi"> DOI: 10.1124/dmd.112.045575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1124%2Fdmd.112.045575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22648560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1698-1711&author=T.+A.+Zvyagaauthor=S.-Y.+Changauthor=C.+Chenauthor=Z.+Yangauthor=R.+Vuppugallaauthor=J.+Hurleyauthor=D.+Thorndikeauthor=A.+Wagnerauthor=A.+Chimalakondaauthor=A.+D.+Rodrigues&title=Evaluation+of+six+proton+pump+inhibitors+as+inhibitors+of+various+human+cytochromes+P450%3A+focus+on+cytochrome+P450+2C19&doi=10.1124%2Fdmd.112.045575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19</span></div><div class="casAuthors">Zvyaga, Tatyana; Chang, Shu-Ying; Chen, Cliff; Yang, Zheng; Vuppugalla, Ragini; Hurley, Jeremy; Thorndike, Denise; Wagner, Andrew; Chimalakonda, Anjaneya; Rodrigues, A. David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1698-1711</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole, dexlansoprazole, pantoprazole, and rabeprazole, were shown to be weak inhibitors of cytochromes P 450 (CYP3A4, -2B6, -2D6, -2C9, -2C8, and -1A2) in human liver microsomes.  In most cases, IC50 values were > 40 μM, except for dexlansoprazole and lansoprazole with CYP1A2 (IC50 = ∼8 μM) and esomeprazole with CYP2C8 (IC50 = 31 μM).  With the exception of CYP2C19 inhibition by omeprazole and esomeprazole (IC50 ratio, 2.5 to 5.9), there was no evidence for a marked time-dependent shift in IC50 (IC50 ratio, ≤2) after a 30-min preincubation with NADPH.  In the absence of preincubation, lansoprazole (IC50 = 0.73 μM) and esomeprazole (IC50 = 3.7 μM) were the most potent CYP2C19 inhibitors, followed by dexlansoprazole and omeprazole (IC50 = ∼7.0 μM).  Rabeprazole and pantoprazole (IC50 = ≥25 μM) were the weakest.  A similar ranking was obtained with recombinant CYP2C19.  Despite the IC50 ranking, after consideration of blood plasma levels (static and dynamic), protein binding, and metab.-dependent inhibition, it is concluded that omeprazole and esomeprazole are the most potent CYP2C19 inhibitors.  This was confirmed after the incubation of the individual PPIs with human primary hepatocytes (in the presence of human serum) and by monitoring their impact on diazepam N-demethylase activity at a low concn. of diazepam (2 μM).  Data described herein are consistent with reports that PPIs are mostly weak inhibitors of cytochromes P 450 in vivo.  However, 2 members of the PPI class (esomeprazole and omeprazole) are more likely to serve as clin. relevant inhibitors of CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Il9jjcdDvrVg90H21EOLACvtfcHk0li46KojpL2O3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShtbjK&md5=4f2d29cbfbda06e4181f6e869ed37c3d</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045575%26sid%3Dliteratum%253Aachs%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DChang%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DThorndike%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DEvaluation%2520of%2520six%2520proton%2520pump%2520inhibitors%2520as%2520inhibitors%2520of%2520various%2520human%2520cytochromes%2520P450%253A%2520focus%2520on%2520cytochrome%2520P450%25202C19%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1698%26epage%3D1711%26doi%3D10.1124%2Fdmd.112.045575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paiva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H.</span><span> </span><span class="NLM_article-title">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography–tandem mass spectrometry</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2755</span><span class="NLM_x">–</span> <span class="NLM_lpage">2762</span><div class="note"><p class="first last">(Caco-2)</p></div><span class="refDoi"> DOI: 10.1002/jps.23194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Fjps.23194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=22611052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=2755-2762&author=X.+Caiauthor=A.+Walkerauthor=C.+Chengauthor=A.+Paivaauthor=Y.+Liauthor=J.+Kolbauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Approach+to+improve+compound+recovery+in+a+high-throughput+Caco-2+permeability+assay+supported+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fjps.23194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Cai, Xianmei; Walker, Aaron; Cheng, Charles; Paiva, Anthony; Li, Ying; Kolb, Janet; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2755-2762</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The Caco-2 cell culture system is widely employed as an in vitro model for prediction of intestinal absorption of test compds. in early drug discovery.  Poor recovery is a commonly encountered issue in Caco-2 assay, which can lead to difficulty in data interpretation and underestimation of the apparent permeability of affected compds.  In this study, we systematically investigated the potential sources of compd. loss in our automated, high-throughput Caco-2 assay, sample storage, and anal. processes, and as a result found the nonspecific binding to various plastic surfaces to be the major cause of poor compd. recovery.  To minimize the nonspecific binding, we implemented a simple and practical approach in our assay automation by preloading collection plates with org. solvent contg. internal std. prior to transferring incubations samples.  The implementation of this new method has been shown to significantly increase recovery in many compds. previously identified as having poor recovery in the Caco-2 permeability assay.  With improved recovery, permeability results were obtained for many compds. that were previously not detected in the basolateral samples.  In addn. to recovery improvement, this new approach also simplified sample prepn. for liq. chromatog.-tandem mass spectrometric anal. and therefore achieved time and cost savings for the bioanalyst. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3d7jZyPfxPLVg90H21EOLACvtfcHk0ligN-vMI0jNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D&md5=16cfacab071344c98a95dc8c6f4483af</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fjps.23194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23194%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DApproach%2520to%2520improve%2520compound%2520recovery%2520in%2520a%2520high-throughput%2520Caco-2%2520permeability%2520assay%2520supported%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D2755%26epage%3D2762%26doi%3D10.1002%2Fjps.23194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25d"><span><span class="NLM_label">(d) </span> PAMPA Evolution. <a href="http://www.pion-inc.com/Products/PAMPA_Evolution/en" class="extLink">http://www.pion-inc.com/Products/PAMPA_Evolution/en</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PAMPA+Evolution.+http%3A%2F%2Fwww.pion-inc.com%2FProducts%2FPAMPA_Evolution%2Fen."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kieltyka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baglieri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. Z.</span><span> </span><span class="NLM_article-title">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span><div class="note"><p class="first last">(liver microsome metabolic stability).</p></div><span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+high-throughput+bioanalytical+platform+using+automated+infusion+for+tandem+mass+spectrometric+method+optimization+and+its+application+in+a+metabolic+stability+screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25eR"><div class="casContent"><span class="casTitleNuber">25e</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0ligN-vMI0jNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit25e&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520high-throughput%2520bioanalytical%2520platform%2520using%2520automated%2520infusion%2520for%2520tandem%2520mass%2520spectrometric%2520method%2520optimization%2520and%2520its%2520application%2520in%2520a%2520metabolic%2520stability%2520screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS','PDB','5JRS'); return false;">PDB: 5JRS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00722">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48411"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00722">10.1021/acs.jmedchem.6b00722</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and the associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00722/suppl_file/jm6b00722_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00722/suppl_file/jm6b00722_si_001.csv">jm6b00722_si_001.csv (1.61 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for compound <b>23</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00722%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00722" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799411f3fc5d1db","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
